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Rheumatoid arthritis
Rheumatoid arthritis (RA) is an autoimmune disease affecting the articulating 
joints. It typically starts in the distal joints of hands and feet and manifests in a 
symmetrical fashion. The disease culminates in a chronic inflammation of these 
joints leading to severe swelling and destruction of bone and cartilage (Figure 
1). This obviously impairs mobility of the joint and limits its function. Patient’s 
quality of life is further compromised due to pain accompanying the chronic 
inflammation (1).
Incidence of RA is 1% worldwide, but 
varies between different populations 
(2). Also, incidence among women is 
elevated compared to men, indicating 
a hormonal influence on disease. This is 
further supported by the fact that disease 
activity is reduced during pregnancy, but 
increases post-partum (3). The actual 
cause however, has not been found and 
it is most likely to be multi-factorial, 
such as genetic predisposition and 
exposure to detrimental environmental 
factors (4). Periodontitis has also been 
described as a risk factor for RA, as 
periodontitis prevalence is increased 
among RA patients (5). Recently, however, 
periodontitis has emerged as a potential 
cause of RA. Specific bacterial strains that 
cause periodontitis have unique enzymes 
that are potentially involved in generating 
autoantigens (6).
Systemic immune characteristics of rheumatoid arthritis
Immunologically, RA is characterized by the presence of anti-citrullinated proteins 
antibodies (ACPAs) and rheumatoid factor (RF) (7), which are antibodies against 
immune globulins. Both these antibodies are directed against autoantigens, 
the patient’s own proteins, and classify RA as an autoimmune disease. The fact 
that several auto-antibodies arise in RA indicates an important role of B-cells 
in the pathogenesis. These cells originate from the bone marrow and migrate 
to secondary lymphoid organs such as spleen and lymph nodes (8). There they 
Figure 1. Comparison normal and arthritic 
joint
A normal articulating joint is displayed 
with cartilage layers on the bones and a 
thin synovial lining supplying synovial fluid 
for smooth movement in the joint. The 
arthritis joint shows degraded cartilage and 
bone. Moreover, the synovium is thickened 
and covers the cartilage surfaces causing 
degradation and the proliferating synovium 
also degrades the bone tissue.
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take up (auto)antigens and upon stimulation by T helper cells B-cells start to 
produce antibodies against the autoantigen (8). A critical role of B-cells in RA 
has been established by treatment of patients with anti-CD20 therapy (9). This 
treatment depletes the B-cell pool (10) of the patients for up to a year and disease 
progression is halted (11).
Another cell type of the adaptive immunity, the T-cell, also plays an important 
role in the pathogenesis of RA and the synovial cellular infiltrate consists largely 
of T-cells (12). Current treatments, however, have significantly decreased the 
number of infiltrated T-cells. In addition, T-cell responses against collagen type II 
(13) and microbial antigens have been reported in RA patients (14). Over recent 
years many studies have been performed on a T helper subset, the Th17 cell. 
This particular T helper cell produces the cytokine interleukin 17 (IL-17) and a 
crucial role for IL-17 has been shown for cartilage destruction, osteoclastogenesis 
(15) and promoting pro-inflammatory cytokine production by other cells. Again, 
new treatment strategies have shown that T-cells play a role in RA. Early anti-CD4 
biological lacked efficacy (16;17), however biologicals blocking the interaction 
between antigen presenting cells (APCs) and T-cells were proven to be effective in 
the treatment of RA (18;19). Additionally, preliminary data suggest IL-17 targeting 
as an efficacious therapy for rheumatoid arthritis (20;21). These studies have 
shown that RA is a systemic disease and that the interface between the innate 
and the adaptive immunity is of crucial importance. 
Histopathology of rheumatoid arthritis
When the arthritic joint is examined more closely several features are observed 
in RA patients. The synovium is heavily infiltrated with inflammatory cells, such as 
T- and B-cells from the adaptive immune system (22) and macrophages from the 
innate immune system. In fact, macrophage infiltration into the joint is a measure 
of disease activity (23). Moreover, the inflammatory cell infiltrate develops into 
secondary lymphoid organs with antibody producing plasma cells, showing that 
immune activation is present inside the joint (24). In addition, the synovium 
lining layer increases in thickness during arthritis. Synovium is normally only 
one cell layer thick, but the synovial fibroblasts in the lining start to proliferate 
and deposit extracellular matrix and thereby thicken the synovial lining (25). 
The thickened lining in conjunction with the infiltrated macrophages forms villi 
due to proliferation and develops into pannus tissue. This tissue covers the bone 
and cartilage surfaces and breaks down the extracellular matrix surrounding 
the chondrocytes causing cartilage erosion. Also the bone structures in the 
joint are subject to destruction (26). Circulating monocytes extravasate into the 
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joint and under stimulation from the proper growth factors they can form large 
multinucleated cells that develop into osteoclasts that absorb bone (27).
To supply the increasing demand for nutrients by the active inflammation in 
the joint new blood vessels develop in the synovium (28;29). This is, however, 
not an accurately orchestrated event and creates leaky vessels. Therefore, 
it becomes easier for attracted leukocytes to extravasate to the site of 
inflammation. Leukocytes are drawn to the site of inflammation by cyto- and 
chemokines produced by cells in the inflamed joint. Cyto- and chemokines 
are chemical messengers that attract new inflammatory cells amplifying the 
ongoing inflammation. Additionally, these inflammatory cells of both the innate 
and adaptive immunity have close interactions in the inflamed joint (30). These 
histopathological changes underline the importance of the local events in RA and 
how those processes contribute to the pathogenesis of RA.
Toll-Like Receptors
Since the discovery of Toll-Like Receptors (TLRs) an entire new field of research 
has opened in immunity and inflammation. TLRs are a family of 13 receptors and 
belong to the Pattern Recognition Receptors (PRR), together with C-type lectins, 
NOD-like receptors, and RIG-like helicases. All these receptors recognize patterns 
in microbial products rather than specific antigens. Therefore, these TLRs detect 
a broad range of microbial threats to the host. TLRs are type I transmembrane 
glycoproteins with a small intracellular signaling domain called TIR domain, 
sharing a high degree of homology with the IL-1 receptor (31). The extra cellular 
structure of TLR4 is very complex and consists of many leucine-rich repeats that 
fold into β-sheets, creating the typical horse shoe shape of TLRs (32). With this 
large extracellular domain TLRs recognize their ligands.
TLR ligands are called Pathogen Associated Molecular Patterns (PAMPs). TLRs 
are expressed either extracellularly or intracellularly and this also determines 
the type of ligand they detect (33). The extracellular TLRs (TLR1, 2, 4, 5, and 6) 
recognize microbial products that are on the surface of invading pathogens. TLR1, 
2, and 6 recognize lipopeptides from the cell wall of Gram positive bacteria and 
TLR4 is activated by lipopolysaccharide present in the cell wall of Gram negative 
bacteria. TLR5 is a specific TLR to detect flagellin on bacteria. TLRs expressed 
intracellularly (TLR3, 7, 8, 9) are receptors that sense RNA and DNA from viruses 
or bacteria and TLR11 detects an intracellular protein from Toxoplasma gondii 
(34). For the remaining TLRs (TLR10, 12, and 13) no function or ligand has been 
described yet.
12
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Besides ligands derived from bacteria and viruses many studies have indicated 
that TLRs can also be activated by endogenous proteins or oligosaccharides. 
These are named Damage Associated Molecular Patterns (DAMPs), as they are 
released from damages tissue (35;36). Some endogenous ligands belong to a 
group of proteins called Alarmins or acute phase proteins, such as S100 proteins 
and serum amyloid A proteins (37;38). These are produced in large amounts 
during inflammation at the site of inflammation or systemically by the liver. In 
addition, DAMPs can be released upon tissue injury and necrosis (39). For instance 
heat shock proteins which normally reside intracellularly are released from 
necrotic cells and can subsequently stimulate TLRs. Also breakdown products 
of extracellular matrix have been shown to stimulate TLRs (40). Fragments of 
hyaluronan and fibronectin are capable of activating TLR4 and, interestingly, 
these breakdown products are also present in the inflamed joints of RA patients 
(41-43).
Toll-Like receptor activation and intracellular signaling
TLR activation requires dimerization to induce subsequent signaling (44). TLR2 
dimerizes with either TLR1 or TLR6 in order to recognize lipoproteins, whereas 
other TLRs form a homodimer upon ligand binding (45). TLR4 activation requires 
a more orchestrated sequence of events  (46). LPS binding protein extracts 
LPS from more complex structures and transfers it to CD14 present on the cell 
membrane. CD14 transports the LPS molecules to myeloid differentiation factor-2 
(MD-2), which forms a hydrophobic pocket for the LPS molecule. MD-2 with the 
LPS initiates homodimerization of TLR4 and subsequently induces intracellular 
signaling.
TLR signaling can be divided in two different signaling pathways, MyD88 
dependent and MyD88 independent or TIR-domain-containing adapter-inducing 
interferon-β (TRIF) pathway (Figure 2) (47). The MyD88 pathway is used by 
all TLRs except TLR3. Upon TLR dimerization myeloid differentiation primary 
response gene 88 (MyD88) is recruited to the intracellular TIR domain of the 
TLR protein and binding of MyD88 requires the adaptor protein Mal (48). The 
formed complex initiates assembly of IL-1R-associated kinase (IRAK) and tumor 
necrosis factor (TNF) receptor-associated factor 6 (TRAF6) complex (49). This 
subsequently activates Transforming growth factor β–activated kinase 1 (TAK1) 
and eventually NF-κB, a pro-inflammatory transcription factor  (50), which in turn 
induces expression of various cyto- and chemokines. The MyD88 independent, or 
TRIF, pathway is utilized by TLR3 and TLR4 (51). To initiate signaling through the 
TRIF pathway, TLR4 needs to be internalized into endosomes (52). TLR4 requires 
the adapter molecule TRIF-related adaptor molecule (TRAM) in order to bind TRIF 
13
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(53), whereas TLR3 can directly bind TRIF. This leads to subsequent activation of 
Receptor-Interacting Protein 1 (RIP1) and TANK-binding kinase 1 (TBK1), which 
causes late NF-κB activation (54) or interferon regulatory factor (IRF) activation, 
respectively. The transcription factor IRF3 induces expression of type I interferons 
(55).
Figure 2. Toll-Like receptor signaling pathways 
Upon ligand binding by myeloid differentiation factor-2 (MD-2) at the cell surface TLR4 forms 
homodimers and initiates signaling. Myeloid differentiation primary response gene (88) (MyD88) 
binds through Mal to the intracellular domain of TLR4. This is followed by the formation of a protein 
complex containing IL-1R-associated kinase (IRAK) and tumor necrosis factor (TNF) receptor-associated 
factor 6 (TRAF6). A central triple MAPKinase, transforming growth factor β–activated kinase 1 (TAK1), 
is subsequently activated and pro-inflammatory gene transcription is induced by NF-κB. When TLR4 is 
taken up in an endosome TLR4 can initiate TRIF signaling. Binding of TIR-domain-containing adapter-
inducing interferon-β (TRIF) to TLR4 requires TRIF-related adaptor molecule (TRAM) and initiates 
activation of Receptor-Interacting Protein 1 (RIP1)  and TANK-binding kinase 1 (TBK1). These signaling 
molecules activate the transcription factors NF-κB and IRF3 respectively.
14
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Toll-Like receptors on antigen presenting cells
TLRs play an important role in controlling the activity of the innate immunity. 
APCs sense the microbial products with TLRs and this activates the APC, which in 
turn leads to activation of the adaptive immunity (Figure 3). APCs take up foreign 
particles or proteins and after intracellular processing they present parts of the 
particle to T-cells and a specific immune reaction towards the antigen is started 
(8). This presentation is termed signal 1 in antigen presentation. Signal 2 for the 
T-cells is given by the APC in co-stimulatory signals expressed on the cell surface, 
such as CD80 or CD86. The third signal is formed by the cytokines produced by 
the APCs and has an important role in controlling T-cell differentiation (56;57). 
TLR stimulation on APCs leads to enhanced antigen presentation, up regulation 
of co-stimulatory molecules and increased pro-inflammatory cytokine expression 
and forms therefore a bridge between the innate and adaptive immunity.
Toll-Like Receptors on non-immune cells
Besides the important role of TLRs on APCs TLRs are also expressed and functional 
on non-immune cells, including the cells present in the joint such as endothelial 
cells, chondrocytes and fibroblasts. Stimulation of TLRs on endothelial cells 
promotes proliferation of the endothelial cells and subsequent angiogenesis 
Figure 3. Toll-Like receptors form the bridge between innate and adaptive immunity.
Dendritic cells (DC) have cell-cell contact with T-cells through MHC-II with antigen (DC) and the 
T-cell Receptor  (1). Additionally, a co-stimulatory signal is given to the T-cell by the DC through 
engagement of CD80/86 and CD28 (2). The final instructions given by antigen presenting cells 
(APCs) is mediated by cytokines (3). These proteins create an environment that determines 
the T-cell subset that is formed. 
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(58). TLR stimulation on chondrocytes induces matrix metalloproteinase 
(MMPs) expression that degrades the extracellular matrix of chondrocytes and 
thereby causes cartilage erosion (59). Fibroblasts have been perceived as simple 
bystanders during inflammation for a long time. Over recent years, however, it 
has appeared that fibroblasts are actively involved in joint inflammation and can 
actually initiate inflammation (60-62). TLR activation on fibroblasts is a potent 
trigger for cyto- and chemokine production and creates a more inflammatory 
environment in the joint cavity. In addition, fibroblasts are major contributors to 
cartilage erosion by producing MMPs during inflammation (63). This illustrates 
that TLRs are also important on non-immune cells and could play an important 
role in innate joint inflammation.
Figure 4. Putative inflammatory loop in rheumatoid arthritis
Cells in the joint are activated through TLR stimulation (1). This leads to the production of cyto- and 
chemokines that will draw inflammatory cells to the joint and initiates joint inflammation. During 
this inflammatory process the adaptive immunity will be involved by formation of antigen specific 
antibodies and activation of T-cells (2). This will result in joint destruction and endogenous TLR ligands 
(DAMPs) are released from this process (3). These DAMPs, and potential exogenous TLR ligands 
(PAMPs), can restimulate the TLRs on cells in the joint and the infiltrated inflammatory cells causing 
further aggravation of the arthritis and joint destruction.
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Putative perpetuating cycle of inflammation involving Toll-Like receptors
Toll-Like receptors appear to play a role in RA. TLRs are potentially involved in 
sustaining the inflammatory loop in chronic inflammation (Figure 4) (64;65). 
Either PAMPs or DAMPs trigger TLR activation and initiate an inflammatory 
response. After the first response the adaptive immunity will be involved and 
antigen specific T- and B-cells arise, increasing inflammation and joint destruction. 
During this process TLR stimulating ligands are generated by degradation of 
extracellular matrix or released from necrotic cells, such as fibronectin (40), 
heat shock proteins (36), hyaluronic acid fragments (35), and supposedly serum 
amyloid A proteins (66). These products in turn stimulate TLRs, further enhancing 
inflammation and increasing joint destruction.
Toll-Like receptors in rheumatoid arthritis
An increasing body of evidence indicates a role of TLRs in rheumatoid arthritis. 
TLR2 and TLR4 have been found in arthritic synovium and their expression is 
elevated compared to healthy controls (67-69). In addition to that, TLR7 and TLR8 
expression on macrophages and monocytes was found to be increased in RA 
patients (70). Besides increased expression of TLRs in synovium, these receptors 
are also functional. TLR2 activation increased chemokine expression (71) and 
stimulation of TLR2 and TLR4 on synovial tissue also shows increased response 
by producing increased levels of pro-inflammatory cytokines (72), which possibly 
fuels the inflammation. In addition, TLR2 and TLR4 stimulation induces RANKL 
expression in synovial fibroblasts, promoting osteoclastogenesis and subsequent 
bone erosion (73). Finally, spontaneous cytokine release from synovial explants 
can be decreased by over expressing a TLR signaling inhibitor (74;75) or by 
blocking TLR2 or TLR4 (76;77).
In addition to the ex vivo experiments with patient material, a study performed 
in patients with recent onset of RA has shown that these patients are TLR4 
hyperresponsive (78). Moreover, it was shown that patients with a mutation 
in TLR4, causing TLR4 hyper-responsiveness, did not respond to single disease-
modifying anti rheumatic drugs (DMARD) therapy and required combination 
DMARD therapy (79). Unfortunately, the exact role of TLRs in the pathogenesis 
of RA remains to be determined. This will be rapidly clarified when specific TLR 
inhibitors become available for patient treatment.
Toll-like receptors in experimental arthritis
In experimental arthritis models the role of TLRs in the pathogenesis has been 
extensively studied. The use of gene knock out animals has given a good insight 
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into the role of TLRs in disease progression. This has revealed that TLR2 is involved 
in joint inflammation induced by bacterial ligands injected directly into the joint 
cavity (80). Moreover, joint inflammation induced by intra-articular injections 
of zymosan is also partially TLR2 mediated (81). However, further investigation 
revealed that TLR2 deficiency in a systemic T-cell driven arthritis model 
increased inflammation and arthritis due to lack of proper inhibitory regulatory 
T-cell development (77). Other TLRs, such as TLR3 and TLR7, are possibly also 
involved in chronic experimental arthritis involving the adaptive immunity (82-
84). Interestingly, TLR expression is regulated by IL-17 (85). This important T-cell 
derived cytokine in arthritis therefore creates a feed forward loop between IL-17 
and TLR expression that can promote IL-17 driven processes.
Toll-Like receptor 4 in experimental arthritis
TLR4 has attracted considerable attention over recent years as a pivitol receptor 
in inflammation and immune activation. TLR4 has been shown to be particularly 
important in generating Th17 cells. Lack of TLR4 in the spontaneous IL-1Ra-/- 
arthritis model showed that TLR4 is involved in aggravating arthritis and promotes 
the development of Th17 in this T-cell driven arthritis (77). This was confirmed 
in another autoimmune model of arthritis in which Th17 levels were decreased 
when TLR4 was (71;86). The importance of TLR4 on APCs in experimental arthritis 
is further illustrated by animals lacking a natural TLR4 inhibitor (RP105) on APCs, 
that show increased arthritis and joint pathology (87), TLR4 blockade also showed 
therapeutic efficacy and reduced joint pathology (88). Taken together, these data 
suggest an important role of TLR4 in aggravating arthritis by increasing systemic 
Th17 levels and mediating joint destruction.
Controlling negative feedback on inflammation
Inflammatory signals elicit also negative feedback to limit progression and 
detrimental effects of inflammation. Besides several factors known to interfere 
with either receptor ligand interactions or signaling, a newly described pathway 
has attracted attention. This pathway involves a complex event that can be divided 
in three parts (89). First, an initial inflammatory trigger via TLRs induces expression 
of pro-inflammatory cytokines and type I interferons (90). Second, these products 
subsequently stimulate cells in an auto and paracrine manner inducing receptor 
expression of the TAM family, consisting of Tyro3, Axl, and Mer (89). And lastly, 
stimulation of these TAM receptors by their natural ligands Growth arrest specific 
6 (Gas6) and Protein S (Pros1) induces expression of suppressor of cytokine 
signaling (SOCS)1 and 3 (89;91). Both proteins are known to down regulate 
inflammation by interfering with downstream TLR signaling (92). SOCS1 directly 
interacts with Mal, blocking TLR2 and TLR4 signaling (93), whereas SOCS3 affects 
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the TRAF6 and TAK1 complex (94). Both events prevent further downstream 
signaling and subsequent activation of pro inflammatory transcription factors, 
such as NF-κB (95;96). The relevance of SOCS3 in experimental arthritis has been 
shown before by ectopic overexpression of SOCS3 in APCs, which ameliorated CIA 
and impaired T-cell development (97).
Therefore the TAM receptors form a potential new therapeutic tool to treat 
arthritis. Activation of these receptors does not block all pro-inflammatory activity 
of the immune system, but enhances the negative feedback that is potentially lost 
in autoinflammatory and autoimmune diseases. This enhancement can possibly 
halt progression of disease while not interfering with the natural host defense 
mechanisms.
Aim and outline of this thesis
The role of TLRs has been established in experimental animal models of arthritis 
and more evidence is gathered that TLRs and TLR activation play a role in RA. 
Further investigation on which cell compartment and where, systemic vs local, 
TLRs plays a dominant role is necessary for a complete understanding of the role 
of TLRs in arthritis. The TLR4 signaling pathways pose promising targets and by 
using gene therapy and knockouts we have studied the role of two TLR4 signaling 
pathways; the MyD88 dependent and the TRIF pathway. With this understanding 
novel methods to interfere with TLR4 activation were developed and tested.
To identify in which cell compartment TLR4 plays a dominant role in experimental 
arthritis bone marrow transplantation was performed to distinguish between 
bone marrow derived cells and resident cells (chapter 2). Interestingly, TLR4 
expression in both compartments was necessary to develop full blown arthritis. 
This important role of TLR4 expression locally in the joint was confirmed in a 
study where IL-1 was overexpressed intraarticularly. Compared with wild type 
animals, TLR4 deficient mice showed reduced joint destruction, indicating a role 
of TLR4 in the local inflammatory process (chapter 3). Locally TLR4 is involved 
in a putative inflammatory feedback loop in which endogenous ligands for TLR4 
play a crucial role. We have shown that a commonly used putative endogenous 
ligand, serum amyloid a, has inflammatory capacities due to minor amino acid 
changes, while its natural counterpart has only marginal effects (chapter 4). TLR4 
is commonly regarded as a key receptor in determining the antigen presenting 
cell (APC) activity. For that reason we attempted to knock down TLR4 on splenic 
APCs and thereby modulating the adaptive immunity during arthritis. 
19
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Remarkably, knock down of TLR4 splenic APCs did not ameliorate experimental 
arthritis, but caused an unexpected slight increase in arthritis (chapter 5). 
Several TLR4 signaling pathways have been studied. TLR4 signaling involves 
TGF-β activated Kinase 1 (TAK1) activation and results in activating the pro-
inflammatory transcription factor NF-κB. Here, we found that TAK1 is crucial in 
the monocyte and macrophage population and that TAK1 inhibition in these cells 
ameliorates experimental arthritis (chapter 6). However, TAK1 is not a suitable 
target to block TLR4 signaling in rheumatoid arthritis synovial fibroblasts (chapter 
7). TRIF signaling is largely unstudied and supposedly anti-inflammatory (98). 
Therefore, we determined the role of this pathway in T-cell dependent flare-up of 
experimental arthritis. Interestingly, TRIF appears to play a proinflammatory role 
during this T-cell dependent flare of arthritis (chapter 8).
A new successful approach to block TLR signaling and treat arthritis is described 
(chapter 9). This new approach is focused on increasing negative feedback on 
inflammation rather than blocking proinflammatory signals. This study shows 
that stimulation of a recently discovered family of receptors, the TAM receptors, 
that regulate TLR signaling can ameliorate arthritis.
Finally, the results of this thesis are summarized and the implications of the 
results are discussed (chapter 10).
20
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Abstract 
A prominent role of Toll-like receptor 4 (TLR4) in arthritis is emerging. TLR4 is 
functional on immune cells and stromal cells. The aim was to investigate the 
involvement of TLR4 on bone marrow (BM) derived and resident cells in arthritis.
Reciprocal sex-mismatched BM transplantation was performed between IL-
1Ra-/-TLR4+/+ and IL-1Ra-/-TLR4-/- double knockout animals in Balb/c background. 
Arthritis was assessed macroscopically and by histopathology. Immunity was 
evaluated by splenic cytokine production and flow cytometry on draining lymph 
node (DLN) cells. Arthritis progression was reduced to similar extent in animals 
lacking TLR4 on BM-derived, resident cells, or both. Histology revealed that joint 
inflammation was partially TLR4 dependent on either BM-derived or resident 
cells. TLR4 plays an additive role on BM-derived and resident cells in promoting 
cartilage erosion. In contrast, TLR4 was equally important on BM-derived and 
resident cells in mediating bone erosion. Systemically, TLR4 on both BM-derived 
and resident cells contributed to IL-17 production by splenic T-cells, whereas in 
the draining lymph nodes of arthritic joints this was not the case. Interestingly, 
in DLN the dominant cells producing IL-17 were CD4 negative and cell numbers 
were determined by TLR4 on the BM-derived cells. TLR4 is necessary on both 
BM-derived and resident cells for full-blown joint swelling, inflammation, and 
bone erosion. Furthermore, TLR4 on BM-derived and tissue resident cells show 
an additive effect in cartilage destruction. Interestingly, TLR4 on BM-derived and 
tissue resident cells are both required for IL-17 production in spleen, whereas 
only on BM-derived cells in DLN.
27
TLR4 participates on BM-derived and resident cells in experimental arthritis
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease culminating in inflamed 
joints. Chronic inflammation will lead to destruction of bone and cartilage in 
the joint and severely impair mobility. Although the initiating factor of RA is 
unknown, several mechanisms have been found to drive inflammation, such as 
Toll-like receptors (TLR). Expression of TLR2 and TLR4 has been found in synovial 
tissue of RA patients (1). Moreover, spontaneous cytokine release from synovial 
explants is partly mediated by TLR4 (2;3).
TLRs comprise a family of 13 different receptors that belong to the pattern 
recognition receptors and are involved in the innate immunity by recognizing 
pathogen associated molecular patterns (PAMPs) present on microorganisms. 
Upon receptor ligation, antigen presenting cells (APCs) upregulate co-stimulatory 
molecules on the cell surface and release cytokines, which act as second and 
third signals in T-cell activation. Therefore, TLRs play a crucial role in controlling 
T-cell differentiation and proliferation and form the bridge between the innate 
and adaptive immunity. 
Besides hematopoietic cells, TLRs are also present and functional on non-immune 
cells. For instance, TLR function on endothelial cells has been shown to be involved 
in angiogenesis (4) and upregulation of adhesion molecules (5). Moreover, TLR4 
expressed on endothelial cells only was sufficient for neutrophil influx and 
bacteria clearance (6). In addition, TLRs on chondrocytes has been implicated in 
mediating its own degradation by induction of matrix degrading enzymes (7). TLR 
expression and function on synovial fibroblast has been extensively studied and 
provided evidence that TLRs play a role on fibroblasts in the pathogenesis of RA 
(8-10).
In addition to recognizing microorganisms, TLRs can also be activated by 
endogenous ligands. These damage associated molecular patterns (DAMPs) and 
alarmins are released during inflammation, necrosis, or in response to tissue 
injury. Several of these DAMPS have been found in the arthritic joint, such as 
fibronectin (11), heat shock proteins (12), and breakdown products of hyaluronic 
acid (13). This could lead to an inflammatory loop where the breakdown products 
of inflammation stimulate TLRs and maintain inflammation.
Previous studies have demonstrated that TLR4 plays an important role in 
experimental arthritis. Blocking of TLR4 by B. quintana LPS decreased arthritis 
severity and joint pathology in a prophylactic and therapeutic manner (14). Further 
investigation of a spontaneous arthritis model, the IL-1 receptor antagonist (IL-
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1Ra) knock-out mice, showed that lack of TLR4 did not affect disease incidence, 
but reduced Th17 levels before disease onset and diminished arthritis severity 
in late stages of disease (15). This is in agreement with recent studies indicating 
a relevant role of Th17 cells in RA pathogenesis (16). These studies showed that 
TLR4 is not involved in onset of arthritis, but plays an important role in aggravating 
experimental arthritis (14;15;17)
TLR4 is expressed on immune and non-immune cells. Therefore, we set out to 
identify in which cellular compartment TLR4 plays a dominant role in experimental 
arthritis. To this end, a sex-mismatched reciprocal bone marrow transplantation 
between IL-1Ra knockout and IL-1Ra/TLR4 double knockout animals in Balb/c 
genetic background was performed. This enabled to discriminate between bone 
marrow derived cells, as a major source of APCs, and resident cells in the joint, 
such as endothelial cells, fibroblasts and chondrocytes. This will further pinpoint 
the role of TLR4 in arthritis. Here, we show that TLR4 on both BM derived cells 
and resident cells is necessary to obtain full-blown experimental arthritis. TLR4 is 
involved in both cellular compartments in mediating joint destruction and IL-17 
production by splenic T-cells. In draining lymph nodes, however, TLR4 on BM-
derived cells appears to be crucial in generating CD4- IL-17 producing cells.
Material and Methods
Animals
IL-1Ra-/- animals in Balb/c genetic background were kindly provided by M. Nicklin 
and were generated as previously described (18) and the IL-1Ra-/-TLR4-/- were 
generated as reported before (15). TLR4-/- animals were kindly provided by 
S. Akira (19). Animals were housed in filter top cages with food and water ad 
libitum. During transplantation, one week before bone marrow transplantation, 
and until ten days after transplantation, animals were caged in individually 
ventilated cages. Age matched littermates were used in all experiments. Animal 
studies were approved by the Institutional Review Board of Radboud University 
Nijmegen and were performed according the appropriate codes of practice.
Bone marrow transplantation
Age-matched and sex-mismatched bone marrow transplantations were 
performed as described previously (20). Ratio female-male recipients was on 
average 47-53% among groups. Briefly, one week before transplantation mice 
received ciprofloxacin (80 mg/l) and sucrose (6 g/l) in drinking water, until 10 
days after transplantation. Mice were irradiated with 7.5 Gy at four weeks of age 
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followed by intra venous injection of ten million bone marrow cells, harvested 
from femurs and tibias.
Y-chromosome staining
Bone marrow cells were flushed from femurs and forced through 70 µm mesh to 
yield single cell suspension. Cells were taken up in hypotonic 0.57% KCl solution for 
8 minutes at 37˚C followed by fixation in ice cold methanol-acetic acid. Cells were 
dropped on glass slides and Y-chromosome was detection using a biotinylated 
probe (Starfish, Cambio, UK), according to protocol of manufacturer. Briefly, 
probe was denatured for 10 minutes at 65°C en kept at 37°C for 60 minutes. Slides 
were dehydrated by serial ethanol washing followed by 1.5 minute denaturing 
in 70% formamide. Subsequently, slides were quenched in ice cold 70% ethanol 
for 4 minutes and dehydrated by serial ethanol washing. Probe was incubated 
overnight on the slides in a humidified chamber at 37°C. The probe was detected 
with streptavidin-FITC and cells were counterstained with DAPI. For each slide 
over 100 cells were counted in multiple areas of the slide and positive number of 
cells was expressed in percentages.
Clinical evaluation of arthritis
Development of arthritis was macroscopically scored using an arbitrary scoring 
system as follows: 0, no redness or swelling; 0.25, slight redness; 0.5 slight 
redness and swelling; 0.75-1.0, mild redness and swelling; 1.25-1.5, moderate 
redness and swelling; 1.75-2, severe redness and swelling. Only ankle joints that 
developed arthritis were evaluated.
Histology
Ankle joints were isolated and fixed in 4% paraformaldehyde for minimally 8 
days followed by decalcification in 5% formic acid and subsequently embedded 
in paraffin. Heamatoxlylin and eosin staining of 7 µm sections were used to 
determine inflammation (score 0-5) in a blinded manner, at least two section per 
joint. Safranin O and fast green staining was used to score cartilage destruction, 
on a scale from 0 to 5 in a blinded manner. At least 4 cartilage surfaces of three 
sections per joint. Bone erosion was scored on Safranin O stained sections in a 
blinded manner and at least 10 bone surfaces were scored in at least two sections 
per joint.
Cell isolation, purification, stimulation
At 25 weeks of age mice were sacrificed and cells were isolated. Peritoneal 
macrophages were isolated by lavage of the peritoneum with ice cold phosphate 
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buffered saline (PBS). Spleens were forced through 70 µm mesh and after 
erythrocyte lysis by osmotic shock. Cells (200,000 per well) were stimulated 
in RPMI 1640 (Invitrogen) with penicillin/streptomycin, pyruvate, and 100 µg/
ml LPS. Spleens were forced through 70 µm mesh and after erythrocyte lysis by 
osmotic shock. CD11b+ cells were isolated using specific MACS CD11b+ beads 
(Miltenyi, Utecht, The Netherlands). T-cells were subsequently isolated with anti-
CD3 MACS beads (Miltenyi, Utecht, The Netherlands). Cells (200,000 per well) 
were stimulated in RPMI 1640 (Invitrogen) with 10% FCS, penicillin/streptomycin, 
pyruvate, 50 ng/ml PMA, 1 µg/ml Ionomycin. Draining lymph nodes were 
extracted from knees and groins and a single cell suspension was obtained by 
forcing lymph nodes through 70 µm mesh and cultured in RPMI 1640 (Invitrogen) 
supplemented with 5% FCS penicillin/streptomycin, pyruvate, 50 ng/ml PMA, 1 
µg/ml Ionomycin, and Brefeldin A (BD Pharmingen).
RNA isolation and quantitative PCR analysis
Total RNA was extracted from cells using TRI reagent (Sigma) according to 
manufacturer’s protocol. Isolated RNA was treated with DNAse followed by 
reverse transcription of 1 µg RNA into cDNA using Moloney murine leukemia 
virus reverse transcriptase 0.5ug/µl ologo(dT) primers, and 12.5 mM dNTPs 
(Invitrogen). Quantitative real-time PCR was performed using the StepOnePlus 
sequence detection system (Applied biosystems, Foster City, CA) PCR was 
performed in a total reaction volume of 12.5 µl consisting of appropriate cDNA. 
Five µM of forward and reverse primer and the SYBR green PCR  master mix 
(Applied biosystems). PCR protocol consisted of 2 min at 50°C and 10 min of 
95°C, followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C. Quantification 
of PCR signals was achieved by calculating the difference between the cycle 
threshold value (Ct) of the gene of interest with the Ct value of their reference 
gene glycerldehyde-3-phophate dehydrogenase (GAPDH) for each sample (delta 
Ct) and expressed as relative mRNA expression (2-ΔCt).
Flow cytometric analysis DLN cells
Stimulated DLN cells (4 hours) were stained with anti-mouse CD4-APC (1:200) 
(BD Pharmingen) or IgG2a-APC controle (BD pharmingen) for 30 minutes at 4°C. 
Subsequently, cells were stained intracellularly with anti-IL17-FITC and anti-
IFNγ-PE or with their controls IgG1-PE and IgG1-FITC, respectively, according to 
instructions by manufacturer (BD Pharmingen). Stained cells were analyzed using 
FACScalibur (Becton Dickinson) and analyzed with FlowJo software.
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Cytokine measurements
IL6, IL-17A, and IFNγ levels in culture supernatants were measured on a 
Luminex-100 System (Luminex corp.) using a bead-based multiplex immunoassay 
(Milliplex, Merck Millipore). Data analysis was performed with Bio-Plex Manager 
software (Bio-Rad Laboratories).
Statistics
Statistical differences were determined by one-way ANOVA and appropriate post-
test in GraphPad 5.0 software, p values below 0.05 were considered significant.
Results
Complete bone marrow reconstitution and functional TLR4 chimeras
BM engraftment efficiency was determined by staining BM-derived cells with a 
Y-chromosome probe at time of sacrifice. Eighty percent of cells stained positive 
for the Y-chromosome probe in a female recipient of male BM (Figure 1A), 
whereas no cells contained a Y-chromosome in male recipients that received 
female bone marrow (Figure 1A-B). Reconstitution with TLR4-/- BM abolished the 
LPS response of peritoneal macrophages by 87% (Figure 1C). Conversely, TLR4+/+ 
BM restored the LPS response in peritoneal macrophages of TLR4-/- recipients 
(Figure 1C). These results indicate nearly complete reconstitution of the BM and 
functional TLR4 chimeras.
Figure 1. Engraftment assessment
Bone marrow cells were isolated from femurs at time of sacrifice and stained for Y-chromosome. A) 
Male bone marrow cells engrafted in female recipient mice stained with biotinylated Y-chromosome 
probe and detected with streptavidin-FITC. B) No Y-chromosomes were detected in a male recipient of 
female bone marrow. C) Peritoneal macrophages were isolated by lavage with cold PBS and stimulated 
with 100 ng/ml LPS. LPS response is reconstituted in TLR4-/- animals engrafted with TLR4+/+ BM and 
LPS response was abolished in TLR4+/+ animals that received TLR4-/- BM, determined by IL-6 mRNA 
expression, in TLR4-/- animals engrafted with TLR4+/+ BM. Data represented as mean ± SEM. Statistics: 
One-Way ANOVA, with Bonferonni post test (** p<0.01). n: TLR4+ host/TLR4+ BM = 6, TLR4+ host/
TLR4- BM = 7, TLR4- host/TLR4 BM = 6, TLR4- host/TLR4+ BM = 6.
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TLR4 on BM and resident cells contribute equally to arthritis
Arthritis incidence was monitored after BM transplantation (Figure 2A) and 
ranged from 50% to 87% between groups. Animals that expressed TLR4 on both 
resident and BM derived cells showed increased arthritis severity as compared to 
the animals that lacked TLR4 on either BM derived cells, resident cells, or both cell 
compartments (Figure 2B). This indicates that TLR4 on BM and resident cells are 
equally important in the progression of joint inflammation in this spontaneous 
poly-articular arthritis model.
TLR4 on BM and resident cells mediates joint pathology 
To evaluate the contribution of TLR4 on BM-derived and resident cells to 
inflammation, and cartilage and bone erosion, ankle joints were evaluated 
histologically. Only a trend was observed in the inflammation score of ankle 
joints from animals in all groups in which TLR4 was lacking (Figure 3A). Cartilage 
erosion, however, was significantly reduced in complete TLR4 knockout animals 
(Figure 3B). This points towards an additive contribution for TLR4 on both resident 
and BM derived cells in cartilage degradation, since both chimeras showed 
an intermediate degree of cartilage erosion. Bone erosion was significantly 
Figure 2. Arthritis incidence and severity of TLR4 chimeras
Arthritis development was evaluated over time by macroscopic scoring of the ankle joints. A) 
Disease incidence of bone marrow chimeras. B) Arthritis severity of bone marrow chimeras, 
arbitrary score of positive ankle joints (scale 0-2). Statistics: Data represented as mean + SEM. 
Two-Way ANOVA, with Bonferonni post test, compared to TLR4+ host/TLR4+ BM (* p< 0.05, ** 
p<0.01, *** p<0.001). n: TLR4+ host/TLR4+ BM = 9, TLR4+ host/TLR4- BM = 9, TLR4- host/TLR4 
BM = 13, TLR4- host/TLR4+ BM = 6.
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diminished when TLR4 was absent on either BM-derived cells, resident cells, 
or both and this suggests a crucial role of TLR4 expression on BM and resident 
cells together for bone erosion in experimental arthritis (Figure 3C). Figures 3D-G 
show representative histopathological images of the influence of TLR4 on either 
cellular compartment on the severity of joint inflammation and destruction.
TLR4 controls macrophage IL-6 and T-cell IL-17 production during arthritis
To determine the effect of TLR4 chimerism on innate immune cell activation 
during arthritis, splenic CD11b+ macrophages were isolated at 25 weeks of age 
and stimulated with PMA and ionomycin for imprinted cytokine production. No 
differences were observed in IL-1β, IL-23, or TGFβ mRNA expression in CD11b+ 
macrophages. However, Figure 4A shows that TLR4 on BM derived cells is 
responsible for IL-6 production by CD11b macrophages in the spleen, as a clear 
trend in IL-6 production can be observed. This suggests that TLR4 is involved in 
controlling IL-6 production by splenic macrophages. To examine whether this 
altered APC activity affected adaptive immunity, CD3+ cells from spleen were 
isolated at 25 weeks of age and IFNγ and IL-17A production was determined 
on mRNA and protein level. Figure 4B shows that IFNγ was only marginally 
affected by the absence of TLR4 on BM or resident cells, however a clear trend 
was observed in complete TLR4 knockout animals. Total lack of TLR4 caused a 
strong reduction of 78% in IL-17 production by splenic T-cells (Figure 4C). Again, 
the chimeric animals showed an intermediate level of IL-17 production. This 
suggests an additive contribution for TLR4 on both resident and BM derived cells 
in differentiation of splenic T-cells toward the Th17 subset.
TLR4 on BM-derived cells is responsible for CD4-IL-17A+ cells in draining lymph 
nodes
Cells from draining lymph nodes (DLN) were isolated and analyzed for the number 
IFNγ and IL-17A producing cells. Similar to the effects on IFNγ production found 
in the spleen, Th1 levels were slightly decreased in complete TLR4 knockouts in 
DLN and also CD4-/IFNγ+ cell numbers were marginally decreased when TLR4 was 
absent on BM derived cells (Figure 5A). In contrast, all chimeras showed a slight 
decrease in the number of Th17 cells in DLN compared with complete TLR4+/+ 
animals (Figure 5B). Interestingly, TLR4 appears to be responsible for promoting 
CD4-/IL-17A producing cells in DLN. Animals in which BM-derived cells lacked 
TLR4 showed significantly reduced levels of CD4-/IL-17A+ cells in DLN, whereas 
a TLR4-/- host with TLR4+/+ BM showed an intermediate level of CD4-/IL-17+ cells 
(Figure 5B). This indicates a crucial role of TLR4, in particular on BM-derived cells, 
in the development of CD4- IL-17A producing cells at the site of inflammation.
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Figure 3. Histological analysis of ankle joints
Knee joints were isolated and fixed in paraformaldehyde and subsequently embedded in paraffin. 7 
µm sections were stained with hematoxylin/eosin (inflammation) or safranin-o/fast green (cartilage 
and bone erosion). A) Microscopic score of inflammation (scale 0-5), infiltrate and exudate combined. 
B) Microscopic score of cartilage erosion (scale 0-5). C) Microscopic score of bone erosion (scale 0-5). 
Data represented as mean ± SEM. Statistics: One-Way ANOVA with Bonferonni post test (* p<0.05). n: 
TLR4+ host/TLR4+ BM = 11, TLR4+ host/TLR4- BM = 13, TLR4- host/TLR4 BM = 20, TLR4- host/TLR4+ 
BM = 12. D-G) Representative histological pictures of safranin O stained sections for determining bone 
and cartilage erosion. Magnification: 200x. Closed arrow heads: cartilage erosion, open arrow heads: 
bone erosion. Arbitrary scoring scales used in this experiment; inflammation, most infiltrated synovium 
obtained a score of 5; cartilage erosion, complete erosion is scored 5; bone erosion, complete breach 
of bone is scored 5. 
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Discussion
Previous publications point at a role for TLR4 in sustaining the putative 
inflammatory loop in the chronic phase of arthritis (21). To further pinpoint the 
role of TLR4 in experimental arthritis we performed a BM transplantation to 
discriminate between bone marrow derived and resident cells. 
In this study we found that TLR4 activation on both the resident cells and BM-
derived cells is important in the chronic phase of experimental arthritis. This 
revealed a complex interplay between BM-derived cells and resident cells in 
generating IL-17 producing T-cells and TLR4-mediated joint pathology. 
The decrease in arthritis severity in BM chimeras where TLR4 was lacking indicates 
that TLR4 is involved on both BM derived cells and resident cells in controlling 
inflammation. Lack of TLR4 on the BM derived inflammatory cells in the inflamed 
joint possible causes reduced activation by endogenous ligands derived from 
the destructive inflammation. This reduced activation will subsequently lead to 
reduced recruitment of other inflammatory cells into the joint. TLR4 on resident 
cells on the other hand, can also control chemokine production and fibroblasts 
are likely candidates for production of chemokines upon TLr4 stimulation. 
Additionally, fibroblasts are also important in cartilage breakdown by forming 
pannus tissue and producing matrix metallo-proteinases (MMPs). In contrast 
to inflammation, TLR4 appears to play an additive role on BM derived cells and 
resident in cartilage breakdown. TLR4 activation is an important proinflammatory 
signal for fibroblasts (22) and chondrocytes (23) to produce MMPs, but also 
macrophages contribute to the MMPs present at the site of inflammation (24). 
It appears that both the BM cells and the resident cells produce factors crucial 
in controlling osteoclast activity. Likely candidates are IL-6 by BM cells and TGF-β 
by resident tissue cells. Both these factors are also involved in development 
of Th17  (25;26) and this T-cell subset is strongly correlated with bone erosion 
(27). In accordance, when TLR4 is lacking on BM cells, resident cells, or both a 
trend towards decreased Th17 levels was observed in DLN of inflamed ankle 
joints. This is in line with previous studies showing a crucial role of TLR4 in T-cell 
differentiation (28).
This mechanism is perhaps also accountable for the results found on IL-17 
production by splenic T-cells, since the resident cells also appear, surprisingly, 
to be important in controlling IL-17 production by splenic T-cells on both mRNA 
and protein level. Several cytokines are important in developing Th17 cells, such 
as IL-1β, IL-6, IL-23, and TGF-β. Unfortunately, we were not able to determine 
the levels of cytokines, such as IL-6 and IL-17, directly at the site of inflammation 
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which could have given insight in the local process. Nonetheless, this experiment, 
and other research groups, has shown that IL-6 is derived from TLR4+ BM cells 
(29). The IL-1β production was found to be dependent on both the BM and 
resident cells (29-31) and also the TGF-β production was suppressed when TLR4 
is absent on BM, resident cells or both (29). Taken together, it appears that both 
the factors derived from BM cells and from splenic resident cells are crucial for 
the development of IL-17 producing cells. It has been shown before that splenic 
stroma cells are involved in maturing DCs in the spleen (32), and TLR4 on these 
stromal cells could potentially play a role in maturing the DCs. Therefore, the role 
of TLR4 is not confined to the BM cell compartment in the systemic development 
of IL-17 producing T-cells.
Figure 4. Cytokine production of spleen cells
Spleen were isolated at 25 weeks of age and CD11b+ and CD3+ cells were selected using MACS beads. 
Cells were stimulated with PMA and ionomycin for 24 hours. A) IL-6 mRNA expression and IL-6 protein 
production by CD11b+ cells isolated from spleen upon stimulation with PMA/ionomycin. B-C) IFNγ 
and IL-17A mRNA expression and protein expression by purified splenic CD3+ cells upon stimulation 
with PMA/ionomycin. Data represented as mean ± SEM. Relative expression: 2-dCt. Group size IL-6 
measurements: TLR4+ host/TLR4+ BM (n= 4 mRNA, n=10 protein), TLR4+ host/TLR4- BM (n= 7 mRNA, 
n=11 protein), TLR4- host/TLR4 BM (n= 3 mRNA, n=13 protein), TLR4- host/TLR4+ BM (n= 6 mRNA, 
n=11 protein). Group size  IFNγ/IL-17A measuments: TLR4+ host/TLR4+ BM (n= 4 mRNA, n=5 protein), 
TLR4+ host/TLR4- BM (n= 5 mRNA, n=7 protein), TLR4- host/TLR4 BM (n= 6 mRNA, n=6 protein), TLR4- 
host/TLR4+ BM (n= 6 mRNA, n=9 protein).
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Locally in the DLN we did find an essential role of TLR4 on BM derived cells in 
generating IL-17 producing T-cells, but not the Th17 cell. The nature of these CD4- 
IL-17 producing cells in our study remains unclear. Multiple studies have recently 
shown that also other than CD4+ T-cells can produce IL-17. A subset of CD8+ 
T-cells, the Tc17 cells, have been described to produce IL-17 and are involved 
in chemically induced diabetes (33) and psoriatic skin lesions (34). In addition, 
another T-cell population was found to produce IL-17 but did not express CD4 or 
CD8. These cells have been found in kidneys of SLE patients (35) and in respiratory 
infection in mice (36). Cells that are on the border of the innate and adaptive 
immunity, such as NKT cells, are also capable of producing IL-17.  These cells have 
been shown to produce vast amounts of IL-17 upon CD3 and IL-23 stimulation 
(37) and in particular the NK1.1- iNKT cells (38). Moreover, the iNKT cells have 
been shown to be important in experimental arthritis (39). Lastly, the γδ T-cells 
have been shown to produce IL-17 in response to mycobacterium infection (40) 
and IL-23 alone is sufficient to induce IL-17 production in these cells. Interestingly, 
IL-23R+ IL-17 producing γδ T-cells have been found in increased numbers in 
ankylosing spondylitis patients (41). Moreover, in arthritic mice the Vγ4+ γδ T-cells 
were particularly important in collagen-induced arthritis (42). Most importantly, 
unpublished observations showed us that 80% of IL-17 producing cells in the DLN 
of IL-1Ra-/- animals are γδ-TCR positive. This points towards an important role of 
this innate T-cell in IL-1Ra-/- animals. Whether the CD4- IL-17 producing cells in 
our BM chimeras are the γδ T-cells remains to be determined, but in any case it 
appears that TLR4 is important in controlling the IL-17 production by CD4- cells. 
The net effect on clinical outcome of TLR4 absence on BM cells, resident cells, or 
both was equal in our disease model. In other models a similar phenomenon was 
found as clinical disease outcome in infective pyelonephritis, abscess formation, 
was equal in bone marrow chimeras and total TLR4-/- animals (43).  Moreover, an 
alcohol induced liver damage model also showed similar liver damage when TLR4 
was lacking on the BM, residents cells or both (29). TLR4 probably plays different 
roles on BM and resident cells, nevertheless the net clinical outcome is identical. 
On BM cells TLR4 probably controls macrophage and dendritic cell activation and 
thereby controlling IL-17 production by CD4- cells in the joint. On resident cells 
TLR4 is possibly involved in regulating adhesion molecules on endothelium and 
cyto-, and chemokine expression by fibroblasts, which will determine leukocyte 
migration and extravasation into the joint as well as inducing TGFβ to drive 
Th17 differentiation. Despite different mechanisms and involvement of TLR4 on 
different cell types, the net outcome on disease severity is similar.
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In summary, we have shown an equally important role of TLR4 on BM cells and 
resident cells in joint swelling and joint pathology of experimental arthritis. 
BM cells and resident cells both determine IL-17 production by splenic T-cells. 
However, BM cells are crucial in the development of CD4- IL-17 producing cells 
that requires further identification. This study shows that TLR4 inhibition on 
specific cell types could be used to ameliorate arthritis and potentially decreases 
side effects.
Figure 5. Flow cytrometry of draining lymph node cells
A) Cells from DLN of the ankle joints were isolated at 25 weeks of age, with full-blown arthritis (end-
point) and stained for CD4 (extracellular) and IFNγ (intracellular). B) Cells from DLN of ankle joints 
stained for CD4 (extracellular) and IL-17A (intracellular). C) Representative FACS-plots of DLN cells 
gated negative for CD4 of three separate experiments and measurements. Data represented as mean 
± SEM. Statistics: Two-Way ANOVA with Bonferonni post test (** p<0.01, *** p<0.001). n: TLR4+ host/
TLR4+ BM = 8, TLR4+ host/TLR4- BM = 6, TLR4- host/TLR4 BM = 7, TLR4- host/TLR4+ BM = 6.
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Abstract
Toll-like receptors (TLRs) may contribute to the pathogenesis of chronic 
inflammatory destructive diseases through recognition of endogenous ligands 
produced upon inflammation or degeneration of extracellular matrix. The 
presence of endogenous TLR agonists has been reported in rheumatoid joints. 
In the present study, we investigated the significance of TLR2 and TLR4 activation 
by locally-produced endogenous ligands in the severity of joint inflammation and 
destruction. Local joint pathology independent of systemic immune activation 
was induced by overexpression of IL-1β and TNF in naïve joints using adenoviral 
gene transfer. Here we report that at certain doses IL-1-induced local joint 
inflammation, cartilage proteoglycan depletion and bone erosion is dependent 
on TLR4 activation, whereas TLR2 activation is not significantly involved. In 
comparison, TNFα-driven joint pathology seemed to be less dependent on TLR2 
and TLR4. The severity of IL-1-induced bone erosion and irreversible cartilage 
destruction was markedly reduced in TLR4-/- mice, even though the degree of 
inflammation was similar, suggesting uncoupled processes. Furthermore, the 
expression of Cathepsin K, a marker for osteoclast activity, induced by IL-1β 
was dependent on TLR4. Overexpression of IL-1β in the joint as well as ex vivo 
IL-1 stimulation of patellae provoked the release of endogenous TLR4 agonists 
capable of inducing TLR4-mediated cytokine production. These data emphasize 
the potential relevance of TLR4 activation in rheumatoid arthritis, particularly 
with respect to IL-1 mediated joint pathology.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by 
persistent joint inflammation and concomitant cartilage and bone destruction. 
Despite intensive research, many features of the immunopathology of RA are yet 
to be explored. The discovery of Toll-like receptors (TLRs) as essential components 
of the immune system has introduced new candidates to the field of research 
on the pathogenesis of arthritis. TLRs are a family of evolutionarily conserved 
transmembrane receptors, which are expressed by a variety of immune cells, 
including monocytes, macrophages, dendritic cells, neutrophils, B cells and 
certain types of T cells; however, non-immune cells such as fibroblasts and 
chondrocytes also express TLRs (1;2). The major function of TLRs is to recognize 
pathogen-associated molecular patterns (PAMPs), which are highly conserved 
in evolution and are shared by many microorganisms. At the same time, TLRs 
show considerable target specificity. For instance, diacylated and triacylated 
lipoproteins of Gram-positive bacteria are sensed by TLR2 in co-operation with 
TLR6 and TLR1, respectively; whereas Lipopolysaccharides (LPS) of Gram-negative 
bacteria are recognized by TLR4 (2). 
Signal transduction through TLRs leads to the activation of several transcription 
factors among which NF-κB and activator protein 1 (AP-1). Thereby, TLR activation 
controls the expression of a number of proinflammatory cytokines such as 
Interleukin-1 (IL-1), IL-6 and tumor necrosis factor (TNF), chemokines such as IL-8 
and macrophage inflammatory protein-1, and matrix metalloproteinases (MMPs) 
all of which are relevant to the pathogenesis of RA (3;4).
Besides PAMPs, TLRs are capable of recognizing endogenous ligands produced 
or released upon cell stress, inflammation or degradation of extracellular 
matrix. In this context, TLR4 can recognize some matrix components such 
as heparan sulphate and extra domain A (EDA) of fibronectin (5;6), while 
biglycan, hyaluronan fragments, high mobility group box 1 (HMGB1) and some 
endogenous heat shock proteins activate both TLR2 and TLR4 (7-9). The presence 
of endogenous TLR ligands such as fibronectin fragments, HMGB1 and heat-
shock proteins has been shown in rheumatoid synovium (10-14). It has been 
reported that rheumatoid synovial fibroblast-like cells synthesize EDA-containing 
fibronectin (15). Furthermore, some inflammatory cytokines of high interest in 
the field of rheumatology such as TNFα, IL-1 and IL-6 can induce the expression 
of HSP70 in cultured synovial fibroblast-like cells (12). Another endogenous TLR4 
ligand, the calcium-binding protein S100A8, has also been found in RA synovial 
membrane (16;17). Considering the highly inflammatory character of RA and the 
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accompanying damage to the extracellular matrix, other endogenous TLR ligands 
are also very likely to be present in arthritic joints. 
The idea of the involvement of TLR2 and TLR4 in RA is supported by their enhanced 
expression in blood and synovial cells of RA patients (18-21). In addition, monocyte-
derived dendritic cells and synovial macrophages from RA patients are over-
responsive to TLR2 and TLR4 stimulation compared to cells from healthy controls 
or cells from patients with other forms of inflammatory arthritis (22;23). Factors 
other than the level of TLR2 and TLR4 expression were suggested to contribute to 
the increased activation. As TLR-mediated inflammatory responses may induce 
further tissue damage and promote the generation of more endogenous ligands, 
it has been hypothesized that TLRs can engender a self-sustaining inflammatory 
loop responsible for chronic progression of inflammation (24;25). Nevertheless, 
the contribution of endogenous TLR ligands in the joint to local inflammatory 
and destructive processes has not thoroughly been studied yet. Therefore, we 
aimed to examine the involvement of endogenous TLR2 and TLR4 activation in 
joint inflammation, cartilage destruction and bone erosion in vivo.
It is of interest that exogenous TLR ligands including LPS have extensively been 
used to aggravate or reactivate arthritis in distinct animal models (26-29); 
however, the worldwide usage of microbial TLR ligands as adjuvants in arthritis 
models complicates the study of the contribution of endogenous ligands in 
arthritic process. In the present study, we used an adenoviral-based cytokine-
overexpressing system instead of the commonly-used arthritis models to 
circumvent the necessity of application of exogenous TLR2 and TLR4 ligands for 
evoking the immune response. TNFα and IL-1bβwere the cytokines overexpressed 
locally in the joints. Years of research has implicated prominent roles of these 
cytokines in arthritis, and their prolonged overexpression in animal joints mimics 
the inflammatory and destructive processes observed in RA. Since the model 
used here does not involve systemic or adaptive immune responses, it enables us 
to specifically study the role of endogenous TLR2 and TLR4 ligands produced at 
the site of inflammation in the affected joints.
Materials and methods
Animals
Male C57Bl/6 mice were purchased from Janvier, France. TLR2-/- and TLR4-/- mice 
in C57Bl/6 background were kindly provided by Prof. S. Akira (Osaka, Japan). 
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The mice were housed in filter-top cages, and water and food were provided 
ad libitum. Gender-matched animals (10-12 weeks of age) were used in all 
experiments. Animal studies were approved by the Institutional Review Board 
and were performed according to the related codes of practice.
Adenoviral vectors
AdIL-1β virus was kindly provided by Dr. C. D. Richards (McMaster University, 
Ontario, Canada) and was engineered as described previously (30). AdTNFα virus 
was a kind gift from Dr. J.K. Kolls (Children’s Hospital of Pittsburgh, Pittsburg, 
USA). Virus construction and production was as reported in previous studies (31). 
The empty viral vector Ad5del70-3 was used as negative control throughout the 
studies. 
Induction of arthritis using adenoviral transfer of IL-1β and TNFα genes
Local joint inflammation and destruction was induced in C57Bl/6 WT, TLR2-/- 
and TLR4-/- mice (n = 6 mice per group) by intraarticular injection of 6 μl saline 
containing 3.105 plaque forming units (PFU) AdIL-1β or 1.107 PFU AdTNFα virus. 
1.107 PFU of the control virus Ad5del70-3 was injected into the contralateral 
knee joint. In the following studies, the dose of AdIL-1β was enhanced to 3.106 
PFU per joint to enforce IL-1β-induced cartilage destruction. Previous reports 
have validated this adenoviral delivery system as an effective means of cytokine 
overexpression in synovial tissue (32;33).
Preparation of patella washouts and measurement of cytokines 
Patellae with surrounding tissue were isolated after intraarticular injection of 
the viruses. Patella washouts were prepared by culturing the patellae in PRMI 
containing 0.1% bovine serum albumin (BSA) for 1 hour at room temperature. 
Cytokine concentrations were determined using the Bioplex cytokine assays from 
Bio-Rad (Hercules, CA, USA) following the manufacturer’s instructions.
Histology
For histological assessment of arthritis, total knee joints were isolated at day 4 of 
viral transduction and fixed during 4 days in 4% formaldehyde, then decalcified in 
5% formic acid and embedded in paraffin. Tissue sections of 7 µm were stained 
using the Haematoxylin & Eosin to study the inflammatory cell influx or using the 
Safranin O staining to determine proteoglycan depletion and cartilage and bone 
destruction. Histopathological changes were scored on a scale from 0 to 3 by two 
observers in a blinded manner as described previously (26). 
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Isolation of RNA from synovial biopsies
Synovial biopsies from knee joints were isolated from lateral and medial sides of 
patellae using a 3 mm punch (Stiefel, Wachtersbach, Germany). Total RNA was 
isolated in 1 ml TRIzol reagent (Sigma, St. Louis, MO, USA), then precipitated with 
isopropanol, washed with 70% ethanol, and dissolved in water. RNA was treated 
with DNase and subsequently reverse transcribed into complementary DNA using 
oligo(dT) primers and MMLV reverse transcriptase.
Quantitative real-time polymerase chain reaction (PCR)
Quantitative real-time PCR was performed using the ABI Prism 7000 Sequence 
Detection System (Applied Biosystems) for quantification with SYBR Green and 
melting curve analysis. Primer sequences (forward and reverse, respectively) were 
as follows: for GAPDH (house-keeping gene), 5’-GGC-AAA-TTC-AAC-GGC-ACA-3’ 
(forward) and 5’-GTT-AGT-GGG-GTC-TCG-CTC-TG-3’ (reverse); for Cathepsin K, 
5’-GAA-GCA-GTA-TAA-CAG-CAA-GGT-GGA-T-3’ (forward) and 5’-TGT-CTC-CCA-
AGT-GGT-TCA-TGG -3’ (reverse). PCR conditions were as follows: 2 minutes at 
50°C and 10 minutes at 95°C, followed by 40 cycles of 15 seconds at 95°C and 1 
minute at 60°C, with data collection during the last 30 seconds. For all PCRs, SYBR 
Green Master Mix was used in the reaction. Primer concentrations were 300 nM. 
The threshold cycle (Ct) value of the gene of interest was corrected for the Ct of 
the reference gene GAPDH to obtain the ∆Ct, then ∆∆Ct was calculated compared 
to Addel control of mice with the same genotype.
Immunohistochemistry
The presence of active osteoclasts was evaluated by immunohistochemical 
staining for Cathepsin K on paraffin sections of the knee joints 4 days after viral 
transduction. The percentage of polymorphonuclear (PMN) and mononuclear 
cells (MNCs) was evaluated using staining for NIMP-R14 and F4/80 markers, 
respectively. Sections were deparaffinized in xylol and rehydrated in serial 
dilutions of ethanol. Endogenous peroxidase was blocked using 1% hydrogen 
peroxide for 15 minutes. For NIMP-R14, five minutes treatment with 0.1% 
trypsine/0.1% CaCl2 (pH 7.8) preceded this step. Sections were incubated with 
the following antibodies for 1 hour: rabbit anti-mouse Cathepsin K antibodies 
(200 μg/ml, kind gift of Dr. E. Sakai, Nagasaki, Japan), rat anti-mouse NIMP-R14 
(500 μg/ml, kind gift of Dr. M. Strath, London, UK) and rat anti-mouse F4/80 
(500 μg/ml, AbD Serotec). Rabbit normal IgG (Santa Cruz Biotechnology) and 
rat IgG2b (BD Pharmingen) were used as negative controls. Subsequently, 
sections were incubated with biotinylated swine anti-rabbit or rabbit anti-rat 
antibodies, followed by peroxidase labeled streptavidin. Color was developed 
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with diaminobenzidine, and tissues were counterstained with Hematoxylin. 
Staining was performed on two tissue sections per mouse (n = 5 WT and n = 6 
TLR4-/- mice). Cathepsin K positive cells were quantified along the bone surfaces 
in the patella-femur area using Leica Qwin software (Leica Microsystems, Rijswijk, 
The Netherlands). Mean number of positive cells per 1000 nm2 for each mouse 
is depicted in the graph. Percentage of NIMP-R14 and F4/80 positive cells was 
scored arbitrarily in two sections per mouse in a blinded manner.
Assessment of endogenous TLR4 ligands in patella washouts upon IL-1 
overexpression or stimulation
HEK293 and HEK293-mTLR4/MD2/CD14 were purchased from InvivoGen and 
cultured according to the manufacturer’s guidelines. For stimulations, 5.104 cells/
well were used in flat-bottom 96-wells plates. To validate the HEK293-mTLR4 
cellular response, cells were stimulated with hIL-1β and hTNFα both 10 ng/ml, 
R&D), Pam3Cys (10 μg/ml, ECM Microcollections), Poly I:C (25 μg/ml, InvivoGen), 
LPS (10, 100 and 1000 ng/ml, Sigma) and Gardiquimod (1 μg/ml) for 24 hours. To 
assess the induction of TLR4 agonists by IL-1 and TNF, one hour patella washouts 
obtained upon several days of in vivo Addel or AdIL-1β overexpression, or 
supernatants of patellae ex vivo cultured with IL-1β or TNFα (10 ng/ml each, n = 
6 patellae per group) for 24 hours were added to HEK293 and HEK293-TLR4 cells 
in a volume ratio of 1:10. Assays were performed in triplicate and human IL-8 was 
measured in culture supernatants as readout using the Bioplex cytokine assays. 
Where mentioned, 1 μg/ml TNF blocker Enbrel (Amgen, Thousand Oaks, CA) was 
added to the cultures in order to inhibit the TLR4-independent TNF-mediated 
response. HEK293-TLR4 cells were preincubated with 1 μg/ml B. quintana LPS as 
a TLR4 antagonist (34;35) for 30 minutes to specifically inhibit the TLR4-mediated 
response.
Statistical analysis
Group measures are expressed as the mean + SEM. Statistical significance was 
assessed using the Mann Whitney U test performed on GraphPad Prism 4.0 
software (GraphPad software Inc., USA). P values lower than 0.05 were considered 
significant.
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Results
Local cytokine production upon adenoviral gene transfer of IL-1β and TNFα
Local IL-1β and TNFα production was determined after adenoviral gene transfer of 
these cytokines into the naïve joints of C57Bl/6 WT mice. Intraarticular injection 
of AdIL-1β or AdTNFα virus in the wild-type mice resulted in the production of 
high levels of the respective cytokine detectable in the patella washouts one 
day after gene transfer (Figure 1). Concentrations of both cytokines decreased 
in time, with low levels being still detectable at day 11 (153.1 ± 20.8 pg/ml IL-1β 
for AdIL-1 and 120.0 ± 29.8 TNFα for AdTNF). Comparison of the local cytokine 
concentration in WT, TLR2-/- and TLR4-/- mice revealed that TLR2 and TLR4 
gene deficiency did not affect the viral transduction or cytokine production, as 
the cytokine expression was similar in the three groups (Figure 1). Furthermore, 
intraarticular injection of a similar dose of the control virus Ad5del70-3 into the 
joint did not induce detectable levels of IL-1β or TNFα (data not shown). 
Joint pathology upon adenoviral overexpression of IL-1β and TNFα
Prolonged expression of IL-1β or TNFα in the knee joints of wild-type mice induced 
pathological changes in the joint resembling those observed in RA. These included 
joint inflammation, i.e. synovial hyperplasia and inflammatory cell influx, bone 
erosion and depletion of matrix proteoglycans (PG) in articular cartilage (Figure 
2). The Ad5del70-3 virus used as negative control throughout the experiments 
sporadically induced very low degree of synovial inflammation, but was unable to 
cause any sign of cartilage or bone damage in WT or TLR-/- animals (Figure 2A). 
Figure 1. Induction of high intraarticular expression of IL-1β and TNFα in WT, TLR2-/- and TLR4-
/- mice
IL-1β or TNFα overexpressing adenoviruses (3.5x105 and 1x107 PFU per joint, respectively) 
were injected into the knee joints of naïve mice and concentrations of the respective cytokines 
were measured using the Bioplex cytokine assays in the patella washouts collected one day after 
injection. Values represent the mean ± SEM of 6 mice per group. Injection of 1x107 PFU per joint 
of the control virus Addel did not induce any detectable levels of cytokines in WT or TLR-deficient 
mice (not shown).
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The severity of synovial inflammation, PG depletion and bone erosion in the WT 
mice was similar for IL-1 and TNF overexpression at the virus doses chosen here. 
Neither AdIL-1β nor AdTNFα induced erosion of cartilage surface at these doses. 
Although IL-1β production upon its adenoviral overexpression was similar in WT 
and TLR-/- mice (Figure 1), the severity of joint inflammation was significantly 
reduced in TLR4-/- mice compared to WT mice at the AdIL-1β dose used here 
(Figure 2B). Immunohistochemical staining for NIMP-R14 and F4/80, markers for 
polymorphonuclear (PMN) and mononuclear cells (MNCs), respectively, revealed 
the presence of PMNs and relatively lower numbers of MNCs (Table 1). Despite 
significant reduction in the extent of synovial inflammation in TLR4-/- mice (Figure 
2B), the composition of exudate as well as infiltrate cells remained unchanged 
(Table 1), suggesting a general effect on various cell types. 
In addition to synovial inflammation, joints of TLR4-/- mice exhibited also less 
severe PG depletion and bone erosion compared to WT mice (Figures 2C and 
D). TLR2-/- animals tended to have reduced joint inflammation and bone erosion; 
however, this reduction did not reach statistical significance (Figures 2B and D). 
Proteoglycan loss in the cartilage of TLR2-/- mice was not affected as well (Figure 
2C). 
In comparison with IL-1, TNFa-induced joint inflammation remained unaffected in 
the knockout mice, and PG depletion and bone erosion seemed less dependent 
on TLR2 and TLR4, as no significant differences were found between WT and 
TLR-/- mice (Figures 2E-G). Representative images of the joint inflammation and 
damage upon IL-1β overexpression in WT mice in comparison with TLR2-/- and 
TLR4-/- mice are shown in Figure 3. 
Table 1. TLR4 deficiency does not affect the composition of inflammatory cells in the joint despite 
significant reduction in the extent of inflammation.
Synovial inflammation was scored on Haematoxylin & Eosin-stained joint sections obtained at day 4 of 
intra articular injection of AdIL-1β (3.5x105 PFU per joint). Percentages of cells expressing NIMP-R14 
and F4/80, markers for polymorphonuclear and mononuclear cells, respectively, in infiltrate and 
exudate cells were scored on immunohistochemically-stained sections. * = P < 0.05 compared to WT 
by Mann-Whitney U test.
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Figure 2. TLR4 dependency of local IL-1-induced joint pathology
A: Minor histological changes at day 4 of intraarticular injection of the Addel control virus (1x107 
PFU per joint). Figures B-G show the histological scores of arthritis in WT (black bars), TLR2-/- (grey 
bars) and TLR4-/- (white bars) mice at day 4 of intraarticular overexpression of AdIL-1β (3.5x105 PFU 
per joint, B-D) or AdTNFα (1x107 PFU per joint, E-G). Synovial inflammation (B and E) was scored on 
Hematoxylin and Eosin-stained tissue sections. Proteoglycan depletion (C and F) and bone erosion (D 
and G) were scored on Safranin O-stained sections. Each parameter was scored on a 0-3-point scale 
in a blinded manner. Values are the mean ± SEM of 6 mice per group. n.s. = not significant, n.d. = not 
detectable. * = P < 0.05 compared to WT by Mann-Whitney U test.
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IL-1-mediated cartilage destruction partially depends on TLR4 activation
Considering the more striking TLR4 dependency of IL-1-driven joint pathology, 
further studies focused on IL-1β-induced arthritis. IL-1 inhibits chondrocyte PG 
and collagen synthesis at low concentrations; however, at high concentrations it 
also stimulates the synthesis of matrix degenerating proteases (36). Therefore, we 
enhanced the dose of AdIL-1β to enforce cartilage destruction. Joint inflammation 
upon intraarticular injection of the enhanced dose of AdIL-1β was increased to 
near maximum score and was similar in WT, TLR2-/- and TLR4-/- animals (Figure 
4A). At this dose, a marked erosion of articular cartilage was observed in the WT 
mice (Figures 4B and C). Interestingly, the severity of cartilage destruction was 
clearly diminished in TLR4-/- mice compared to WT animals despite similar degree 
of joint inflammation (Figures 4B and C). TLR4-/- mice remained significantly 
protected at later time point (day 11 of virus injection), when severe erosion of 
articular cartilage was apparent (data not shown). TLR2-/- animals had a similar 
extent of cartilage erosion as the WT mice, again emphasizing the specific TLR4 
dependency of IL-1-mediated cartilage destruction. 
Severe bone erosion and osteoclast formation upon IL-1β overexpression is 
dependent on TLR4
Prolonged presence of high doses of IL-1β caused severe bone 
erosion in patella as well as femur of WT mice (Figure 5A). Although 
TLR2-/- mice had similar degree of bone erosion as the WT mice, 
TLR4-/- animals expressed substantially less bone erosion (Figure 5A). Remarkably, 
a large number of multinucleated cells with osteoclast-like morphology were 
observed along the outer bone surfaces as well as in the intratrabecular space 
in HE-stained tissue sections of the WT mice. Therefore, we examined the 
expression of the osteoclast marker Cathepsin K using quantitative PCR and 
immunohistochemistry, and compared WT and TLR4-/- mice in this respect. 
Expression of Cathepsin K mRNA in synovial tissue of WT mice was upregulated 
by IL-1 overexpression compared to Addel control (Figure 5B). While TLR2-/- 
mice showed similar upregulation, TLR4-/- mice had approximately 40% lower 
expression (Fig. 5B). On immunohistochemistry, Cathepsin K protein was highly 
expressed in osteoclast-like cells adjacent to the bone surface in WT mice (Figures 
5C and D). Quantitative analysis revealed that, consistent with PCR data, Cathepsin 
K protein expression was significantly reduced in TLR4-/- knee joints compared 
to the WT joints (Figure 5C). A representative picture of the multinucleated 
Cathepsin K-expressing cells is shown in Figure 5D.
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IL-1, but not TNF, induces release of endogenous TLR4 agonists from patella.
In vivo data indicated the involvement of TLR4 activation in the severity of 
joint inflammation and destruction upon overexpression of IL-1β. To assess 
the capability of IL-1β and TNFα to induce endogenous TLR4 agonists, we used 
HEK293 cells stably expressing components of the murine TLR4 complex (TLR4, 
MD2 and CD14). Validation of the cytokine response of this cell line to a range 
of cytokines and TLR ligands revealed that HEK-TLR4 cells produce IL-8 in a dose-
dependent manner upon stimulation with LPS (Figure 6A). While no response to 
TLR2 and TLR7 ligands (Pam3Cys and Gardiquimod, respectively) were observed, 
low response to TLR3 stimulation (Poly I:C) was detected. Importantly, HEK-TLR4 
cells did not respond to IL-1β itself, while being sensitive to TNFα (Figure 6A).
Incubation of HEK-TLR4 cells with patella washouts from AdIL-1β-transduced 
WT joints resulted in robust TLR4 activation and high cytokine production, an 
effect not found upon stimulation with washouts from the Addel-transduced 
Figure 3. Representative images of the knee joints at day 4 of AdIL-1β overexpression
Left panels show synovial inflammation on Hematoxylin and Eosin (H&E)-stained sections and right 
panels show proteoglycan depletion (loss of red staining) on Safranin O-stained sections. Both 
parameters were reduced in TLR4-/- (lower panels) compared to WT (upper panels) and TLR2-/- 
(middle panels) mice. Original magnification x100 for H&E and x200 for Safranin O staining. B=bone, 
C=cartilage, F=femur, JS=joint space, P=patella.
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joints (Figure 6B). This indicates that AdIL-1β overexpression in the joint induces 
the release of endogenous TLR4 ligands from patellae and the surrounding 
synovial tissue. Interestingly, these effects could be mimicked ex vivo when 
naive WT patellae were stimulated with recombinant IL-1β. Patellae with 
minimal surrounding tissue were incubated with IL-1 or TNF for 24 hours and 
the culture supernatants were used to detect TLR4 agonists using the HEK-TLR4 
cell line. Since the latter cells respond to TNFα and TNFα might be present in 
the supernatants, high concentrations of the TNF blocker Enbrel, revealed to 
completely inhibit TNFα effects in the same assay, were added to inhibit non-
specific responses. As expected, supernatants of IL-1-stimulated patellae induced 
TLR4 activation; however, supernatants from TNF-stimulated patellae did not 
(Figure 6C). The negative control cell line HEK293 did not respond to any of these 
stimuli, excluding any non-TLR4 mediated response of the cells (Figure 6C). The 
cytokine response of HEK-TLR4 cells to IL-1-stimulated patella supernatants was 
abolished in the presence of TLR4 antagonist, confirming the TLR4 specificity of 
the response (Figure 6D).
Figure 4. TLR4 dependency of local IL-1 induced cartilage destruction despite similar synovial 
inflammation
Data show joint pathology at day 4 of high AdIL-1β overexpression (3.5x106 PFU per joint). Synovial 
inflammation (A) was scored on Hematoxylin and Eosin-stained, and cartilage destruction (B) was 
scored on Safranin O-stained sections on a 0-3-point scale. Values are the mean ± SEM of at least 
5 mice per group. n.s. = not significant. ** = P < 0.01 compared to WT by Mann-Whitney U test. C: 
Representative images of Safranin O-stained tissue sections showing reduced joint pathology in TLR4-
/- mice compared to WT and TLR2-/- mice. Open and stealth arrows indicate cartilage destruction and 
bone erosion, respectively. Original magnification x100.
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Figure 5. TLR4 dependency of local IL-1-induced bone erosion 
(A) and Cathepsin K expression (B-D) despite similar synovial inflammation at day 4 of high AdIL-1β 
overexpression (3.5x106 PFU per joint). Cathepsin K mRNA expression (B) was measured by quantitative 
real-time PCR. The threshold cycle (Ct) value of Cathepsin K was corrected for the Ct of the reference 
gene GAPDH to obtain the ΔCt, then ΔΔCt was calculated compared to the Addel control. Cathepsin 
K protein expression (C) was detected by immunohistochemistry and quantified using Leica Qwin 
software. Values in A (n ≥ 5) and B (n = 4) are the mean ± SEM. The horizontal bars in C represent the 
mean. n.s. = not significant. * = P<0.05 compared to WT by Mann-Whitney U test. D: Representative 
images of immunohistochemical staining of Cathepsin K, the osteoclast marker involved in bone 
resorption. Positive cells at the outer surface of the bone, mineralized cartilage and the intratrabecular 
space are depicted in the figure. Original magnification x200. P = patella; F = femur.
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Discussion
We have recently demonstrated the involvement of TLR4 activation in two 
chronic destructive models of arthritis, i.e. collagen-induced and spontaneous IL-
1rn-/- arthritis, in which the adaptive immune response represents a central part 
of the pathogenesis (34;37).  The dominant role of TLR4 in the established phase 
of arthritis rather than the onset suggested the contribution of endogenous 
rather than exogenous TLR4 agonists in arthritic process. In the present study, 
we addressed the question whether locally produced endogenous TLR2 or TLR4 
ligands contribute to the severity of inflammatory and destructive processes in 
the joint. Here we used sustained local overexpression of IL-1β and TNFα as model 
cytokines for RA and excluded any effect of TLR2 or TLR4 gene deficiency on the 
viral transduction and the induced cytokine production (Figure 1). The failure to 
distinguish between the immunomodulatory roles of TLRs and their sole innate 
activation by local endogenous ligands has been overcome in this model, as no 
systemic and adaptive immune activation is involved. 
Although both IL-1β and TNFα are produced in high concentrations by inflamed 
RA synovium and similarly stimulate the production of other inflammatory 
mediators such as IL-6, IL-8 and PGE2 (38-40), they exhibit specific characteristics 
as well. IL-1 inhibits chondrocyte anabolic functions and mediates breakdown 
of proteoglycans in cartilage (36). Furthermore, it promotes the production of 
nitric oxide and tissue destructive enzymes, and the activation of osteoclasts and 
bone resorption (39). TNFα is mainly involved in synovial inflammation through 
activation of endothelial cells and amplification of chemokines; however, it also 
contributes to osteoclast differentiation and activation via upregulation of RANKL 
expression on mesenchymal cells and T cells (41). Several animal models of 
arthritis support a central role for IL-1 in driving cartilage destruction, as opposed 
to the role of TNFα particularly in joint inflammation (42;43). In this study, higher 
concentration of AdTNFa virus was used compared to AdIL-1b virus in order 
to achieve similar joint inflammation and destruction and permit an equitable 
comparison of the two cytokines. Comparable degree of synovial inflammation 
and tissue damage induced by IL-1 and TNF would allow the production and 
release of similar amounts of endogenous TLR ligands in case both cytokines 
would possess this capability. 
Histological examination of the joints revealed TLR4 dependency of IL-1-induced 
local joint pathology. TLR4-/- animals were protected against multiple pathological 
effects mediated by IL-1 including synovial inflammation, cartilage proteoglycan 
depletion and bone damage (Figures 2 and 3), whereas the effects of TNF seemed 
less dependent on TLR4. Indeed, the subsequent ex vivo assays confirmed that 
58
Chapter 3
IL-1β was capable of inducing the release of endogenous TLR4 agonists from 
patella, whereas TNFα was not (Figure 6). The difference between IL-1 and TNF in 
this respect might have resulted from differential regulation of matrix degradading 
enzymes or differential induction of intracellularly expressed endogenous ligands; 
however, further studies in this respect are warranted. Involement of TLR4 in 
systemic TNF-driven arthritis models such as TNF transgenic model requires 
further investigation as well, as other immune processes might be involved there. 
Furthermore, a role for TLR4 seems plausible in later phases of TNF transgenic 
arthritis model where the disease pathogenesis becomes IL-1-dependent (44). 
Figure 6. IL-1β, but not TNFα, induces the release of endogenous TLR4 agonists from patellae
A: HEK293-mTLR4/MD2/CD14 cells were stimulated with IL-1β, TNFα and various TLR ligands. 
Stimulations were performed at least in triplicate. B: HEK293-mTLR4 cells were stimulated with patella 
washouts obtained at day 4 or 7 of in vivo Ad5del or AdIL-1β overexpression. A volume ratio of 1:10 
of patella washouts: culture medium was used. C: HEK293 and HEK293-TLR4 cells were stimulated 
with supernatants of patellae ex vivo cultured with IL-1β or TNFα (10 ng/ml each) for 24 hours. A 
volume ratio of 1:10 of the patella supernatants was used in the presence of the TNFα inhibitor Enbrel 
(1 μg/ml). D: HEK293-TLR4 cells were stimulated with E. coli LPS (100 ng/ml) or supernatants of ex 
vivo-cultured patella as in C, either or not following 30 minutes preincubation with TLR4 antagonist (1 
μg/ml). IL-8 was measured in 24 hours-culture supernatants using the Bioplex cytokine assay. Values 
are the mean ± SEM. n = 6 patellae per group in B-D; n.s. = not significant, n.d. = not detectable. 
* = P < 0.05 by Mann-Whitney U test.
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The presence of endogenous TLR2 ligands in the tested conditions cannot be 
excluded and might explain the tendency of reduced joint pathology in TLR2-/- 
animals. Nevertheless, TLR2 deficiency did not exert any considerable influence 
on local joint pathology in this model where adaptive immunity is not involved. 
Of high relevance, IL-1-driven cartilage and bone destruction was still TLR4 
dependent under the condition of similar degree of inflammation, as occurred 
when AdIL-1 dose was enhanced (Figures 4 and 5). This indicates that the role 
of TLR4 in inflammation may be uncoupled from its role in joint destruction and 
suggests that reduced cartilage and bone destruction in TLR4-/- mice does not 
necessarily rely on diminished inflammation. 
Given the poor regenerative capacity of cartilage and conceding the central role of 
IL-1 in cartilage destruction, the substantial role of TLR4 in IL-1-mediated cartilage 
destruction is of crucial importance. Besides enzymes released from synovial 
cells and the consequent breakdown of cartilage matrix, breakdown may have 
resulted from the direct TLR4 activation of chondrocytes and the induction of 
MMPs from the latter. A direct effect of TLR4 activation on chondrocyte anabolic 
function, e.g. collagen type II and aggrecan synthesis, has been reported before 
(1). In addition, TLR4 activation of primary osteoarthritic chondrocytes strongly 
induces MMP and NO release from these cells (45). In vivo evidence supporting 
the contribution of TLR4 to MMP-mediated cartilage destruction comes from 
our previous findings indicating TLR4-dependent expression of the MMP-specific 
aggrecan neoepitope VDIPEN in murine arthritic joints (46). Involvement of TLR4 
in cartilage destruction makes it an intriguing candidate to target in combination 
with TNF in order to provide protection against cartilage destruction, an area 
where TNF blockers seem to fail (47).
A role for TLR4 in driving Cathepsin K expression and the concomitant bone erosion 
(Figure 5) is in line with a previous report on promotion of osteoclastogenesis 
in monocyte cultures by TLR4 stimulation of the co-cultured fibroblast-like 
synoviocytes (48). Moreover, this observation is consistent with recent findings 
in another in vivo model of arthritis in which TLR4 activation was found to be 
partially responsible for Cathepsin K expression in the joint (46). 
The present data point toward a role for TLR4 in the “danger model” of immunity 
and hence, may have implications for other inflammatory and tissue-destructive 
diseases beyond RA. Evidence from non-infectious disease conditions such as 
myocardial and hepatic ischemia-reperfusion injury and non-bacterial lung 
injury supports the involvement of TLR4 activating self molecules in “sterile” 
inflammation (49-52). A role for TLR4 in atherosclerosis, where it might interact 
with endogenous ligands in atherosclerotic plaque, has also been indicated (53). 
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In the context of RA, several reports support the presence of TLR4 agonists in 
RA synovial fluid and serum, and indicate that activation of TLR4 by endogenous 
ligands partially defines the inflammatory character of RA synovial tissue (23;37). 
Indeed, the spontaneous production of proinflammatory cytokines and some 
MMPs by RA synovial membrane cells can be inhibited by overexpression of 
dominant-negative forms of MyD88 and Mal, two essential adaptor molecules in 
signaling through TLR2 and TLR4 (54). 
Endogenous TLR4 agonists may either be derived from the inflammatory or 
necrotic cells, or become released upon degradation of the extracellular matrix 
(ECM). Detection of endogenous TLR4 agonists in supernatants of patellae ex vivo 
cultured with IL-1 where inflammatory cells are absent (Figure 6) suggests resident 
components of the joint such as ECM as one of the sources of TLR4 agonists. 
Arthritic joints most presumably contain multiple TLR4 ligands, some of which 
might have greater clinical impact than others. For instance, concentration of 
EDA+ fibronectin in RA synovial fluid, but not plasma, is revealed to be a valuable 
predictor of radiographic joint destruction in RA patients (55). An important marker 
of inflammation, serum amyloid A (SAA) 3, has recently been reported to activate 
TLR4 using a higher affinity for the TLR4/MD2 receptor complex than the classical 
TLR4 ligand of microbial origin lipid A (56). Importantly, the human homologues 
of SAA3, i.e. SAA1 and SAA2, are upregulated in RA synovium, induced by IL-1β, 
and contribute to the production of MMPs by primary chondrocytes (57), hence 
representing good candidates to activate TLR4. The exact source and nature of 
endogenous TLR4 agonists in our system remain, however, to be determined. 
The relative contribution of various ligands and the insight in the mechanisms 
of TLR4 activation in RA will provide opportunities to develop novel RA-specific 
therapeutic interventions without interfering with innate immune function in 
anti-microbial defense. 
Acknowledgements
We are grateful to Prof. S. Akira (Osaka University, Osaka, Japan) for providing 
TLR2-/- and TLR4-/- mice and to Dr. C. Richards (McMaster University, Ontario, 
Canada) and Dr. J.K. Kolls (Children’s Hospital of Pittsburgh, Pittsburg, USA) for 
providing AdIL-1β and AdTNFα viruses, respectively. We would like to thank 
L. van den Bersselaar, B. Walgreen and M. Helsen for the technical assistance 
throughout the experiments. 
61
Local interleukin-1 driven joint pathology is dependent on Toll-like receptor 4 activation
References
1. Bobacz K, Sunk IG, Hofstaetter JG, Amoyo L, Toma CD, Akira S, Weichhart T, Saemann M, 
and Smolen JS: Toll-like receptors and chondrocytes: the lipopolysaccharide-induced 
decrease in cartilage matrix synthesis is dependent on the presence of toll-like receptor 4 
and antagonized by bone morphogenetic protein 7. Arthritis Rheum 2007, 56: 1880-1893
2. Hopkins PA and Sriskandan S: Mammalian Toll-like receptors: to immunity and beyond. Clin 
Exp Immunol 2005, 140: 395-407
3. Akira S, Uematsu S, and Takeuchi O: Pathogen recognition and innate immunity. Cell 2006, 
124: 783-801
4. O’Neill LA: When signaling pathways collide: positive and negative regulation of toll-like 
receptor signal transduction. Immunity 2008, 29: 12-20
5. Johnson GB, Brunn GJ, Kodaira Y, and Platt JL: Receptor-mediated monitoring of tissue well-
being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002, 168: 
5233-5239
6. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, and Strauss JF, 
III: The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001, 276: 
10229-10233
7. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, Stevenson MA, and Calderwood SK: 
Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor 
(TLR) 2 and TLR4. J Biol Chem 2002, 277: 15028-15034
8. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, Marsche G, Young MF, 
Mihalik D, Gotte M, Malle E, Schaefer RM, and Grone HJ: The matrix component biglycan 
is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin 
Invest 2005, 115: 2223-2233
9. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, Freudenberg M, 
Galanos C, and Simon JC: Oligosaccharides of Hyaluronan activate dendritic cells via toll-like 
receptor 4. J Exp Med 2002, 195: 99-111
10. Pisetsky DS, Erlandsson-Harris H, and Andersson U: High-mobility group box protein 1 
(HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 
2008, 10: 209
11. Roelofs MF, Boelens WC, Joosten LAB, Abdollahi-Roodsaz S, Geurts J, Wunderink LU, 
Schreurs BW, van den Berg WB, and Radstake TR: Identification of small heat shock protein 
B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of 
rheumatoid arthritis. J Immunol 2006, 176: 7021-7027
12. Schett G, Redlich K, Xu Q, Bizan P, Groger M, Tohidast-Akrad M, Kiener H, Smolen J, and 
Steiner G: Enhanced expression of heat shock protein 70 (hsp70) and heat shock factor 
1 (HSF1) activation in rheumatoid arthritis synovial tissue. Differential regulation of hsp70 
expression and hsf1 activation in synovial fibroblasts by proinflammatory cytokines, shear 
stress, and antiinflammatory drugs. J Clin Invest 1998, 102: 302-311
13. Scott DL, Delamere JP, and Walton KW: The distribution of fibronectin in the pannus in 
rheumatoid arthritis. Br J Exp Pathol 1981, 62: 362-368
14. Walle TK, Vartio T, Helve T, Virtanen I, and Kurki P: Cellular fibronectin in rheumatoid 
synovium and synovial fluid: a possible factor contributing to lymphocytic infiltration. Scand 
J Immunol 1990, 31: 535-540
15. Hino K, Shiozawa S, Kuroki Y, Ishikawa H, Shiozawa K, Sekiguchi K, Hirano H, Sakashita E, 
Miyashita K, and Chihara K: EDA-containing fibronectin is synthesized from rheumatoid 
synovial fibroblast-like cells. Arthritis Rheum 1995, 38: 678-683
16. Foell D, Wittkowski H, Vogl T, and Roth J: S100 proteins expressed in phagocytes: a novel 
group of damage-associated molecular pattern molecules. J Leukoc Biol 2007, 81: 28-37
17. Youssef P, Roth J, Frosch M, Costello P, Fitzgerald O, Sorg C, and Bresnihan B: Expression 
of myeloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid 
arthritis synovial membrane. J Rheumatol 1999, 26: 2523-2528
18. Seibl R, Birchler T, Loeliger S, Hossle JP, Gay RE, Saurenmann T, Michel BA, Seger RA, Gay 
62
Chapter 3
S, and Lauener RP: Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis 
synovium. Am J Pathol 2003, 162: 1221-1227
19. Iwahashi M, Yamamura M, Aita T, Okamoto A, Ueno A, Ogawa N, Akashi S, Miyake K, 
Godowski PJ, and Makino H: Expression of Toll-like receptor 2 on CD16+ blood monocytes 
and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2004, 50: 1457-
1467
20. Ospelt C, Brentano F, Rengel Y, Stanczyk J, Kolling C, Tak PP, Gay RE, Gay S, and Kyburz D: 
Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early 
rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. 
Arthritis Rheum 2008, 58: 3684-3692
21. Radstake TR, Roelofs MF, Jenniskens YM, Oppers-Walgreen B, van Riel PL, Barrera P, Joosten 
LA, and van den Berg WB: Expression of toll-like receptors 2 and 4 in rheumatoid synovial 
tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via 
interferon-gamma. Arthritis Rheum 2004, 50: 3856-3865
22. Huang Q, Ma Y, Adebayo A, and Pope RM: Increased macrophage activation mediated 
through toll-like receptors in rheumatoid arthritis. Arthritis Rheum 2007, 56: 2192-2201
23. Roelofs MF, Joosten LAB, Abdollahi-Roodsaz S, van Lieshout AW, Sprong T, van den Hoogen 
FH, van den Berg WB, and Radstake TR: The expression of toll-like receptors 3 and 7 in 
rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 
7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 2005, 52: 
2313-2322
24. Seibl R, Kyburz D, Lauener RP, and Gay S: Pattern recognition receptors and their involvement 
in the pathogenesis of arthritis. Curr Opin Rheumatol 2004, 16: 411-418
25. van den Berg WB, van Lent PL, Joosten LA, bdollahi-Roodsaz S, and Koenders MI: Amplifying 
elements of arthritis and joint destruction. Ann Rheum Dis 2007, 66 Suppl 3: iii45-iii48
26. Joosten LAB, Helsen MM, van de Loo FA, and van den Berg WB: Anticytokine treatment of 
established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-
TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996, 39: 797-809
27. Terato K, Ye XJ, Miyahara H, Cremer MA, and Griffiths MM: Induction by chronic autoimmune 
arthritis in DBA/1 mice by oral administration of type II collagen and Escherichia coli 
lipopolysaccharide. Br J Rheumatol 1996, 35: 828-838
28. Yoshino S and Ohsawa M: The role of lipopolysaccharide injected systemically in the 
reactivation of collagen-induced arthritis in mice. Br J Pharmacol 2000, 129: 1309-1314
29. Yoshino S, Yamaki K, Taneda S, Yanagisawa R, and Takano H: Reactivation of antigen-induced 
arthritis in mice by oral administration of lipopolysaccharide. Scand J Immunol 2005, 62: 
117-122
30. Rowan AD, Hui W, Cawston TE, and Richards CD: Adenoviral gene transfer of interleukin-1 
in combination with oncostatin M induces significant joint damage in a murine model. Am J 
Pathol 2003, 162: 1975-1984
31. Kolls J, Peppel K, Silva M, and Beutler B: Prolonged and effective blockade of tumor necrosis 
factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci U S A 1994, 
91: 215-219
32. de Hooge AS, van de Loo FA, Bennink MB, de Jong DS, Arntz OJ, Lubberts E, Richards 
CD, and vandDen Berg WB: Adenoviral transfer of murine oncostatin M elicits periosteal 
bone apposition in knee joints of mice, despite synovial inflammation and up-regulated 
expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand. Am J 
Pathol 2002, 160: 1733-1743
33. Goossens PH and Huizinga TW: Adenoviral-mediated gene transfer to the synovial tissue. 
Clin Exp Rheumatol 2002, 20: 415-419
34. Abdollahi-Roodsaz S, Joosten LAB, Roelofs MF, Radstake TR, Matera G, Popa C, van der 
Meer JW, Netea MG, and van den Berg WB: Inhibition of Toll-like receptor 4 breaks the 
inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 2007, 56: 2957-
2967
35. Popa C, Abdollahi-Roodsaz S, Joosten LA, Takahashi N, Sprong T, Matera G, Liberto MC, Foca 
A, van DM, Kullberg BJ, van den Berg WB, van der Meer JW, and Netea MG: Bartonella 
63
Local interleukin-1 driven joint pathology is dependent on Toll-like receptor 4 activation
quintana lipopolysaccharide is a natural antagonist of Toll-like receptor 4. Infect Immun 
2007, 75: 4831-4837
36. van de Loo AA and van den Berg WB: Effects of murine recombinant interleukin 1 on synovial 
joints in mice: measurement of patellar cartilage metabolism and joint inflammatio. Ann 
Rheum Dis 1990, 49: 238-245
37. Abdollahi-Roodsaz S, Joosten LAB, Koenders MI, Devesa I, Roelofs MF, Radstake TR, 
Heuvelmans-Jacobs M, Akira S, Nicklin MJ, Ribeiro-Dias F, and van den Berg WB: Stimulation 
of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J 
Clin Invest 2008, 118: 205-216
38. Brennan FM and McInnes IB: Evidence that cytokines play a role in rheumatoid arthritis. J 
Clin Invest 2008, 118: 3537-3545
39. Dinarello CA and Moldawer LL: Proinflammatory and anti-inflammatory cytokines in 
rheumatoid arthritis; a primer for clinicians. Amgen, 2000
40. van der Woude and Huizinga TW: Translating basic research into clinical rheumatology. Best 
Pract Res Clin Rheumatol 2008, 22: 299-310
41. Schett G, Hayer S, Zwerina J, Redlich K, and Smolen JS: Mechanisms of Disease: the link 
between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 2005, 1: 47-54
42. Joosten LAB, Helsen MM, Saxne T, van de Loo FA, Heinegard D, and van den Berg WB: IL-1 
alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-
induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J 
Immunol 1999, 163: 5049-5055
43. van den Berg WB: Joint inflammation and cartilage destruction may occur uncoupled. 
Springer Semin Immunopathol 1998, 20: 149-164
44. Zwerina J, Redlich K, Polzer K, Joosten L, Kronke G, Distler J, Hess A, Pundt N, Pap T, Hoffmann 
O, Gasser J, Scheinecker C, Smolen JS, van den BW, and Schett G: TNF-induced structural 
joint damage is mediated by IL-1. Proc Natl Acad Sci U S A 2007, 104: 11742-11747
45. Kim HA, Cho ML, Choi HY, Yoon CS, Jhun JY, Oh HJ, and Kim HY: The catabolic pathway 
mediated by Toll-like receptors in human osteoarthritic chondrocytes. Arthritis Rheum 
2006, 54: 2152-2163
46. Abdollahi-Roodsaz S, Joosten LA, Helsen MM, Walgreen B, van Lent PL, van den Bersselaar 
LA, Koenders MI, and van den Berg WB: Shift from toll-like receptor 2 (TLR-2) toward TLR-4 
dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with 
TLR-4-mediated interleukin-17 production. Arthritis Rheum 2008, 58: 3753-3764
47. Chopin F, Garnero P, le HA, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, 
Ravaud P, and Thomas T: Long-term effects of infliximab on bone and cartilage turnover 
markers in patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67: 353-357
48. Kim KW, Cho ML, Lee SH, Oh HJ, Kang CM, Ju JH, Min SY, Cho YG, Park SH, and Kim HY: Human 
rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via 
TLR-2 and TLR-4 activation. Immunol Lett 2007, 110: 54-64
49. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, Prestwich GD, Mascarenhas MM, Garg HG, Quinn 
DA, Homer RJ, Goldstein DR, Bucala R, Lee PJ, Medzhitov R, and Noble PW: Regulation of 
lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005, 11: 1173-1179
50. Taylor KR, Yamasaki K, Radek KA, Di NA, Goodarzi H, Golenbock D, Beutler B, and Gallo 
RL: Recognition of hyaluronan released in sterile injury involves a unique receptor complex 
dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem 2007, 282: 18265-18275
51. Oyama J, Blais C, Jr., Liu X, Pu M, Kobzik L, Kelly RA, and Bourcier T: Reduced myocardial 
ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004, 109: 784-
789
52. Tsung A, Hoffman RA, Izuishi K, Critchlow ND, Nakao A, Chan MH, Lotze MT, Geller DA, 
and Billiar TR: Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in 
nonparenchymal cells. J Immunol 2005, 175: 7661-7668
53. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth 
TB, and Arditi M: Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces 
atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl 
Acad Sci U S A 2004, 101: 10679-10684
64
Chapter 3
54. Sacre SM, Andreakos E, Kiriakidis S, Amjadi P, Lundberg A, Giddins G, Feldmann M, Brennan 
F, and Foxwell BM: The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute 
to the inflammatory and destructive processes in a human model of rheumatoid arthritis. 
Am J Pathol 2007, 170: 518-525
55. Shiozawa K, Hino K, and Shiozawa S: Alternatively spliced EDA-containing fibronectin in 
synovial fluid as a predictor of rheumatoid joint destruction. Rheumatology (Oxford) 2001, 
40: 739-742
56. Hiratsuka S, Watanabe A, Sakurai Y, kashi-Takamura S, Ishibashi S, Miyake K, Shibuya M, 
Akira S, Aburatani H, and Maru Y: The S100A8-serum amyloid A3-TLR4 paracrine cascade 
establishes a pre-metastatic phase. Nat Cell Biol 2008, 10: 1349-1355
57. Vallon R, Freuler F, sta-Tsedu N, Robeva A, Dawson J, Wenner P, Engelhardt P, Boes L, 
Schnyder J, Tschopp C, Urfer R, and Baumann G: Serum amyloid A (apoSAA) expression is up-
regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J 
Immunol 2001, 166: 2801-2807
65
66
Chapter 4
Is the SAA we use really SAA?
B. T. van den Brand 
C.E.J. Waterborg
W.B. van den Berg
F.A.J. van de Loo
Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, 
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
68
Chapter 4
Rheumatoid arthritis affects articulating joints resulting in destruction of bone 
and cartilage. The chronic inflammation is maintained by a putative inflammatory 
feedback loop involving Toll-Like Receptors and endogenous proteins, such as 
serum amyloid A (SAA) (1). Here, we would like to address a peculiar observation 
that the recombinant Apo-SAA protein used may not reflect the endogenous SAA 
protein.
Many pro-inflammatory properties have been described for the recombinant Apo-
SAA protein (PeproTech), used by Connolly et al. and many other research groups, 
such as IL-23p19 induction(2), inflammasome activation (3), angiogenesis(4) 
and fibroblast migration(5). The recombinant Apo-SAA commonly used has two 
amino acids substituted when compared with the endogenous Apo-SAA1. These 
modifications are on position 61 and 72 of the recombinant proteins. Amino acid 
61 in Apo-SAA1 is an aspartic acid and the Apo-SAA contains a asparagine (D61N) 
and amino acid 72 is a  histidine in A-SAA1 and an arginine in A-SAA (H72R). Both 
these substitutions are present in a natural isoform of human SAA2 (Apo-SAA2β).
We directly compared both commercially available recombinant Apo-SAA proteins 
for their pro-inflammatory properties. Figure 1A shows the effect of Apo-SAA1 
and Apo-SAA on NF-κB activation in NIH 3T3 murine fibroblast reporter cells. 
The recombinant endogenous Apo-SAA1 only slightly activated NF-κB at high 
concentrations (1.5 fold), whereas the modified recombinant Apo-SAA increases 
NF-κB activation 5.2 fold at a concentration of 50 µg/ml. This shows that Apo-
SAA1 is less potent in stimulating murine fibroblasts, whereas the modified 
Apo-SAA is a potent NF-κB activator. To rule out species differences recombinant 
Apo-SAA1 and recombinant Apo-SAA were used to stimulate rheumatoid arthritis 
synovial fibroblasts (RASF), known to produce and respond to Apo-SAA proteins. 
Figure 1B shows slight IL-8 mRNA regulation by endogenous recombinant Apo-
SAA1. In contrast, recombinant modified Apo-SAA induces IL-8 mRNA in a dose 
dependent manner. Thus, Apo-SAA1 and Apo-SAA also have different potencies 
on human cells. 
Possible explanations for this profound effect on biological activity could involve 
the isoelectric point (pI) of these proteins. Both mutations increase the pI from 
< 7.2 up to 7.2, resulting a shift from a negatively charged protein towards a 
neutral protein (Protein Calculator v3.3, www.scripps.edu) Additionally, tertiary 
protein structure is affected by these substitutions (I-TASSER software; Center for 
Computational Medicine and Bioinformatics University of Michigan) and could 
potentially lead to altered receptor binding and activation. Although this is based 
on theoretical calculations, it might give us an explanation how minor amino acid 
substitutions affect biological activity of proteins and peptides.
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In our hands recombinant Apo-SAA1 and Apo-SAA have different biological 
activities. Apparently, substitution of two amino acids can increase the pro-
inflammatory activity of Apo-SAA1, at least with regard to NF-κB activation 
and IL-8 mRNA induction. In addition, we are not the first questioning the pro-
inflammatory effects of SAA proteins. Björkman et al., reported that freshly 
isolated Apo-SAA1 from arthritis patients lacked biological activity when directly 
compared with Apo-SAA on neutrophils (6).  Whether these differential effects 
of recombinant Apo-SAA1 and Apo-SAA would also be found on more complex 
tissues, such as synovial explants, remains to be determined. We therefore 
recommend to include the endogenous Apo-SAA1 protein, either recombinant 
or isolated, in future studies to exclude misrepresentation of Apo-SAA1 protein 
activity. Additionally, this is an example that we should take care in using minimally 
modified proteins in biological assays.
Figure 1. Effect of Apo-SAA1 (denoted as SAA1) and Apo-SAA (denoted as SAA). 
(A) NF-κB activation in murine NIH 3T3 fibroblasts upon stimulation. Reporter cells stimulated for 6 
hours. (50 µg/ml corresponds to 2 µM.) (B) Stimulation of rheumatoid arthritis synovial fibroblasts 
(RASF), from three individual donors, with Apo-SAA1 and Apo-SAA for 6 hours. All stimuli included 
10 µg/ml polymyxin B to exclude lipopolysaccharide contamination. Relative expression: 2-ΔCt. Data 
represented as mean ± SEM. Statistics: one way-ANOVA, with Bonferroni post test compared to 
medium, *** p<0.001, ** p<0.01.
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Abstract
Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint 
destruction due to chronic inflammation. Antigen presenting cells (APCs) play 
an important role in RA and infiltrate the synovium of joints. Toll-like receptors 
(TLRs), also expressed by APCs, play a role in inflammation and TLR4 is particularly 
important for the aggravation of arthritis. Therefore, we investigated the role of 
TLR4 on APCs during arthritis. Mice with collagen-induced arthritis (CIA) were 
injected intravenously before onset of disease with lentivirus encoding short 
hairpin RNA against TLR4 (shTLR4) to knock down TLR4 gene expression on 
splenic APCs. Disease development was monitored macroscopically and knee 
joints were analyzed for histopathology. Draining lymph nodes were analyzed 
for T-cell subsets by flow cytomerty and inflamed synovium was analyzed for 
cyto- and chemokine mRNA expression. Unexpectedly, shTLR4 treatment led to 
a slight increase in incidence, macroscopic swelling and bone erosion. Analysis 
of T helper subsets revealed only marginal effects of shTLR4 in early stages of 
disease, which dissipated over time. shTLR4 did appear to be effective, since 
IFNγ producing cells were significantly decreased in DLN of shTLR4 treated mice, 
especially the number of CD4- cells producing IFNγ. Analysis of draining lymph 
nodes showed that chemokine production was increased, possibly reflecting the 
increase in swelling and inflammatory cell influx into inflamed knee joints. In 
conclusion, lentivirus encoding a short hairpin RNA against TLR4 targeting APCs 
before disease induction was not effective in ameliorating experimental arthritis. 
Targeting of TLR4 only on APCs might not be suitable to treat arthritis.
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Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by 
chronic synovial inflammation, synovial hyperplasia, and cartilage and bone 
destruction in multiple joints causing pain, discomfort and impairment of mobility 
(1). The mechanisms of initiation and advancement of inflammation in RA are 
still unknown. The discovery of Toll-like receptors (TLRs) as essential components 
of the innate immune system has introduced new candidates implicated in the 
development and progression of RA.
TLRs are part of the family pattern recognition receptors (PRRs) present on several 
immune cells, including macrophages, dendritic cells, B-, and T cells (2). TLRs are 
involved in the recognition of conserved pathogen-associated molecular patterns 
(PAMPs). TLRs can also recognize danger-associated molecular patterns (DAMPS) 
released during inflammation or necrosis (3). 
One of the TLRs that appear to be important for the progression of RA is TLR4. Ex-
pression of TLR4 in synovial tissue of RA patients is increased when compared to 
OA patients and healthy controls (4). The presence of endogenous TLR4 ligands, 
such as fibronectin, has also been demonstrated in synovium of RA patients (5). 
TLR4 also plays an important role in experimental arthritis. Systemic blocking of 
TLR4 in mice after induction of collagen-induced arthritis in mice resulted in de-
creased arthritis severity, breaking an inflammatory loop (6). Additionally, IL-1Ra/
TLR4 double-deficient mice were protected from severe disease and Th17 levels 
were reduced by 50% (7). This confirms the role of TLR4 in generating aggressive 
and destructive Th17 cells. Further studies have suggested a role for TLR4 both 
locally in the joint and systemically in generation of IL-17 producing T cells (8).
Moreover, synovial tissue of RA patients is heavily infiltrated by macrophages 
and this infiltration is strongly correlated with the disease severity (10). TLR4 
activation on macrophages isolated from RA synovium showed an increased 
response when compared to macrophages from other inflammatory disorders 
(9). Due to the increased expression and responsiveness it is conceivable that 
TLR4 is also involved in the inflammatory process in RA. 
Taking together all the evidence that point at TLR4 as a key receptor in 
development of RA and that APCs are key players in RA, we investigated the role 
of TLR4 activation on APCs. We aimed to knock down TLR4 gene expression by 
intravenous injecting lentivirus, specifically targeting splenic APCs (11;12). The 
lentivirus encoded a short hairpin RNA complementary to TLR4 mRNA, thereby 
inducing TLR4 mRNA degradation. We hypothesized that knocking down TLR4 on 
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APCs would lead to a reduction of both clinical and histological characteristics of 
CIA, via inhibition of Th17 differentiation.
Unexpectedly, shTLR4 treatment caused a trend in increased swelling and 
inflammatory cell influx. Additionally, a trend towards increased cytokine 
expression was observed in synovium of shTLR4 treated mice and this was 
accompanied by an increase in chemokine production in DLN and synovium. 
shTLR4 appeared to be functional in vivo since it decreased the number of 
IFNγ producing cells in DLN. This decrease was accompanied by an increase in 
chemokine production and an increased trend in swelling and cellular influx.
Materials and methods
Animals
Male DBA1/J mice aged 10-12 weeks (Janvier, Elavage, France) were housed in 
individually ventilated cages and fed a standard diet with freely available food and 
water. All in vivo studies complied with national legislation and were approved by 
local authorities for the care and use of animals with related codes of practice.
Cell culture
The Human Embryonic Kidney 293T (HEK293T) cell line was used for the 
production of lentivirus. The 3T3 NFκB luciferase fibroblast reporter cell line was 
used in functional assays with the produced lentivirus. Cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM; Gibco - Invitrogen, Paisley, United 
Kingdom) with 10% fetal calf serum (FCS), P/S or gentamycin, 1% pyruvate and 
during lentivirus production, 0.01mM cholesterol (Sigma, Steinheim, Germany) 
was added. Cells were cultured at 37°C and 5% CO
2
.
Production of lentivirus
The transfer vector for the lentivirus coding the short hairpin RNA against TLR4 
(shTLR4) and the short hairpin control (shCon; scrambled), both kindly gifted by P. 
Quax (Leiden University Medical Center). Plasmid DNA was isolated with the use 
of maxi-prep according to manufacturer’s protocol (Qiagen, Hilden, Germany). 
The resulting transfer vector (75,6 μg) was added to 56,35 μg MDL, 26.6 μg VSV-G 
and 18.9 μg RSV-REV and an alcohol precipitation was performed. Hereafter, the 
pellet was dissolved in aqua dest and used for CaPO
4
 transfection of HEK293T 
cells. Medium of day 1 and 2 after transfection was kept in 4°C and purified with 
a 20% sucrose cushion using Discovery 100 Sorvall centrifuge. Pellets were taken 
up in phosphate buffered saline (PBS) and stored at -80°C. Concentration of the 
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lentivirus was determined by performing p24gag ELISA according to manufacturer’s 
protocol (Innogenetics, Gent, Belgium). 
Reporter assay
3T3 NFκB luciferase fibroblast cells were plated in 96 wells plate with 30.000 
cells/well in 50 μl medium. Cells were transfected with 200 ng p24GAG/30.000 
cells in regular medium complemented with 8 μg/ml polybrene (Sigma). At 
day 6, cells were stimulated for 6 hours with lipopolysaccharide (LPS; 100 ng/
ml) or Pam3CysSerLys4 (P3C; 100 ng/ml). Hereafter, cells were lysed, Bright-Glo 
(Promega, Leiden, The Netherlands) was added and luminescence was measured 
using LUMIstar OPTIMA (BMG LABTECH, Cary, USA).
Bone marrow derived dendritic cells
Femurs and tibias of DBA1/J mice were flushed and bone marrow was harvested. 
After preparing a single cell suspension cells were plated (250,000 c ells per cm2) 
with 833 ng p24GAG equivalent of shControl or shTLR4 and 20 ng/ml GM-SCF. 
Medium was changed on day 4 and day 8. 
Induction of CIA
Bovine type II collagen was dissolved in 0.05M acetic acid to a concentration of 
2 mg/ml and was emulsified in equal volumes of Freund’s complete adjuvant (2 
mg/ml of Mycobacterium tuberculosis strain H37Ra) (Difco, Detroit, USA). Mice 
were immunized intradermally at the base of the tail with 100 µl of emulsion 
(50 µg of bovine type II collagen). After 18 days, 40 μg lentivirus, encoding 
shTLR4, shCon, TAK1/K63W or GFP (n=11), dissolved in 200 μl PBS was injected 
intravenously through the tail vain per animal. After 3 days, mice were given an 
intraperitoneal booster injection of 100 µg of type II collagen dissolved in PBS 
on day 21. Two independent observers monitored clinical signs of arthritis in 
paws and ankle joints, macroscopically scored using an arbitrary scoring system 
until the end of the experiment. Cumulative scoring based on redness, swelling, 
and, in later stages, ankylosis was as follows: 0=no changes; 0.25=1-2 toes red or 
swollen; 0.5=3-5 toes red or swollen; 0.5= swollen ankle; 0.5=swollen footpad; 
0.5=severe swelling and ankylosis (redness, excessive edema and deformation), 
with a maximal score of 2 per paw. 
Isolation, culture and stimulation of murine cells
Draining lymph nodes (DLN) were mashed and plated, 300,000 cells/well were 
cultured in RPMI, 5% FCS, 1% pyruvate, gentamycin and stimulated either with 
PMA (50 ng/ml; Sigma), ionomycin (1 µg/ml; Sigma) and golgi-plug Brefeldin A 
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(1 µl/ml; BD Biosciences - Pharmingen, Breda, The Netherlands) for 4 hours for 
fluorescence-activated cell sorting (FACS) staining or with PMA/ionomycin (same 
concentrations) for 24 hours for RNA isolation. 
Antibodies and FACS analyses
Th1 and Th17 cells in DLN were stained using anti-CD4-APC (1:200), then washed 
with PBS and fixed in Cytofix/Cytoperm paraformaldehyde containing saponin 
(BD Biosciences – Pharmingen). Subsequently, cells were washed with ICS 
buffer (PBS, 1% bovine serum albumin (BSA), 2% FCS, 0.1% saponin) and cells 
were stained with IL-17-PE and IFN-FITC. All antibodies were purchased from BD 
Biosciences – Pharmingen. Cells were analyzed using FACSCalibur flow cytometer 
(BD Biosciences – Pharmingen) and analyzed with FlowJo software.
RNA isolation
Synovium and liver samples were disrupted using the MagNaLyser (Roche, 
Woerden, The Netherlands). Total RNA was extracted from tissue homogenates 
and cells with TRIzol (Sigma), precipitated with isoproponal and washed with 70% 
ethanol and dissolved in water. To restrict DNA contamination, all samples were 
treated with DNAase and enzyme was inactivated with EDTA. RNA was reverse 
transcribed into cDNA using oligo-dT primers and reverse transcriptase.  
Quantative PCR
The quantative PCR (qPCR) was performed using the StepOnePlus sequence 
detection system (Applied biosystems, Foster City, USA) in a 96-wells plate. In 
every well, 5 μl SYBR Green Master Mix (Applied biosystems) and 1 μl forward 
and reverse primer (both 5 µM) were added. The genes investigated are shown 
per experiment. cDNA was diluted 1:10. The threshold cycle of the gene of 
interest was corrected for the reference gene glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH) to obtain the ΔCt. Data expressed as relative expression 
(2-dCt).
Histology
Whole knee joints were isolated at day 30 and fixed in phosphate buffered 4% 
formaldehyde for 21 days followed by decalcification with 5% formic acid and 
embedded paraffin wax. Tissue sections of 7µm were stained with hematoxylin 
(Merck, Darmstadt, Germany) and eosin (Merck) (H&E) to study inflammatory 
cell influx, or with safranin-O (BHD chemicals, Poole, UK) and fast green (BHD 
chemicals) to determine bone and cartilage erosion. Three sections per knee 
were scored on a scale from 0-3 in a blinded manner.
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Immunohistochemistry
Expression of GFP was evaluated in paraffin sections of the knee joints. Sections 
were incubated in citric buffer for 2 hours for antigen retrieval. Endogenous 
peroxidase was blocked using 3% H
2
O
2
 for 15 minutes. Tissue sections were 
incubated with rabbit anti-GFP antibodies or rabbit normal IgG (both 1:800; Cell 
Signaling, Boston, USA) overnight at 4°C followed by incubation with goat anti-
rabbit antibodies for 30 minutes. Colour was developed with diaminobenzidine 
and sections were counterstained with hematoxylin.
Measurement of cytokines
IL-6 and KC concentrations in serum were measured on a Luminex-100 System 
(Millipore, Billerica, USA) using a magnetic bead-based multiplex immunoassay 
(Millipore). Data analysis was performed with Bio-Plex Manager software (Bio-
Rad Hercules, Veenendaal, The Netherlands).  
Statistical analysis
All data are expressed as mean ± SEM. Statistical significance was determined 
using the Student’s unpaired t-test or Mann-Whitney U test, as shown per 
experiment, using GraphPad Prism 4.0 software (GraphPad Software, San Diego, 
USA). p-values less than 0.05 were considered statistically significant.
Results
Short hairpin RNA against TLR4 is functional in vitro
The hairpin against TLR4 was validated in vitro using murine NF-κB luciferase 
reporter NIH3T3 fibroblasts. Figure 1A shows that five days after transduction the 
NF-κB activation in 3T3 fibroblasts was decreased by shTLR4 after LPS stimulation. 
Moreover, NF-κB activation by Pam3Cys through TLR2 was not decreased, 
indicating TLR4 specific targeting by shTLR4. To evaluate the effectiveness of 
shTLR4 in target cells, antigen presenting cells, bone marrow derived macrophages 
(BMDM) were generated. Figure 1B shows that shTLR4 treatment reduced TLR4 
messenger RNA (mRNA) expression. shTLR4 treatment also resulted in a reduced 
LPS response, indicated by decreased production of IL-6 upon LPS stimulation 
(Figure 1B). A non significant increase of IL-6 mRNA expression was observed in 
cells treated with shTLR4 after Pam3Cys stimulation. Taken together, these data 
indicate that shTLR4 effectively reduces TLR4 mRNA expression and specifically 
reduces proinflammatory signaling and cytokine expression upon LPS stimulation.
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No reduction of clinical and histological characteristics of CIA with shTLR4
To study the role of TLR4 on APCs during collagen-induced arthritis shTLR4 
lentivirus was injected 5 days before onset of disease. As seen in Figure 2A, a 
trend towards increased disease incidence and disease severity was observed 
in the mice treated with shTLR4 when compared with shCon-treated group. On 
histology, no significant differences were found in bone erosion, cartilage erosion 
and a minor trend in cellular influx (Figure 2B). These data point at a trend towards 
increased inflammation when TLR4 expression was knocked down in APCs.
Increased cytokine expression in synovium of shTLR4 treated mice
To study expression levels of cytokines in synovium that mediate joint pathology, 
mRNA was isolated from synovium. In line with the macroscopic scores, a trend 
of increase in expression of inflammatory cytokines IL-1β and tumour necrosis 
factor α (TNF-α) in synovium with shTLR4 were observed (Figure 3), but not for 
IL-6.
Figure 1. In vitro validation short hairpin 
against TLR4 
Lentivirus expressing the hairpin against TLR4 
(shTLR4) was used to transduce NIH 3T3 murine 
NF-κB luciferase reporter cells. Five days after 
transduction cells were stimulated for 6 hours with 
LPS or Pam3Cys. After cell lysis luciferase activity 
was measured to determine NF-κB activation. 
Data represented as mean±SEM. Statistics: two-
way ANOVA, * p<0.05, *** p<0.001, n=3. Bone 
marrow derived macrophages transduced with 
LV-shTLR4 or LV-shControl. After differentiation 
cells were stimulated, with medium or LPS and 
analyzed for TLR4, IL-6, mRNA expression. Data 
represented as mean±SEM. Relative expression: 
2-dCt.. Statisticstwo way ANOVA, t-test, n=2.
81
The role of Toll-Like Receptor 4 on splenic antigen presenting cells in experimental arthritis
Increased chemokine expression in DLN and synovium
To study if chemokine expression could explain the increased swelling in 
shTLR4 treated animals, production of interferon gamma-induced protein 10 
(IP-10) and regulated and normal T cell expressed and secreted (RANTES) were 
measured in DLN. Figure 4 shows that a minor trend was observed in both IP-
10 and RANTES expression. Further analysis of inflamed synovium showed an 
increased expression of IP-10, RANTED and KC mRNA. This increase in chemokine 
production could explain the trend towards increased arthritis severity of shTLR4 
treated animals.
Figure 2. Clinical and histological characteristics of collagen-induced arthritis with shTLR4 
Individual mice received 40µg of lentivirus intravenously encoding either a short hairpin RNA against 
TLR4 (shTLR4) or a short hairpin control (shCon) on day 18 of CIA. (A) Incidence of and severity of 
arthritis (n=7) (scale 0-2 each hind paw). (B) Inflammation, cartilage erosion, and bone erosion. 
Knee joints (n=8) were isolated, fixed and embedded in paraffin. Tissue sections were stained with 
hematoxylin/eosin or safranin-O/fast green. Three sections per knee were scored on a scale from 0-3 
in a blinded manner. Data presented as mean±SEM. 
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Reduction of IFNγ production in DLN by TLR4 knockdown
It has previously been described that activation of TLR4 is involved in T helper cell 
development and especially Th17 cells. Therefore, we investigated the frequency 
of Th1 and Th17 cells both in DLN and spleen on day 23 and 30 of CIA. In spleens 
we did not observe any differences in Th1 and Th17 levels on both days (data 
not shown). Figure 5A shows that Th1 levels were marginally higher in shTLR4 
treated animals and a clear trend towards decreased Th17 levels was observed 
in DLN of shTLR4 treated mice on day 23. This indicates a functional effect of 
shTLR4. However, this trend was lost at day 30 of CIA (Figure 5B). Interestingly, 
the number of IFNγ producing cells was significantly reduced at day 30 of CIA 
(Figure 5C), which was due to decreased CD4-IFNγ+ cells in DLN. These results 
indicate that treatment with shTLR4 does not affect T helper subsets but does 
affect immunity by decreasing the number of IFNγ producing cells in DLN.
Discussion
In this study we attempted to ameliorate experimental arthritis by targeting TLR4 
on splenic APCs with systemic delivery of lentivirus encosing a short hairpin RNA 
against TLR4.  We hypothesized that reduced TLR4 activation on APCs would 
lead to reduced T-cell activation and subsequent decreased arthritis severity. 
However, we found a trend towards increased ankle joint swelling. Histological 
analysis showed an trend towards increased bone erosion in knee joints of mice 
with collagen-induced arthritis.
Figure 3. Expression levels of inflammatory cytokines in synovium with shTLR4 
Synovium was isolated from mice treated with lentivirus intravenously, encoding either shTLR4 or 
shCon (n=6). mRNA was extracted and analyzed for expression of IL-1β, IL-6, and TNFα. All data are 
presented as mean ±SEM. 
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APCs were targeted by injecting lentivirus intravenously. This delivery route of 
lentivirus preferentially targets macrophages in spleen (12) and also dendritic cells 
(13). Moreover, overexpressing a TAK1 mutant does ameliorate collagen-induced 
arthritis (14). Therefore, this approach was used to target TLR4 expression on 
APCs with lentiviral mediated overexpression of a short hairpin against TLR4 
(shTLR4). Effectiveness of shTLR4 was shown in vitro where NF-κB activation 
was significantly reduced after LPS stimulation by shTLR4 overexpression. In 
the target cells, APCs, shTLR4 was also proven to be effective in decreasing the 
proinflammatory reaction elicited by LPS, showing its effectiveness in achieving 
TLR4 knockdown. In support, shTLR4 was effective in vivo in another inflammatory 
model, where it was shown to reduce TLR4 expression and decrease vein graft 
disease (15).
Figure 4. Chemokine expression in draining lymph nodes and synovium
(A) Inguinal and knee lymph nodes were isolated on day 30 of CIA and a single cell suspension was 
prepared. Cells were stimulated with PMA and ionomycin for 4 hours.  IP-10 and RANTES were 
measured in supernatant. (B) Synovium was isolated from inflamed knee joints at ay 30 of CIA and 
mRNA was isolated and analyzed for IP-10, RANTES and KC expression.
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Despite functional shTLR4 we did not observe decreased arthritis severity in 
animals treated with lentivirus overexpressing shTLR4. In fact, a trend towards 
increased incidence, swelling and cellular influx was observed. Unfortunately, we 
could not directly assess TLR4 protein expression and therefore direct evidence 
of TLR4 knockdown should be gathered in future experiments. However, 
a significant decrease in IFNγ producing cells in draining lymph nodes was 
detected and it therefore appears that shTLR4 was functional. This decrease 
in IFNγ producing cells was mainly in the CD4- population, while leaving Th1 
cell numbers unaffected. These CD4- cells could be NK cells, NKT cells, CD8+ 
cytotoxic lymphocytes or macrophages. Low levels of TLR4 expression has been 
Figure 5. T-cell subsets in 
draining lymph nodes 
Inguinal and knee draining 
lymph nodes were isolated 
on day 23 (A) or 30 (B) of CIA 
and a single cell suspension 
was prepared. Cells were 
stimulated with PMA/
ionomycin in presence of 
Golgi inhibitor for 4 hours. 
Cells were subsequently 
stained for extracellular 
CD4 and intracellular IFNγ 
of IL-17A, to determine 
Th1 and Th17 cell numbers 
respectively. (C) CD4 cells on 
day 30 of CIA in DLN stained 
for IFNγ. Data represented 
as mean±SEM, n=4 (day 
23) n=7 (day 30). Statistics: 
Student’s T-test, * p < 0.05.
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detected on NK cells (16), but whether these cells are targeted by intravenously 
injected lentivirus remains unclear. IFNγ production by NKT cells also involves 
TLR4 activation on dendritic cells (17). Additionally, TLR4 on APCs is involved in 
generating IFNγ producing CD8+ T-cells and reduced TLR4 expression could lead 
to diminished levels of CD8+ IFNγ producing T-cells. Lastly, macrophages also 
produce IFNγ (18) and direct targeting of TLR4 on macrophages could decrease 
IFNγ production due to decreased activation. 
The observed decrease in IFNγ production by DLN cells could partly account for 
the trend towards increased bone erosion. IFNγ has been widely regarded as a 
proinflammatory cytokine, but several reports point to a regulatory role of IFNγ 
(19). Moreover, lack of IFNγ leads to increased severity of CIA and antigen-induced 
arthritis (20;21). Additionally, TLR4 knockouts showed reduced IFNγ production 
in inflamed joints during antibody induced arthritis (22).Therefore, a decrease in 
IFNγ production could lead to increased arthritis severity. IFNγ is known to inhibit 
Th17 development (19), which in turn is involved in bone erosion (23). However, 
further studies are necessary to confirm the number of Th17 cells in the inflamed 
joint after shTLR4 treatment.
RANTES is known to attract Th17 cells (24) and we did observe an increase 
of RANTES mRNA expression in inflamed synovium of shTLR4 treated mice. 
Additionally, an increase in IP-10 and KC mRNA expression was found, providing 
a possible explanation for the increased swelling in shTLR4 treated mice. The 
mechanism how TLR4 knockdown in splenic APCs results in a local increase 
of chemokine production remains unclear. Unpublished observations in our 
lab indicate a possibly different role of TLR4 on macrophages and DCs. Where 
knockdown of TLR4 on macrophages reduces inflammatory cytokine production 
upon LPS stimulation, an increase in MHCII transactivator Ciita expression as 
well as MHC-II itself is found in DCs. Since shTLR4 was administered prior to the 
booster injection with bovine collagen type II, increased MCHII expression and 
activation could result in enhanced antigen presentation, T-cell activation and 
subsequent increased production of chemokines, such as T-cell derived RANTES. 
However, more studies are required to dissect the role of TLR4 on different types 
of APCs in activating T-cells.
Additionally, TLR4 is expressed and functional on other cells in addition to APCs 
and a role of TLR4 on these cells cannot be neglected. TLR4 is also expressed and 
functional on other hematopoietic cells, such as B-cells and activated T-cells (2). 
In addition, the contribution of TLR4 on non-hematopoietic cells, such as synovial 
fibroblasts, appears to play a role in the pathogenesis of arthritis. A previous 
report has indeed shown a role of TLR4 on local resident cells in experimental 
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arthritis (8). Therefore, we question whether TLR4 targeting on APCs is a suitable 
therapeutic approach for arthritis. Further studies are needed to identify the 
exact role of TLR4 on APCs during inflammation and arthritis.
Several other reports indicate a regulatory role of TLR4 during infection and 
inflammation. LPS treated pDCs have anti-inflammatory effects during chronic 
kidney disease by inducing Treg cells (25). Moreover, B. pertussis in acute lung 
infection induced IL-10 production through TLR4 in macrophages and DCs 
resulting in IL-10 secreting T-cells and subsequently decreases inflammation. 
Additionally, TLR4 defective mice showed increased numbers of neutrophils 14 
days post infection and lymphocytes 21 days post infection in lavage fluid of 
infected lungs. Additionally, at these later time points IL-1β, IL-6 and MIP-1α were 
increased in TLR4 deficient mice (26). Imado et al., suggested that TLR4 signaling 
is necessary for the induction of tissue protective factors and protects against 
graft-versus-host disease. However, excessive signaling is detrimental and TLR4 
stimulation is a delicate balance between tissue protection and inflammation 
(27). Lastly, in an animal model for MS a protective role for TLR4 was found, 
where TLR4 knockout animals showed increased pathology due to increased IL-6 
and IL-23 production resulting in increased Th17 levels (28). Again, a delicate role 
for TLR4 was determined, since immunization did not involve a booster injection 
overriding the potential regulatory role of TLR4.
In conclusion, collagen-induced arthritis could not be treated with specifically 
targeting TLR4 on splenic APCs by lentiviral mediated overexpression of shTLR4. 
In fact, arthritis severity showed a trend towards increased severity, most likely 
due to increased chemokine expression in inflamed joints. Direct evidence of 
TLR4 knockdown was not observed and should be confirmed in further studies. 
Additionally, different strategies to inhibit TLR4 on APCs should be explored, such 
as TLR4 inhibitors in lipoplexes or lentiviral mediated ectopic overexpression of 
TLR4 inhibitors should be attempted (29;30). This will rule out any possible off-
target effects of short RNA strands or activation of RNA sensing receptors (31). 
Moreover, TLR4 appears to have more effects than merely proinflammatory and 
its role on different subsets of APCs warrants further investigation.
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Abstract
Antigen presenting cells (APCs) play an important role in arthritis and APC 
specific gene therapeutic targeting will enable intracellular modulation of cell 
activity. Viral mediated overexpression is a potent approach to achieve adequate 
transgene expression levels and lentivirus (LV) is useful for sustained expression 
in target cells. Therefore, we studied the feasibility of lentiviral mediated 
targeting of APCs in experimental arthritis. Third generation VSV-G pseudotyped 
self-inactivating (SIN)-LV were injected intravenously and spleen cells were 
analyzed with flow cytometry for green fluorescent protein (GFP) transgene 
expression and cell surface markers. Collagen-induced arthritis (CIA) was induced 
by immunization with bovine collagen type II in complete Freund’s adjuvant. 
Effect on inflammation was monitored macroscopically and T-cell subsets in 
spleen were analyzed by flow cytometry. Synovium from arthritic knee joints 
were analyzed for proinflammatory cytokine expression. Lentiviruses injected 
via the tail vein preferentially infected the spleen and transduction peaks at day 
10.  A dose escalating study showed that 8% of all spleen cells were targeted 
and further analysis showed that predominantly Ly6C+ and F4/80+ cells in spleen 
were targeted by the LV. To study the feasibility of blocking TAK1-dependent 
pathwhays by this approach, a catlytically inactive mutant of TAK1 (TAK1-K63W) 
was overexpressed during CIA. LV-TAK1-K63W significantly reduced incidence 
and arthritis severity macroscopically. Further histological analysis showed a 
significant decrease in bone erosion in LV-TAK1-K63W treated animals. Moreover, 
systemic Th17 levels were decreased by LV-TAK1-K63W treatment in addition 
to diminished IL-6 and KC production in inflamed synovium. In conclusion, 
systemically delivered LV efficiently targets monocytes and macrophages in 
spleen that are involved in autoimmune arthritis. Moreover, this study confirms 
efficacy of TAK1 targeting in arthritis. This approach may provide a valuable tool 
in targeting splenic APCs, to unravel their role in autoimmune arthritis and to 
identify and validate APC specific therapeutic targets.
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Introduction
Inflammatory diseases, such as rheumatoid arthritis, are characterized by 
infiltration of leukocytes into the inflamed tissue consisting of various immune 
cells from both the innate and adaptive immune system. Macrophages in 
arthritis have been extensively studied and play an important role in maintaining 
inflammation and joint destruction (1;2). Moreover, a general approach of 
macrophage specific targeting with lipoplexes ameliorates experimental arthritis 
(3;4).
Specifically modulating macrophage activity during inflammatory conditions is a 
suitable approach to limit systemic side effects of treatment. In addition, gene 
therapy can be  a powerful  technique to achieve intracellular modulation of 
protein expression or signaling. Effective gene therapeutic treatment of collagen-
induced arthritis has been achieved by ectopic overexpression of suppressor 
of cytokine signaling 3 (SOCS3) in splenic antigen presenting cells (APCs) (5). 
In addition, knock down of TNF receptor I by overexpression of a short hairpin 
was also effective in ameliorating experimental arthritis (6). Both studies used 
adenoviral vectors, ensuring a high, but transient transgene overexpression. 
Over recent years, HIV based lentiviral vectors have been optimized regarding 
safety and production and proved to be a valuable tool in order to get long term 
transgene expression.
Multiple studies have evaluated the feasibility of intravenous injection of 
lentivirus. These studies shown that the spleen is one of the organs predominantly 
targeted by lentivirus injected intravenously (7). Further analysis on localization 
on GFP expression in the spleen showed large fluorescent clusters overlapping 
the marginal zone (8). Cell surface markers revealed that mostly MHC-II positive 
cells were targeted by lentivirus (8;9), indicating preferential targeting of APCs by 
lentivirus.
Specific targeting of APCs by lentivirus makes it possible to study the role of these 
APCs in inflammatory conditions. In addition, specific interference with gene 
expression can possibly identify new therapeutic targets in APCs. To validate 
macrophage targeting a known potent therapeutic target was used, TGF-beta 
activated kinase 1 (TAK1). This MAP kinase is a key signaling protein as it is used by 
many pro-inflammatory signals. Toll-Like receptor and cytokine receptor activates 
intracellular signaling which converges to TAK1 and subsequently activate AP-1 
and NF-κB. Therefore, TAK1 poses a compelling target to block pro-inflammatory 
 
 
94
Chapter 6
signaling. Moreover, TAK1 has been shown to be important in autoimmune 
arthritis (3) and is a suitable target to validate macrophage specific targeting by 
lentiviral vectors.
In this study, we validated intravenous lentivirus injections into DBA1/J mice by 
determining expression kinetics, a dose escalating study, and analysis of targeted 
cells. This has shown that predominantly splenic F4/80+ and Ly-6C+ cells are 
targeted by this approach. To evaluate the gene therapeutic potential of LV-
mediated targeting of splenic APCs, a TAK1 kinase negative mutant (TAK1-K63W) 
was over expressed during collagen-induced arthritis. TAK1-K63W decreased 
knee joint inflammation macroscopically and systemic Th17 levels in the spleen 
were reduced. In addition, bone erosion was diminished by TAK1-K63W and 
pro-inflammatory cytokine expression in synovial tissue was decreased. This 
study shows that intravenous delivery of lentiviral vectors enables evaluation of 
therapeutic targets in splenic monocyte/macrophage-like cells that are important 
cells in autoimmune diseases.
Material and Methods
Ethics Statement and mice
All in vivo studies complied with national legislation and were approved by local 
authorities (Animal Ethics Committee, Radboud University Nijmegen. Permit 
number: 2009-177) for the care and use of animals with related codes of practice.
Male DBA/1 mice aged 10-12 weeks (Janvier, Elavage, France) were housed in 
top-filter cages and fed a standard diet with freely available food and water. 
Induction and monitoring of collagen-induced arthritis
Bovine type II collagen was dissolved in 0.05M acetic acid to a concentration of 2 
mg/ml and was emulsified in equal volumes of Freund’s complete adjuvant (2mg/
ml of Mycobacterium tuberculosis strain H37Ra) (Difco, Detroit, MI) Mice were 
immunized intradermally at the base of the tail with 100ul of emulsion (50ug 
of bovine type II collagen). Subsequently, mice were given an intra-peritoneal 
booster injection of 100ug of type II collagen dissolved in phosphate buffered 
saline (PBS) on day 21. Two independent observers monitored clinical signs of 
arthritis in paws and ankle joints, macroscopically. Cumulative scoring based on 
redness, swelling, and, in later stages, ankylosis was as follows: 0=no changes; 
0.25=1-2 toes red or swollen; 0.5=3-5 toes red or swollen; 0.5= swollen ankle; 
0.5=swollen footpad; 0.5=severe swelling and ankylosis, with a maximal score of 
2 per paw.
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Plasmids
For generation of recombinant lentiviral vectors we used of the third-generation 
self-inactivating transfer vector pRLL-cPPT-PGK-mcs-PRE-SIN (PGK-empty) 
containing the human phosphoglyceratekinase (PGK) promoter (kind gift from 
J. Seppen, AMC Liver Center, Amsterdam, The Netherlands). For cloning we 
used cloned Pfu DNA polymerase (Stratagene, La Jolla, CA) and T4 DNA Ligase 
(New England Biolabs, Ipswich, MA). All generated constructs were verified by 
sequencing. The cDNA sequences of a kinase-inactive mutant of human TAK1 
(K63W) were PCR cloned from pEGFP-C1-TAK1-K63W into NheI/NsiI sites of PGK-
SIN using the following primers: RV 5’-ATGCATTCATGAAGTGCCTTGTCAG-3’, FW 
5’-GCTAGCGCCACCATGTCGACA GCCTCCGCCGCC-3’ (non-tagged, Kozak sequence 
for enhanced translation introduced).
Lentiviral vector production
Packaging of VSV-G pseudotyped recombinant lentiviruses was performed by 
transient transfection of 293T cells. One day prior to transfection, 293T cells 
were seeded in a T75 flask at 1x105 cells/cm2 in DMEM supplemented with 
10% FCS, 1 mM pyruvate, 40 µg/ml gentamicin and 0.01 mM water-soluble 
cholesterol (Sigma). Cells were co-transfected with 19 µg transfer vector, 14 
µg gag/pol packaging plasmid (pMDL-g/p-RRE), 4.7 µg rev expression plasmid 
(RSV-REV) and 6.7 µg VSV-G expression plasmid (pHIT-G) by calcium phosphate 
precipitation. Transfections were performed in 6 ml DMEM without antibiotics 
and cholesterol and cultured for 16 hours. Thereafter medium was replaced with 
fully supplemented DMEM and supernatant harvested after 24 and 48 hours. 
Cell debris was removed by centrifugation at 1500 rpm for 5 minutes at 4 °C, 
followed by passage through a 0.45 µm pore polyvinylidene fluoride Durapore 
filter (Millipore, Bedford, MA, USA). For concentration by ultracentrifugation 
28 ml supernatant was overlaid on 4 ml 20% sucrose solution and centrifuged 
at 25.000 rpm for four hours in a Surespin 630 rotor (Thermo Fisher Scientific, 
Waltham, MA). Pelleted viruses were resuspended in sterile PBS and stored at 
-80 °C. Viral titers were determined by assaying p24gag values with a commercial 
enzyme-linked immunosorbent assay (ELISA) kit (Abbott Diagnostics, Hoofddorp, 
the Netherlands) and expressed as ng p24gag/µl.
In vivo imaging
In vivo bioluminescent imaging was performed on an IVIS Lumina system (Caliper 
Life Sciences, Hopkinton, MA, USA), 10 minutes after intraperitonal injection 
of 150 mg/kg D-Luciferine (Caliper Life Sciences) dissolved in PBS. Mice were 
anesthetized with isoflurane/oxygen, placed on their back into the light tight 
96
Chapter 6
chamber and imaged for 4 minutes with a sensitive CCD camera. Images taken 
were quantified using the Living Image 3.0 software (Caliper Life Sciences). 
Luciferase activity is presented in photons emitted per second per square cm.
RNA isolation and quantitative PCR analysis
Spleen, synovium, and liver samples were disrupted using the MagNaLyser 
(Roche). Total RNA was extracted from the tissue homogenates and from cells 
using TRI reagent (Sigma) according to manufacturer’s protocol. Isolated RNA was 
treated with DNAse followed by reverse transcription of 1µg RNA into cDNA using 
Moloney  murine leukemia virus reverse transcriptase 0.5µg/µl oligo(dT) primers, 
and 12.5mM dNTPSs (Invitrogen). Quantitative real-time PCR was performed 
using the StepOnePlus sequence detection system (Applied biosystems, Foster 
City, CA) PCR was performed in a total reaction volume of 12.5 µl consisting of 
appropriate cDNA. Five µM of forward and reverse primer and the sYBR green 
PCR  master mix (Applied biosystems). PCR protocol consisted of 2 min at 50°C 
and 10 min of 95°C, followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C. 
Quantification of PCR signals was achieved by calculating the difference between 
the cycle threshold value (Ct) of the gene of interest with the Ct value of their 
reference gene glycerldehyde-3-phophate dehydrogenase (GAPDH) for each 
sample (delta Ct)
Histology
Spleens were isolated and fixed in  in phosphate buffered 4% paraformaldehyde 
and embedded in in paraffin wax. Whole knee joints were dissected and fixed in 
phosphate buffered 4% paraformaldehyde followed by decalcification with 5% 
formic acid, and embedded in paraffin wax. Serial tissue sections (7µm) were 
stained with Safranin O (BDH chemicals, Poole, UK) and counterstained with 
fast green (BHD Chemicals) or with hematoxylin / eosin (Merck, Germany) and 
eosin (Merck, Germany) (H&E). Serial sections were scored for histopathologic 
changes on a 0-3 scale, by 2 independent observers in a blinded manner. Joint 
inflammation was determined by the presence of synovial cell infiltrates and 
inflammatory cell exudates. Connective tissue destruction was determined by 
cartilage and bone erosion.  
FACS analysis
Spleens from mice were mashed, filtered and erythrocytes were removed 
by osmotic shock and directly stained for GFP expression and CD3 (1:200 
eBioscience), CD19 (1:50 BD Pharmingen), F4/80 (1:400, Biolegend), and Ly-
6C (1:800, Biolegend) cell surface markers. For T-cell subset analysis in arthritic 
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mice CD3+ cells were isolated from spleen using the Pan T cell Isolation Kit 
(Miltenyi Biotec, Germany) according to manufacturer instructions. Purified 
CD3+ cells were stimulated in RPMI 1640 (Invitrogen) supplemented with 10% 
FCS penicillin/streptomycin and pyruvate with 50ng/ml PMA, 1ul/ml/10^6 cells 
Brefeldin A (BD Pharmingen) and 1ug/ml ionomycin. After 4 hours of stimulation 
cells were stained with anti-mouse CD4-APC (1:200) (BD pharmingen) or IgG2a-
APC controle (BD pharmingen) for 30 minutes at 4°C. Subsequently, cells were 
stained intracellular with anti-IL17-FITC and anti-IFNg-PE or with their controls 
respectively IgG1-PE and IgG1-FITC according to instructions by manufacturer (BD 
Pharmingen). Stained cells were analyzed using FACScalibur (Becton Dickinson) 
and analyzed with FlowJow software.
Bone marrow derived dendritic cells
Femurs and tibia’s of DBA1/J mice were flushed and bone marrow was harvested. 
After preparing a single cell suspension cells were plated (250,000 c ells per cm2) 
with 833 ng p24GAG equivalent and 20 ng/ml GM-SCF. Medium was changed on 
day 4 and day 8. 
Statistics
Statistical differences were determined by one-way ANVA or student’s T-test 
(two sided) and GraphPad 5.0 software. P values below 0.05 were considered 
significant.
Results and Discussion
Expression kinetics is dependent on route of administration
Although previous studies have shown efficient transduction of spleen cells 
by intravenously delivered lentivirus, there are considerable differences 
between Balb/c and C57Bl/6 mice(10). Therefore the kinetics of lentiviral 
mediated transgene expression needs to be  determined in DBA1/J mice, an 
autoimmune prone strain used for the CIA model. We injected 10 µg p24GAG 
equivalent (approximately 5x10^8 viral particles) of lentivirus encoding luciferase 
intravenously via the retro orbital sinus and luciferase activity was determined by 
in vivo imaging. Figure 1A shows that maximal luciferase activity was reached at 
day 7 after virus injection. Organ distribution of the luciferase activity is shown in 
Figure 1B and strikingly a substantial level of luciferase activity was found around 
the throat of the animals. These are possibly the submandibular lymph nodes 
draining the eye, but the precise localization was not identified. To avoid targeting 
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this particular site and achieve more efficient delivery of LV to the spleen the 
retro orbital sinus injection site was compared with tail vein injections. Figure 1C 
shows that the expression kinetics of lentivirus injected via tail vein in spleen and 
liver are different from injection via retro orbital sinus. Maximal luciferase activity 
peaks at day 10 and expression levels of luciferase were elevated compared to 
retro orbital sinus injections. Tail vein injection also showed more luciferase 
activity in the liver and spleen area (Figure 1B and 1D). Unexpectedly, luciferase 
activity was also detected around the knee joint. This is most likely to originate 
from the bone marrow, as these cells are also transduced by lentivirus injected 
intravenously (7;10;11). Additionally, these results were also observed with retro 
orbita plexus injections (data not shown). It appears that injection of lentivirus via 
the tail vein favors transgene expression levels and location and all subsequent 
experiments were performed with tail vein injections. Injection directly into a 
Figure 1. Transgene expression kinetics.
Every animal received 10 µg of p24GAG equivalent of lentivirus encoding firefly luciferase intravenously. 
Luciferase activity was determined after injection of luciferine using biophotonic imaging with the IVIS 
Lumina. Region of interest was placed over abdomen of mice. Kinetics of transgene expression (A) 
and organ distribution of transduction (B) after  lentivirus injection via the retro orbital sinus, n=6. 
B). Comparison between retro orbital sinus and tail vein injection (n=2 in both groups) for abdominal 
expression (C) and localization of transgene expression in tail vein injected animals (D).
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vein is potentially preferable over retro orbital sinus as the distribution of the 
lentivirus throughout the body is better than into a sinus, which has a slow blood 
flow.
Dose escalating study of lentivirus
After establishing the delivery route and transgene expression kinetics the optimal 
dose was determined by injecting increasing doses of lentivirus encoding GFP. 
Figure 2A shows that increasing doses of lentivirus also resulted in increasing 
percentage of GFP positive cells in spleen with 7.4% of total spleen cells were GFP 
positive when injected with 40 µg of p24GAG equivalent of lentivirus. Analysis 
of the GFP mRNA expression showed an increase in GFP mRNA with increasing 
dose of lentivirus, except at 10 µg lentivirus due to large variation. In addition, 
GFP mRNA expression showed a 12 fold increase in spleen compared to liver 
samples (Figure 2B). Together with the luciferase activity measurements shown 
in Figure 1D we concluded that lentivirus efficiently transduces cells in the spleen. 
Although maximal expression of GFP was not reached we used 40 µg of p24GAG 
LV per animal in subsequent as a safe dose showing no side effects. GFP is known 
to elicit a specific immune response (12), but no increase in splenic cell number 
was observed in the dose escalating study (data not shown).
Figure 2. Dose finding of intravenous lentivirus injection.
Increasing doses of lentivirus encoding GFP were injected via the tail vein and GFP expression was 
analyzed 10 days after injection. A) Total spleen cells were analyzed by flow cytometry for GFP 
expression. Statistics: one-way ANOVA with Bonferonni post test compared to PBS injected animals, 
n=4 per group.  ** p<0.01, *** p<0.001. B) GFP mRNA expression in liver and spleen samples. Relative 
expression = 2-ΔCt. Data represented as mean±SEM. 
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Figure 3. Localization splenic GFP expression and identification of transduced cell types by cell 
surface marker analysis.
A) Increasing doses of lentivirus encoding GFP were injected via the tail vein and GFP expression was 
analyzed by immunohistochemistry ten days after virus injection. Representative histological images 
of experiment (magnification 200x), dotted line outlines white pulpa. W = white pulpa, R = red pulpa. 
Arrow heads indicate GFP positive cells. B) Flow cytometric analysis of GFP expressing cells 4 and 7 days 
after virus injection. Data represented as average (±SEM) GFP positive cells in gate indicated on x-axis 
(n=4). C) Representative plots of cell marker and GFP FACS analysis.
101
Intravenous delivery of lentivirus preferentially targets splenic APCs
Macrophages and monocytes are preferentially targeted by lentivirus
Immunohistochemistry was done to determine the location of GFP expression in 
the spleen. Figure 3A shows that with increasing dose of lentivirus also more GFP 
protein is detected. GFP expression was detected around the white pulpa near the 
marginal zone, in line with other reports (8;13). In a separate experiment it was 
determined which cells are targeted by lentivirus in the spleen, leukocytes were 
isolated from spleen and GFP expression was determined in combination with cell 
surface markers (Figure 3B). This confirmed that lentivirus only marginally targets 
T- and B-cells, since the IHC showed that there was no GFP expression in the white 
pulpa of the spleen. In contrast, it appears that lentivirus preferentially targets 
F4/80+ and Ly-6C+ cells as 30-40% of cell populations were GFP positive. The GFP 
expression in F4/80+ cells remains stable for up to ten days after virus injection 
(data not shown). This preferential targeting of the APC population has also been 
described by others (8;9). The monocyte population shows a sharp drop off in 
GFP expression between day 4 and 7 after virus injection. This probably reflects 
migration or differentiation of Ly-6C+ monocytes, whereas the F4/80 expressing 
macrophages present in the red pulpa reside in the spleen (14). The antigen 
presenting cell (APC) population in the spleen consists of many different subtypes 
of dendritic cells and macrophages. Here, we show a preferential targeting of 
the macrophage and monocyte population, but identification of the exact APC 
subpopulation remains to be determined.
Lentivirus targets cells that play an important role during arthritis.
Next, we evaluated if the targeted cells also play a functional role in inflammatory 
diseases. Therefore mice immunized with bovine collagen type II were injected 
with lentivirus encoding a kinase negative mutant of TAK1 (TAK1-K63W) to 
decrease inflammatory signaling by Toll-Like Receptors and cytokines. This target 
was identified as an important signaling molecule in experimental arthritis and 
provides a suitable target to study the efficacy of intravenous injection of lentivirus 
(3). Figure 4A shows that disease incidence is decreased in animals injected with 
lentivirus overexpressing the negative TAK1 mutant. In addition, macroscopic 
swelling of the knee joints was significantly decreased at time of sacrifice (Figure 
4B). Further histological analysis (Figure 4C-E) showed only a trend towards 
decreased inflammation and cartilage erosion. Bone erosion, however, was 
significantly decreased in mice treated with TAK1-K63W. This is in line with the 
altered Th17 population, which plays an important role in osteoclast activity and 
bone erosion (15). In addition, Ly-6C positive cells are precursors of osteoclasts 
(16) and inhibition of pro-inflammatory signaling on these cells possibly also 
inhibits osteoclast formation. A strong trend is found towards decreased levels 
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Figure 4. Effect of splenic TAK1 targeting on arthritis incidence and knee joint swelling.
A) Arthritis incidence was monitored over time macroscopically. B) Swelling of knee joints 
macroscopically at time of sacrifice (day 30 of CIA). Data represented as mean±SEM. Statistics 
macroscopic scoring: Student’s t-test, n=7 per group. ** p<0.01. C-E) Knee joints were isolated and 
evaluated for pathohistological features. C) Inflammation scores determined on HE stained sections. D) 
Cartilage erosion scores determined on safranin-O stained sections. E) Bone erosion scores determined 
on safranin-O stained sections. F-G) Representative histological images for bone erosion of knee joints. 
Original magnification 100x. Bone erosion indicated with arrow head. P=patella, F=femur. Statistics 
histology: Student’s t-test, n=8 for GFP, n=6 for TAK1-K63W. * p<0.05.
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of cell influx into the joint and Swirski and colleagues have described a pool of 
cells in the spleen that migrate towards the site of inflammation (17). These cells 
were CD11b and Ly-6C positive and we have found Ly-6C+ cells expressing GFP 
after lentivirus administration (Figure 3B). Additionally, Ly6C-high expressing 
monocytes are attracted to the site of inflammation from the bone marrow in a 
kidney injury model (18). Taken together, lentivirus injected intravenously could 
possibly target this pool of migrating monocytes in the spleen. 
Local inflammation decreased upon lentiviral targeting of macrophages and 
monocytes
From the inflamed joints synovium was extracted and mRNA analysis showed 
that proinflammatory cytokine mRNA expression was decreased when mice 
were treated with lentivirus encoding the TAK1 mutant (Figure 5). Although 
not significant, IL-1β production shows a trend towards diminished production 
in the inflamed synovium and might underly the trend in decreased cartilage 
erosion. The decrease in IL-6 production also supports the diminished levels of 
Th17, as IL-6 is a crucial factor for Th17 development (19) . Moreover, RANK and 
Figure 5. Proinflammatory cytokine expression in synovium of arthritic animals.
Synovium was isolated from arthritic animals and disrupted. Total mRNA was isolated and analyzed 
for A) cytokines (IL-1β, IL-6, KC) and B) RANK, and RANKL mRNA expression. Data represented as 
mean±SEM. Relative expression = 2-ΔCt. Statistics: Student’s t-test, n=6. * p<0.05.
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RANK ligand, important for osteoclast formation and function are decreased in 
synovium of inflamed knee joints (Figure 6B) (20). Together with altered systemic 
Th17 levels, this possibly causes the decrease in bone erosion. Additionally, 
production of the chemokine KC is significantly reduced and possibly explains 
the clear trend in reduced inflammation observed on histology. This shows that 
targeting the macrophages and monocytes in the spleen and liver can have distal 
effects on the inflamed tissue and shows the importance of this cell population 
in experimental arthritis.
Lentivirus targets cells controlling the adaptive immunity
To study if the targeted cells are involved in controlling the adaptive immunity, 
T-cell subsets were determined in the spleen. At a systemic level, the TAK1 mutant 
had only marginally effects on Th1 development in the spleen. However, Th17 
cell population was significantly decreased in the spleen by overexpression of 
the TAK1 mutant (Figure 6A). This suggests that lentivirus delivered intravenously 
also targets cells that are involved in controlling the adaptive immunity. This is in 
Figure 6. T-cell subsets in spleen during arthritis after TAK1 targeting in splenic APCs.
A) Spleen cells were isolated and stimulated with PMA, ionomycin, and Brefeldin A for 4 hours and 
subsequently stained for CD4, IFNγ, and IL-17. Percent positive cells from CD4 gate is shown. B) 
Representative FACS analysis plots. IL-17 and IFNγ positive cells in CD4+ gate shown. Data represented 
as mean±SEM. Statistics: Student’s t-test, two tailed, n=7. * p<0.05. 
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line with previous studies that showed transduction of MHC-II+ cells  in spleen 
(9) and targeting of dendritic cell precursors and influence T-cell proliferation 
(21). In addition, systemic lentivirus delivery has been used to induce tolerance in 
collagen-induced arthritis and showed clear potential in affecting T-cell function, 
with decreased proliferation (11).
Bone marrow derived DCs express reduced levels of IL-12 and IL-23
To evaluate how TAK1-K63W overexpression interferes with activation of the 
adaptive immunity we generated bone marrow derived DCs transduced with LV-
GFP or LV-TAK1-K63W. These DCs were analyzed for IL-12p35, IL-12p40, and IL-
23p19 mRNA expression and showed diminished levels of IL-12p35 and IL-23p40 
and an increase in the IL-12p40 subunit. These decreased levels could cause the 
decrease in Th1 and Th17 development during the CIA. Additionally, the increase 
in IL-12p40 could enhance the inhibition on Th1 and Th17 development, since the 
IL-12p40 subunit can antagonize the function of IL-12 (22) and IL-23 (23). These 
data show an important role for TAK1 in DCs in controlling the adaptive immunity.
TAK1 as therapeutic target in arthritis has been established by Courties 
and colleagues (3), in which TAK1 expression was knocked down using RNA 
interference and ameliorated collagen-induced arthritis. That study also showed 
altered T-cell subsets upon TAK1 targeting in APCs, but also showed a more 
efficacious therapy on arthritis severity. In the present study we overexpressed a 
negative mutant of TAK1 which is a competitive mutant and complete blockade of 
TAK1 cannot be achieved. In addition, lentivirus tropism is possibly more selective 
than lipoplexes. Nevertheless, we find matching results with TAK1 targeting in 
collagen-induced arthritis. 
Figure 7. IL-12 and IL-23 mRNA expression decreased in bone marrow derived DCs
Bone marrow cells were harvested and transduced with either LV-GFP or LV-TAK1-K63W and 
subsequently differentiated into dendritic cells. After ten day differentiation period, mRNA was 
collected and analyzed for IL-12p35, IL-12p40, and IL-23p19. Data represented as mean±SEM, Relative 
expression = 2-ΔCt, n=2.
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Interestingly, a novel role for TAK1 has been described recently (24;25). Both 
studies have investigated the role of TAK1 in the production of pro-inflammatory 
cytokines and, remarkably, TAK1 negatively regulates cytokine production in 
myeloid cells. In these studies lipopolysaccharide was used as stimulus, which 
is a very potent activator of neutrophils and macrophages. In addition, cytokine 
production was only determined over 24 hours. In contrast, collagen-induced 
arthritis involves a more complex process than a single stimulation and the clinical 
features of collagen-induced arthritis were studied for 12 days on our study.
In summary, this study shows an effective method to target a monocyte and 
macrophage population in spleen that is involved in inflammation and immunity. 
Blocking almost all pro-inflammatory signals, by overexpression of a TAK1 
mutant, disrupts progression of experimental arthritis and impairs T-helper cell 
development. Injection of lentivirus intravenously provides a straightforward 
tool to study potential therapeutic targets in monocytes and macrophages 
during inflammatory conditions. Additionally, this study confirms the efficacy of 
TAK1 targeting in arthritis and emphasizes the role of this crucial MAP kinase in 
monocytes and macrophages during autoimmune arthritis.
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Abstract
Activated synovial fibroblasts are key players in the pathogenesis of rheumatoid 
arthritis (RA) by driving inflammation and joint destruction. Numerous molecules 
including cytokines and toll-like receptor (TLR) ligands induce pro-inflammatory 
signalling and gene expression through a hierarchical network of kinases. 
Upstream mitogen-activated protein kinase kinase kinases (MAP3Ks) represent 
an attractive target for RA treatment. In this study we sought to determine the 
role of the MAP3K transforming growth factor-β activated kinase 1 (TAK1) in 
cytokine and TLR-mediated signalling. TAK1 activity was inhibited using either 
a small molecule inhibitor or lentivirally-overexpressed kinase-inactive TAK1-
K63W mutant in murine embryonic and human dermal and synovial fibroblasts. 
Fibroblasts were stimulated with IL-1, TNF, TLR2 or TLR4 agonists and responses 
were evaluated using transcriptional reporters, Western blotting and analysis of 
gene expression of collagenases (MMP3,13), cytokines (IL-1β,-6) and chemokines 
(IL-8, MCP-1). TAK1 inhibition abrogated cytokine- and TLR-induced NF-κB and 
Saa3-promoter reporter activation in murine and human dermal fibroblasts. 
In synovial fibroblasts, TAK1 regulated IL-1 and TNF-α mediated NF-κB, but not 
Saa3-promoter reporter activation. Inducible mRNA expression of cytokines, 
collagenases and chemokines, except MCP-1,  was TAK1-dependent for IL-1, TNF 
and TLR2 signalling. Unexpectedly, TLR4-mediated NF-κB reporter activation and 
inducible mRNA expression was fully TAK1-independent. Accordingly, NF-κB p65 
and p38 MAPK phosphorylation was unaffected by TAK1 inhibition. In general, 
TAK1 crucially regulates IL-1 and TNF signalling in fibroblasts. Interestingly, TLR4 
signalling is specifically TAK1-independent in synovial fibroblasts. Consequently, 
therapeutic TAK1 inhibition in arthropaties may not dampen the damage-
associated molecular pattern-mediated TLR4 activation of synovial fibroblasts. 
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Introduction
Rheumatoid arthritis (RA) is a systemic chronic autoimmune disease that mainly 
affects the synovial joints that ultimately leads to joint destruction. Prior to 
and during joint inflammation the synovial lining tissue, consisting of synovial 
fibroblasts and macrophages, becomes activated and hyperplastic resulting in 
invasion and degradation of adjacent cartilage and bone. In both experimental 
and human arthritis, synovial fibroblasts have been identified as cells that actively 
drive inflammation and joint destruction (1, 2). Moreover, transmigration of 
activated RA synovial fibroblasts has been implicated in mediating the spreading 
of destructive arthritis to unaffected joints (3). Due to their key role in RA 
pathogenesis, synovial fibroblasts are major target cells for treatment of disease. 
Synovial fibroblasts are potently activated by cytokines, such as IL-1 and TNF 
(4-6), and toll-like receptor (TLR) ligands (7-9). TLRs 2 and 4 are predominantly 
expressed in synovial fibroblasts and their expression is increased in RA patients 
(8, 10). Although TLRs are primarily activated by exogenous pathogens, they also 
recognize endogenous damage-associated molecular patterns (DAMPs) that are 
abundantly present in arthritic joints (7, 11). In experimental arthritis, it has been 
demonstrated that TLR4 activation promotes the onset and severity of disease 
(12). Moreover, DAMP-mediated activation of TLR4 specifically in synovium has 
been found to be crucially involved in joint destruction (13).
After ligation of their respective receptors, expression and secretion of 
pro-inflammatory mediators including cytokines, chemokines and matrix 
metalloproteinases (MMPs) is induced through multiple signalling cascades 
including nuclear factor-κB (NF-κB) and the mitogen-activate protein kinase 
(MAPK) families p38, c-Jun-N-terminal kinase (JNK), and extracellular-signal 
regulated kinase (ERK) (reviewed in (14)). These kinases are regulated through 
phosphorylation by their upstream kinases IκB kinase (IKK) and MAPK kinase 
(MAPKK), respectively. In turn, MAPKK kinases (MAP3Ks) control the activation of 
IKK and MAPKK and are activated through interactions with receptor-associated 
proteins, such as IL-1R-associated kinases (IRAKs) and TNFR-associated factors 
(TRAFs). The MAP3K family comprises numerous members of which MEK kinase-1, 
-2 (MEKK1,-2) and transforming growth factor-β activated kinase 1 (TAK1) are 
most abundantly expressed in RA synovial fibroblasts (15).
TAK1 has been identified as the key regulator of IL-1, TNF and TLR-induced 
activation of NF-κB and MAPK pathways in mice (16-18). Inhibition of TAK1 
catalytic activity prevented chemical-induced inflammation in mice (19). However, 
studies using cell-type specific TAK1-deficient mice have also revealed that TAK1 
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is a crucial regulator of homeostasis in cartilage, skin, epithelium and liver (20-
23). Therefore, insight into the cell-specific regulation of signalling pathways by 
TAK1 is indispensable for developing a treatment based on its inhibition. 
Until now, it has been shown that TAK1 regulates the IL-1-induced JNK pathway 
and activator protein-1 (AP-1) transcription factor in synovial fibroblasts (24). 
Here, we investigated the role of TAK1 in TNF-, TLR2-, and TLR4-mediated signal 
transduction and induction of pro-inflammatory gene expression in murine 
embryonic and primary human dermal and synovial fibroblasts. The present 
study reveals that TLR4 signalling is specifically TAK1-independent in synovial 
fibroblasts.  
Materials and methods
Patients and samples
Synovial tissue was obtained from RA (n=4) and osteoarthritis (OA) (n=2) patients 
undergoing open joint replacement surgery or arthroscopic synovectomy at 
the Clinic of Orthopedics, Waldkrankenhaus “Rudolf Elle”, Eisenberg, Germany 
(kindly provided by R.W. Kinne, University of Jena). Informed patient consent 
was obtained and the study was approved by the Ethics Committee of University 
Hospital Jena. RA and OA patients were classified according to the ACR criteria. 
Clinical characteristics of patients are described in Huber et al. (25). Synovial 
fibroblasts were purified from synovial tissue as previously published (26). Briefly, 
the tissue samples were minced, digested with trypsin/collagenase p (Sigma, 
St. Louis, MO), and the resulting single cell suspension was cultured for seven 
days. Non-adherent cells were removed by medium exchange. Fibroblasts were 
obtained by negative isolation using Dynabeads M-450 CD14 MACS purification. 
Human dermal fibroblasts were obtained from skin biopsies of healthy volunteers 
at the Radboud University Nijmegen Medical Centre (kind gift from J. Schalkwijk, 
Department of Dermatology).
Cell culture
Mouse embryonic fibroblasts (NIH-3T3) were maintained in DMEM supplemented 
with 1 mM pyruvate, 40 μg/ml gentamicin, and 5 or 10% fetal calf serum (FCS), 
respectively. Stable transcriptional reporter cell line NIH-3T3-5xNF-κB-luciferase 
was described before (27). Human dermal and synovial fibroblasts were cultivated 
in DMEM supplemented with 1mM pyruvate, 80 μg/ml gentamicin, and 10% FCS. 
Cells were kept at 37 °C in a humid atmosphere containing 5% CO2.
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Plasmids
For generation of recombinant lentiviral vectors we used of the third-generation 
self-inactivating transfer vector pRLL-cPPT-PGK-mcs-PRE-SIN (PGK-empty) 
containing the human phosphoglyceratekinase (PGK) promoter (kind gift from 
J. Seppen, AMC Liver Center, Amsterdam, The Netherlands). For cloning we 
used cloned Pfu DNA polymerase (Stratagene, La Jolla, CA) and T4 DNA Ligase 
(New England Biolabs, Ipswich, MA). All generated constructs were verified 
by sequencing. A lentiviral transcriptional luciferase reporter containing four 
tandemly-arranged NF-kB binding sites (pTRH2-NF-ºB-Luc) was purchased from 
System Biosciences (Mountain View, CA). Construction of the Saa3-promoter 
luciferase reporter is described in previously (27). The cDNA sequences of 
a non- and EGFP-tagged kinase-inactive mutant of TAK1 (K63W) were PCR 
cloned from pEGFP-C1-TAK1-K63W (kind gift from M. Kracht, Rudolf-Buchheim-
Institute for Pharmacology, Giessen, Germany) into NheI/NsiI sites of PGK-empty 
using the following primers: RV 5’-ATGCATTCATGAAGTGCCTTGTCAG-3’, FW 
5’-GCTAGCGCCACCATGTCGACA GCCTCCGCCGCC-3’ (non-tagged, Kozak sequence 
for enhanced translation introduced), and FW 5’-GCTGGTTTAGTGAACCGTCAG-3’ 
(EGFP-tagged). 
Lentiviral vector production
Packaging of VSV-G pseudotyped recombinant lentiviruses was performed by 
transient transfection of 293T cells. One day prior to transfection, 293T cells 
were seeded in a T75 flask at 1x105 cells/cm2 in DMEM supplemented with 
10% FCS, 1 mM pyruvate, 40 μg/ml gentamicin and 0.01 mM water-soluble 
cholesterol (Sigma). Cells were co-transfected with 19 μg transfer vector, 14 
μg gag/pol packaging plasmid (pMDL-g/p-RRE), 4.7 μg rev expression plasmid 
(RSV-REV) and 6.7 μg VSV-G expression plasmid (pHIT-G) by calcium phosphate 
precipitation. Transfections were performed in 6 ml DMEM without antibiotics 
and cholesterol and proceeded for 16 hours. Thereafter medium was replaced 
with fully supplemented DMEM and supernatant harvested after 24 and 48 
hours. Cell debris was removed by centrifugation at 1500 rpm for 5 minutes at 4 
°C, followed by passage through a 0.45 μm pore polyvinylidene fluoride Durapore 
filter (Millipore, Bedford, MA, USA). For concentration by ultracentrifugation 
28 ml supernatant was overlaid on 4 ml 20% sucrose solution and centrifuged 
at 25.000 rpm for four hours in a Surespin 630 rotor (Thermo Fisher Scientific, 
Waltham, MA). Pelleted viruses were resuspended in sterile PBS and stored at 
-80 °C. Viral titers were determined by assaying p24gag values with a commercial 
enzyme-linked immunosorbent assay (ELISA) kit (Abbott Diagnostics, Hoofddorp, 
the Netherlands) and expressed as ng p24gag/μl.
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Luciferase measurements
For in vitro reporter studies, cells were seeded at 5x104 cells per well in a Krystal 
2000 96-wells plate (Thermo Labsystems, Brussels, Belgium) and transduced for 4 
hours with 25 ng p24gag equivalents lentivirus in 50 μl medium supplemented with 
8 μg/ml polybrene (Sigma). Transduction efficiency was 80-100% and comparable 
between donors (data not shown). Consecutively, cells were  serum starved (1% 
FCS) for two days, pre-incubated for one hour with indicated concentrations 
TAK1 inhibitor (11,12-dihydro-5Z-7-oxozeaenol, AnalytiCon Discovery, Potsdam, 
Germany) or dimethyl sulfoxide (DMSO) as vehicle control and stimulated with 
recombinant murine or human IL-1β (1 ng/ml, R&D Systems Europe, Oxford, UK), 
TNFa (10 ng/ml, Abcam, Cambridge, UK), E. Coli LPS (1 mg/ml, Sigma), Pam3Cys 
(1 μg/ml, EMC Microcollections, Tübingen, Germany) for indicated hours. Cells 
were lysed in ice-cold lysis buffer (0.5% NP-40, 1 mM DTT, 1 mM EDTA, 5 mM 
MgCl2, 100 mM KCl, 10 mM Tris-HCl pH 7.5, 1x protease inhibitor cocktail (Roche, 
Mannheim, Germany)). Luciferase activity was quantified using the Bright-Glo 
luciferase assay system (Promega, Madison, WI, USA) by adding an equal volume 
of Bright-Glo to the cell lysate. Luminescence was quantified in a luminometer 
(Lumistar, BMG, Offenburg, Germany), expressed as relative light units (RLU) and 
normalized to total protein content of the cell extracts. 
Western blot analysis
Synovial fibroblasts were seeded at 1x106 cells per well in 6-wells plates and serum 
starved (1% FCS) for forty eight hours. Cells were pre-incubated for one hour with 
500 nM TAK1 inhitor or DMSO, followed by stimulation with human IL-1β (1 ng/
ml) or LPS (1 μg/ml) for 5 and 30 minutes, as indicated. Lysis was performed in 
10 mM TrisHCl (pH 7.05), 50 mM NaCl, 30 mM sodium pyrophosphate, 1% Triton 
X-100, 2 mM Na3VO4, 50 mM NaF, 20 mM ß-glycerophosphate, 1 µg/ml pepstatin, 
10 µg/ml leupeptin, 1 mM PMSF, 1 µM microcystin. Cell lysates were subjected 
to SDS-PAGE on 8% gels and western blotting was performed as described (28). 
Proteins of interest were detected by antibodies against phospho(S536)-p65 
(Cell Signaling, Danvers, MA, USA), p65 (C-20, Santa Cruz, CA, USA ), phospho 
(TY180/2)-p38 (Invitrogen) and p38 (29).
RNA isolation
Cells were seeded at 90% confluency in 24-wells plates and serum starved (1% 
FCS) for forty eight hours. Consecutively, cells were pre-incubated with TAK1 
inhibitor or DMSO for one hour and stimulated as mentioned above. Thereafter, 
cells were washed in ice-cold PBS and total RNA was extracted using TRI reagent 
(Sigma). Isolated RNA samples were treated with RNase-free DNase I (Qiagen, 
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Venlo, the Netherlands) for 15 minutes. Synthesis of cDNA was accomplished 
by reverse transcription PCR using an oligo(dT) primer and Moloney murine 
leukemia virus Reverse Transcriptase (Invitrogen). 
Quantitative PCR
QPCR was performed using SYBR Green PCR Master mix and the ABI 7000 Prism 
Sequence Detection system (Applied Biosystems Inc., Foster City, CA) according to 
the manufacturer’s instructions. Primers were designed over exon-exon junctions 
in Primer Express (Applied Biosystems Inc.) and used at 300 nM in the PCR 
reaction. PCR conditions were as follows: 2 minutes at 50 ºC and 10 minutes at 95 
ºC, followed by 40 cycles of 15 seconds at 95 ºC and one minute at 60 ºC. Gene 
expression (cycle threshold, Ct) values were normalized using glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as the reference gene (ΔCt = Ctgene – CtGAPDH). 
Primers sequences are listed in Supplementary Data.
Statistics
Data are represented as means+SEM and significant differences were calculated 
using a one-way analysis of variance (ANOVA) or Repeated Measures ANOVA 
followed by Bonferroni’s Multiple Comparison test (GraphPad Prism, San Diego, 
CA, USA), where appropriate. P-values of less than 0.05 were regarded significant.
Figure 1. TAK1-dependent NF-kB activation in murine fibroblasts. TAK1 inhibition by an inhibitor 
and LV-TAK1-K63W 
(a). NIH-3T3-5xNF-κB-luciferase cells were either transduced with indicated p24gag equivalents LV-
K63W (triangles) and control lentivirus (PGK-empty) or pre-treated with indicated concentrations 
inhibitor (squares) and vehicle. Two days post-transduction or one hour after pre-treatment, 
respectively, cells were stimulated with IL-1β (1 ng/ml) for 6 hours. (b) NIH-3T3-5xNF-κB-luciferase 
fibroblasts were pre-treated with 500 nM inhibitor or vehicle and, stimulated for 6 hours with murine 
IL-1β (1 ng/ml), TNFα(10 ng/ml), LPS (TLR4, 1 μg/ml) and Pam3Cys (TLR2, 1 μg/ml). (a and b) NF-
κB activation was measured by luciferase assay and data are expressed as the percentage of activity 
compared to controls (mean±SEM, n=3-5). (c) Induction of Saa3 mRNA expression by IL-1β TNFα, LPS 
(TLR4) and Pam3Cys (TLR2) in NIH-3T3 stably transduced with LV-TAK1-K63W or PGK-empty. Data 
are represented as fold induction (mean+SEM, n=3)) over untreated cells. * P<0.05, *** P<0.001 by 
ANOVA.
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Results
TAK1 regulates cytokine- and TLR-induced NF-κB activation in murine fibroblasts 
TAK1 has been identified as the crucial mediator of IL-1- and TNF-induced activation 
of NF-κB, JNK and p38 MAPK signal transduction pathways in NIH-3T3 fibroblasts 
(29). Using a 3T3 NF-κB reporter cell line, we investigated TAK1-inhibitory efficiency 
of a small molecule inhibitor (19) and lentivirally-overexpressed kinase-inactive 
TAK1-K63W mutant (LV-K63W) (Figure 1A). Maximal inhibition of IL-1β-induced 
NF-κB activity was achieved at 500 nM inhibitor (66.2±8.6%) or 150 ng p24gag 
equivalents LV-K63W per 5x104 cells (65.4±6.2%), respectively. There were no 
significant differences in maximal inhibition between inhibitor and LV-K63W, and 
aforementioned concentrations were applied throughout following experiments. 
Next, we analysed TAK1-mediated regulation of TLR-induced signal transduction 
(Figure 1B). Treatment of fibroblasts with inhibitor resulted in a significant 
reduction in NF-κB activation (~60%, P < 0.05) induced by TLR2 (Pam3Cys) and 
TLR4 (LPS) agonists. As a control, IL-1- and TNF-induced NF-κB activation were 
also potently suppressed by inhibitor. Finally, we evaluated the effect of TAK1 
inhibition on the inducible expression of serum amyloid A3 (Saa3), which has 
been identified as a strictly TAK1-dependent TNF target gene (29) (Figure 1C). 
Stable transduction with LV-K63W also completely prevented induction of Saa3 
expression by IL-1b and LPS. These results confirm the crucial role of TAK1 in 
mediating cytokine- and TLR-mediated signal transduction in murine fibroblasts. 
Figure 2. TAK1-dependent NF-kB and Saa3-promoter activation in human dermal fibroblasts. 
Dermal fibroblasts were co-transduced with 150 ng LV-TAK1-K63W / PGK-empty and 25 ng LV-Saa3/
NF-κB-Luc, serum-starved for two days and thereafter stimulated with human IL-1β(1 ng/ml), TNFα (10 
ng/ml), LPS (TLR4, 1 μg/ml) for 6 hours. NF-κB (a) and Saa3-promoter (b) activation were determined 
using a luciferase assay. Data are expressed as the percentage of activity compared to PGK-empty 
(mean+SEM, n=4). Induction of IL-1β, IL-6 and IL-8 mRNA expression by IL-1β was determined by RT-
PCR (c). Data are represented as fold reduction compared to PGK-empty (2-ΔΔCt, ΔΔCt= ΔCt K63W - ΔCt 
control). Statistical differences were determined using ANOVA. ** P<0.01, *** P<0.001
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TAK1-dependent signalling in primary human dermal fibroblasts
Since activated fibroblasts play an important role in the pathogenesis of chronic 
inflammatory diseases (1, 30), inhibition of inflammatory signal transduction 
represents a straightforward treatment strategy. Therefore, we assessed the 
contribution of TAK1 to pro-inflammatory signal transduction in primary human 
dermal and synovial fibroblasts. Overexpression of TAK1-K63W in dermal 
fibroblasts completely abrogated IL-1β-induced NF-κB activation (Figure 2A). Also 
NF-κB activation through TNF-α (66.2±2.5%) and TLR4- (68.5±4.6%) was strongly 
reduced. Since SAA3 is a pseudogene in humans and TAK1 directly regulates the 
transcriptional activity of the Saa3 promoter (29), we additionally used a Saa3-
promoter luciferase reporter for studying the effect of TAK1 inhibition in human 
fibroblasts (Figure 2B). TAK1 crucially regulated IL-1, TNF- and TLR4-mediated 
activation of Saa3-promoter reporter as revealed by an approximately eighty 
percent reduction of luciferase activity. Reduction of NF-κB and Saa3-promoter 
activation through TAK1 inhibition correlated with a suppression of IL-1β, IL-6 and 
IL-8 gene expression (Figure 2C). These data identify TAK1 as a pivotal regulator of 
pro-inflammatory signalling in dermal fibroblasts.
Cytokine- and TLR-mediated induction of transcriptional reporters and pro-
inflammatory genes in synovial fibroblasts
In order to identify TAK1-dependent signalling pathways in synovial fibroblasts, 
we first validated whether cytokines and TLR ligands induced NF-κB and Saa3-
promoter transcriptional reporters (Figure 3A,B) and pro-inflammatory gene 
expression (Figure 3C-F). We found strong upregulation of both reporter activities 
upon IL-1, TNF and TLR4 stimulation, whereas TLR2 stimulation only led to 
marginal induction. Accordingly, expression of NF-κB target genes IL-1β, IL-6 and 
IL-8 was strongly upregulated upon cytokine and TLR stimulation. Additionally, we 
detected significantly induced expression of AP-1 (MMP3/13) (31) and interferon 
regulatory factor-3 (MCP-1) (32) transcription factor target genes.
TLR4-mediated signalling is TAK1-independent in synovial fibroblasts
Next, we repeated experiments as described above in the presence of TAK1 
inhibitor. Consistent with our previous results in murine and human dermal 
fibroblasts, IL-1 (47.9±7.9%) and TNF-mediated (48.4±6.2) NF-κB activation was 
significantly reduced through TAK1 inhibition (Figure 4A). In contrast, induction 
of Saa3-promoter activation was unaffected by treatment with TAK1 inhibitor 
(Figure 4B). Surprisingly, both NF-κB and Saa3-promoter activation through TLR4 
triggering demonstrated TAK1-independent, as indicated by a complete lack of 
inhibition of transcriptional reporters upon inhibitor treatment. These 
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Figure 3. Induction of transcriptional reporters and pro-inflammatory gene expression in synovial 
fibroblasts
Fibroblasts were transduced with 25 ng LV-Saa3/NF-κB-Luc, serum-starved for two days and 
thereafter stimulated with indicated ligands for 6 hours. NF-κB (a) and Saa3-promoter (b) activation 
were determined using a luciferase assay. Data are represented as fold induction over basal levels 
(mean+SEM, n=4). Induction of pro-inflammatory gene expression was determined by RT-PCR (c-f). 
Synovial fibroblasts were serum-starved for two days, pre-incubated for one hour with vehicle, and 
either left untreated or stimulated for 6 hours with IL-1β (1 ng/ml, c), TNFα (10 ng/ml, d), LPS (TLR4, 1 
μg/ml, e), and Pam3Cys (TLR2, 1 μg/ml, f). Data are represented as fold induction (2-ΔΔCt) compared 
to untreated cells (means+SEM, six donors). Statistical differences were determined using ANOVA. 
*P<0.05, ** P<0.01, *** P<0.001.
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results prompted us to investigate phosphorylation of components of the NF-κB 
and MAPK pathway by Western blotting (Figure 4C,D). Stimulation of synovial 
fibroblasts with IL-1 and LPS clearly induced phosphorylation of p38 MAPK 
and the p65 subunit of NF-κB. In the presence of TAK1 inhibitor, IL-1β-induced 
phosphorylation of both substrates was considerably reduced. Corroborating 
the data above, TAK1 inhibition failed to affect phosphorylation induced by LPS. 
To conclude, we analysed the effect of TAK1 inhibition on the induction of pro-
inflammatory genes by cytokines (Figure 5A,B) and TLR agonists (Figure 5C,D). 
Indeed,  induction of NF-κB target genes IL-1β, IL-6 and IL-8 through IL-1 and 
TNF was significantly reduced by TAK1 inhibitor treatment. Corresponding with 
the established regulation of JNK-AP-1 pathway by TAK1 (24), IL-1 and TNF-
induced MMP3 expression was also clearly reduced. The IRF3-target gene MCP-1 
demonstrated TAK1-independent for all applied stimuli. Whereas TAK1 inhibition 
resulted in suppression of TLR2-induced IL-1β, IL-6 and MMP3 expression, TLR4-
induced gene expression was completely unaffected by inhibitor treatment. 
Together these data reveal TAK1-independent TLR4 signal transduction that is 
specific for synovial fibroblasts. 
Figure 4. TAK1-independent TLR4 signalling and Saa3-promoter activation in synovial fibroblasts
Fibroblasts were transduced with 25 ng LV-Saa3/NF-κB-Luc and consecutively serum-starved for two 
days, pre-treated with 500 nM inhibitor or vehicle for one hour, and either left untreated or stimulated 
with human IL-1β (1 ng/ml), TNFα (10 ng/ml), LPS (TLR4, 1 mg/ml) for 6 hours. NF-κB (a) and Saa3-
promoter (b) activation were measured using a luciferase assay and data are represented as relative 
activity (mean+SEM, four donors, quadruplicate measurements) compared to untreated cells. Western 
blot analysis of NF-κB p65 and p38 MAPK phosphorylation (c and d). Fibroblasts were serum-starved 
for two days, pre-treated with 500 nM inhibitor or vehicle for one hour, and stimulated with human IL-
1β (c) and LPS (d) for indicated time points. A representative picture of two donors is shown. Statistical 
differences were determined using ANOVA. *** P < 0.001.
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Discussion
Given the multitude of activating molecules and redundancy and complexity 
of MAPK signalling (33, 34), upstream MAP3Ks are of particular interest as 
therapeutic targets as they potentially couple multiple receptors to downstream 
signalling pathways. In this study, we investigated the role of the MAP3K TAK1 in 
mediating pro-inflammatory signalling in several types of fibroblasts and revealed 
specific TAK1-independent TLR4 signalling in human synovial fibroblasts. 
Although there is substantial evidence that IL-1 signals through both TAK1 and 
MEKK3 (35, 36) information on a physiological role of these two kinases in synovial 
fibroblasts is limited. In two studies, analysis of MAP3K expression on mRNA and 
protein level in synovial fibroblasts revealed abundant expression of TAK1 and 
Figure 5. Effects of TAK1 inhibition on induction of pro-inflammatory gene expression in synovial 
fibroblasts
Fibroblasts were serum-starved for two days, pre-treated with 500 nM inhibitor or vehicle for one hour, 
and left untreated or stimulated with human IL-1β (1 ng/ml, a), TNFα (10 ng/ml, b), LPS (TLR4, 1 μg/
ml, c) and Pam3Cys (TLR2, 1 μg/ml, d) for 6 hours. Expression of indicated genes was measured using 
RT-PCR. Data are represented as fold reduction (2-ΔΔCt) compared to DMSO-treated cells (mean+SEM, 
six donors). Statistical differences were determined using Repeated Measures ANOVA. * P < 0.05, ** 
P < 0.01. 
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trace amounts of MEKK3 (15). Knock down of MEKK3 did not affect IL-1β-induced 
MAPK activation and TAK1 was identified as the crucial mediator in JNK, but 
not ERK or p38 MAPK pathways. siRNA-mediated suppression of TAK1 did not 
significantly inhibit NF-κB nuclear translocation and DNA binding, but suppressed 
IL-6, a typical NF-κB target gene (24). Hence, our results, using transcriptional 
reporter systems confirm that a significant portion of NF-κB activation through 
IL-1R and TNFR is mediated by TAK1.
Unexpectedly, we discovered that TAK1 plays no role in TLR4-induced NF-κB 
activation and pro-inflammatory gene expression in synovial fibroblasts. Several 
studies have emphasized a central role for TAK1 in LPS/TLR4-mediated NF-κB 
activation in murine macrophages, embryonic fibroblasts, B-cells, and human 
HEK293 cells (16, 17, 37, 38). In addition, we have revealed that TAK1 regulates 
NF-κB in murine NIH-3T3 fibroblasts and primary human dermal fibroblasts. 
TLR4 activates signal transduction through TRIF- (TIR-domain-containing 
adapter-inducing interferon-β) and MyD88-dependent pathways. Upon ligand 
binding MyD88 is recruited, which subsequently leads to the recruitment and 
phosphorylation of IRAK proteins, which then interact with TRAF6. The activated 
complex activates downstream IKK and MAPKKs through an interaction with 
TAK1. The TRIF-dependent pathway activates the interferon regulatory factor-3 
(IRF3) pathway through TANK binding kinase-1 (TBK1). NF-κB and MAPK pathways 
are activated through interaction with receptor interacting protein-1 (RIP1), 
which consecutively interacts with TRAF6 and TAK1 (39). Maximal induction of 
inflammatory cytokines such as TNFα and IL-6 is dependent on the activation of 
both TRIF and MyD88 pathways (40). Based on these studies, we expect TAK1-
dependent regulation of MyD88- and TRIF-dependent NF-κB and MAPK activation, 
but not the IRF3 pathway. The latter was confirmed by our RT-PCR analysis results, 
which indicated indeed that regulation of the IRF3 target gene MCP-1 (32) was 
not inhibited by treatment of synovial fibroblasts with TAK1 inhibitor. Inhibition of 
IL-1β-induced NF-κB activation by inhibitor treatment suggested a MyD88-TAK1-
IKK pathway in synovial fibroblasts. Based on the latter, and our observations that 
TAK1 does not mediate TLR4 signal transduction in synovial fibroblasts, at least 
two mechanism might underlie these remarkable results. 
First, the TLR4-MyD88-IKK/MAPK pathway can be regulated by a MAP3K other 
than TAK1. Recent investigations have unravelled a TAK1-independent and 
MEKK3-dependent mechanism for TLR8-mediated IKK and JNK activation (41), 
and a similar pathway was discovered for IL-1 mediated NF-κB activation (42). 
As in our study, NF-κB activity is not completely inhibited by the TAK1 mutant or 
the TAK1 inhibitor, and knowledge on regulation of MEKK3 in synovial fibroblasts 
is very limited. Therefore, MEKK3 is a likely candidate that accounts for TAK1-
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independent signalling in synovial fibroblasts. Thus, a divergence of IL-1R/TLR 
MyD88-dependent pathways into IL-1R-TAK1- and TLR4-MEKK3 routes could be 
a possibility.
Second, TLR4 signalling through the MyD88-dependent pathway might be less 
dominant or even ablated in synovial fibroblasts. A possible mechanism for 
such phenomenon has been described for LPS-tolerance induction in human 
monocytes and dendritic cells (43, 44). Upon restimulation with a TLR4 ligand 
tolerized cells show decreased TLR4-MyD88 complex formation, which results in 
impaired IRAK-1 phosphorylation (45). Moreover, it has been shown that IRAK-M 
is upregulated in RA synovial fibroblasts, which acts as a negative regulator of the 
MyD88-dependent pathway, and is associated with tolerance induction (46, 47). 
If this were to take place in synovial fibroblasts, we would expect predominant 
signal transduction through TRIF. However, in the case of pre-dominant TRIF 
signalling we would still expect activation of the TRIF-TRAF6-TAK1 pathway, 
unless TAK1 can be bypassed for NF-κB and MAPK signalling in this route.
Circumventing TAK1 in TLR4 mediated NF-κB activation can be achieved by TANK, 
which was shown to slightly induce NF-κB transcription after overexpression (48). 
Another pathway without involvement of TAK1 mediated NF-κB activation has 
been discovered in IL-1 signalling (49). In this pathway, TRAF6 is associated with 
p62, which activates atypical protein kinase C and this subsequently leads to 
NF-κB activation. 
Not only TLR4 signalling, but also cytokine-induced Saa3-promoter activation 
was specifically TAK1-independent in synovial fibroblasts. This promoter is 
synergistically activated through cooperation of NF-κB and CAAT/enhancer-
binding protein (C/EBP) transcription factors (50, 51). Since IL-1/TNF-induced 
NF-κB activition proved to be TAK1-dependent, the lack of Saa3-promoter 
activation upon TAK1 inhibition could point towards differential regulation of 
C/EBP transcription factors  in synovial versus dermal fibroblasts. 
In conclusion, using a previously characterized dominant-negative mutant or small 
molecule inhibitor of TAK1, we have found a more restricted role for this MAP3K in 
mediating pro-inflammatory signalling in synovial fibroblasts. This phenomenon 
proved independent from disease as it was observed both in RA and OA patients. 
In the light of the recently established role of TLR4 in experimental arthritis (12, 
13, 52), insight into TLR4 signalling in synovial fibroblasts is of particular interest 
for understanding pathogenesis and treatment. The underlying mechanism for 
TAK1-independent regulation of TLR4 signalling, potentially TLR4 tolerance or 
involvement of an alternative MAP3K, remains to be addressed in future research. 
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Abstract 
TLR4 activation increases Th17 development and plays a role in autoimmunity. 
TLR4 uses two distinct signaling pathways, the proinflammatory MyD88 pathway 
and the TRIF pathway. The putative anti-inflammatory TRIF pathway is less 
well studied in arthritis. Therefore, the role of TLR4 and TRIF signaling in T-cell 
dependent flare-up of experimental arthritis was studied. Antigen-induced 
arthritis (AIA) was induced in wild type, TRIF-/- and TLR4-/- (C57Bl/6). Three 
weeks after primary arthritis, smoldering inflammation was flared. T helper 
subsets, cytokine and chemokine production were determined 4 hours and 4 
days after flare-up. Joint swelling and pathology were determined four days after 
flare-up. TLR4 deficiency decreased Th17 levels by 44% in the inflamed synovium 
immediately after flare-up, whereas TRIF deficiency did not affect Th17 levels. 
IL-6 production, however, was increased in TRIF-/- animals. Four days after flare-
up, both TRIF-/- and TLR4-/- showed reduced numbers of Th17 in draining lymph 
nodes, 50 and 58% respectively. Additionally, a trend in reduced IP-10 and 
RANTES production was observed in draining lymph nodes of TRIF-/-, possibly 
explaining the reduced swelling and inflammation in TRIF knock out animals. TLR4 
is important in Th17 cell numbers immediately after flare-up inflammation and 
during resolution of inflammation. TRIF signaling, however, appears to control 
Th17 cell numbers only during the resolution phase. The chemokine RANTES 
appears to be an important factor in Th17 accumulation. Moreover, TRIF signaling 
is involved in swelling and inflammatory cell influx into the inflamed joint, for 
which IP-10 is potentially an important chemokine. 
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Introduction
Rheumatoid arthritis is a disease with unknown etiology affecting the articulating 
joints. The chronic inflammation results in destruction of the joint causing pain 
and immobility. Toll-Like Receptors (TLRs) have emerged over recent years as 
important players in inflammatory and autoimmune diseases, such as arthritis. 
TLRs bridge the innate and adaptive immunity by determining antigen presenting 
cell (APC) activity and thereby controlling T-cell activation (1).
TLR4 has been extensively studied in experimental arthritis models (2-4), were it 
was found that TLR4 has been found to have an aggravating role in established 
arthritis. TLR4 is a unique TLR in the fact that it uses two signaling pathways, 
the MyD88 dependent and a MyD88 independent pathway (5). The latter uses 
TIR-domain-containing adapter-inducing interferon-β (TRIF), resulting in NF-κB 
and interferon regulatory factor 3 (IRF3) activation respectively (6). The MyD88 
pathway is shared with nearly all TLRs, making it subject of many studies. The TRIF 
pathway is only shared with TLR3 and is a crucial pathway during viral infections 
(7), because it induces type I IFN production. Although important, it is less well 
studied and its role in inflammatory conditions should be evaluated.
TRIF signaling results in activation of IRF3 and subsequent production of IFNα and 
IFNβ (6), which in turn can induce expression of suppressor of cytokine signaling 
(SOCS) proteins (8). These proteins have anti-inflammatory capacities by blocking 
downstream signaling of TLRs and cytokines (9). Moreover, TRIF signaling induces 
IL-27 production that controls Th17 development (10). Type I IFNs also have 
direct effect on the adaptive immunity as they are involved in isotype switching 
of antibodies (11) and control T-cell activation directly (12). Therefore, TRIF 
signaling and the accompanied type I IFN production play a complex role during 
inflammation and possibly also in arthritis.
In this study we investigated the role of TLR4 and TRIF in antigen-induced arthritis 
(AIA). A primary inflammation was flared-up after three weeks where it develops 
in a T-cell dependent local inflammation. Considering the anti-inflammatory 
effects of TRIF and type I IFNs we anticipated an increase in inflammation and 
joint destruction. However, we found a proinflammatory role of TRIF signaling 
in this T-cell dependent flare-up of arthritis, as Th17 numbers subsided more 
rapidly and swelling and cellular infiltrate were reduced in TRIF knockout animals. 
Additionally, TLR4 was important in Th17 cell numbers in the arthritic joint, but 
played a minor role in joint destruction.
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Material and Methods
Mice
C57BL/6 wild type, TLR4 knock outs (kind gift from Akira, Tokyo, Japan), and TRIF 
knock outs (kind gift from Bruce Beutler, The Scripps Research Institute, US) mice 
were housed in individually ventilated cages and fed a standard diet with freely 
available food and water. Animal studies were approved by the Institutional 
Review Board of Radboud University Nijmegen and were performed according 
the appropriate codes of practice.
Antigen induced arthritis
Mice were immunized with 100 µg of mBSA (Sigma), emulsified in 100 µl Freund’s 
complete adjuvant (Difco Laboratories, Detroit, MI< USA). Injections were divided 
over both flanks and footpads of the forelegs. Heat Killed Bordetella pertussis 
(RIVM, Bilthoven, The Netherlands) was administered intra peritoneally as an 
additional adjuvant. Two subcutaneous booster injections with in total 50 µg 
mBSA/Freund’s complete adjuvant were given in the neck region 1 week after 
the initial immunization. Three weeks after these injections, primary AIA was 
induced by injecting 60 µg mBSA in 6 µl of phosphate buffered saline into the 
right knee joint, resulting in chronic arthritis. At week three of arthritis, 2 µg of 
mBSA was injected intraarticularly into the arthritic joint to induce a flare-up of 
the smoldering inflammation.
Joint swelling
Joint swelling was assessed by measuring the accumulation of 99 mTc in the 
inflamed joint due to increased blood flow and edema. For this, 0.74 MBq of 
99 mTc in 200 µl of saline was injected subcutaneously. After several minutes 
of distribution throughout the body, gamma radiation in the knee joints was 
measured externally. Swelling was expressed as the ratio of gamma counts in the 
right (inflamed) knee joint to gamma counts in the left (control) knee joint. Ratios 
higher than 1.1 were considered to represent joint swelling.
Histology
Knee joints were isolated and fixed in 4% paraformaldehyde for minimally 8 
days followed by decalcification in 5% formic acid and subsequently embedded 
in paraffin. Haematoxylin and eosin staining of 7 µm sections were used to 
determine inflammation (score 0-5) and safranin-O and fast green staining was 
used to score bone erosion (score 0-5) and cartilage destruction (score 0-5).
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RNA isolation and quantitative PCR analysis
Synovium was disrupted with MagnaLyze (Roche) and total RNA was extracted 
using TRI reagent (Sigma) according to manufacturer’s protocol. Isolated RNA was 
treated with DNAse followed by reverse transcription of 1 ug RNA into cDNA using 
Moloney murine leukemia virus reverse transcriptase 0.5ug/ul ologo(dT) primers, 
and 12.5mM dNTPSs (Invitrogen). Quantitative real-time PCR was performed 
using the StepOnePlus sequence detection system (Applied biosystems, Foster 
City, CA) PCR was performed in a total reaction volume of 12.5 µl consisting of 
appropriate cDNA. Five µM of forward and reverse primer and the sYBR green 
PCR  master mix (Applied biosystems). PCR protocol consisted of 2 min at 50°C 
and 10 min of 95°C, followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C. 
Quantification of PCR signals was achieved by calculating the difference between 
the cycle threshold value (Ct) of the gene of interest with the Ct value of their 
reference gene glycerldehyde-3-phophate dehydrogenase (GAPDH) for each 
sample (delta Ct) and expressed as relative mRNA expression (2-dCt).
Synovium cell isolation
Procedure has been used as described before (13). Briefly, knee joint synovium 
was dissected, and synovial biopsy specimens were incubated with enzymatic 
digestion buffers (Liberase; Roche) for 30 minutes at 37°C. A 70-μm nylon cell 
strainer (BD Falcon) was then used to process the digested tissue. The cell 
preparation was collected in RPMI with 10% fetal calf serum (FCS). To isolate the 
single mononuclear cells, Lympholyte-M (Cederlane) was used, according to the 
manufacturer’s protocol. All cells were cultured in RPMI 1640 (Gibco-Invitrogen) 
supplemented with 10% FCS. 
Flow cytometric analysis spleen and draining lymph nodes (DLN) cells
DLNs were disrupted by a 70 µm mesh and cells were stimulated in RPMI 1640 
(Invitrogen) supplemented with 5% FCS penicillin/streptomycin, pyruvate, 50ng/
ml PMA, 1 ug/ml Ionomycin, and Brefeldin A (BD Pharmingen). After 4 hours of 
stimulation cells were stained with anti-mouse CD4-APC (1:200) (BD pharmingen) 
or IgG2a-APC controle (BD pharmingen) for 30 minutes at 4°C. Subsequently, 
cells were stained intracellularly with anti-IL17-FITC and anti-IFNg-PE or with 
their controls respectively IgG1-PE and IgG1-FITC according to instructions by 
manufacturer (BD Pharmingen). Stained cells were analyzed using FACScalibur 
(Becton Dickinson) and analyzed with FlowJow software.
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Cytokine measurements
IL6, KC, IL-β, TNF-α, IL-17A, and IFNγ levels in patella wash outs were measured on a 
Luminex-100 System (Luminex corp.) using a bead-based multiplex immunoassay 
(Milliplex, Merck Millipore). Data analysis was performed with Bio-Plex Manager 
software (Bio-Rad Laboratories).
Statistics
Statistical differences were calculated using GraphPas 5.0 software with one-way 
ANOVA analysis. TLR4 and TRIF knockouts were compared to wild tipe animals. P 
values under 0.05 were considered significant.
Figure 1. T helper subsets in inguinal lymph nodes and synovium after primary arthritis 
induction
Seven days after arthritis induction with 60 µg mBSA intraarticularly cells from inguinal lymph 
nodes (A)and synovium (B) were isolated and stained for extracellular CD4 and intracellular IFNγ 
and IL-17A. Data represented as mean ± SEM, DLN n=6, synovium n = 3.
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Results
TRIF and TLR4 are not involved in primary antigen-induced arthritis
To evaluate the role of TRIF signaling and TLR4 activation in AIA TRIF and TLR4 
knockouts were immunized and arthritis was locally induced. No differences were 
found on joint pathology (data not shown), indicating that TRIF and TLR4 play a 
minor role in primary AIA. To study the effects of TRIF and TLR4 on T-cell skewing 
we analyzed the Th1 and Th17 cells in DLN and synovium of the affected joints. 
Figure 1 shows that neither TRIF signaling nor TLR4 is involved in regulating Th1 
and Th17 cell numbers in DLN. In synovium, however, a non-significant increase 
in Th1 and decrease of Th17 was observed in TRIF knockouts. This shifts the T-cell 
balance towards Th1 in TRIF-/- compared to wild types and TLR4-/-.
Figure 2. Cytokine release from synovium 4 hours after flare-up
Four hours after flare-up injection with 2µg mBSA patella and surrounding synovial tissue was extracted 
and incubated in RPMI medium for 1 hour. IL-6, IL-1β, TNF-α, IP-10, and RANTES were measured with a 
bead-based multiplex immunoassay. Data represented as mean ± SEM, statistics: one-way ANOVA, with 
Bonferonni post test (TRIF-/- and TLR4-/-compared to WT), n=6, * p<0.05.
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TRIF regulates IL-6 production and TLR4 determines chemokine production 
during flare-up
To study the role of TRIF signaling and TLR4 activation in flare-up of smoldering 
arthritis a non-arthritic dose of antigen was injected three weeks after the primary 
arthritis. The flare-up resulted in vast amounts of IL-6 produced in synovium 
(Figure 2). TRIF signaling appears to be an important inhibitor of IL-6 production, 
since TRIF knockout animals showed significant elevated production of IL-6. In 
addition, TNFα and IL-1β showed a clear trend towards increased production 
in TRIF knockouts. This indicates that TRIF signaling inhibits the cytokine burst 
immediately after reactivation of inflammation, most likely through upregulation 
of suppressor of cytokine signaling (9). Interestingly, production of chemokines 
IP-10 and RANTES was not increased in TRIF knockouts. These chemokines 
are regulated differently than the NF-κB dependent genes that are increased. 
Cytokine expression in TLR4 knockouts was only marginally affected. The TRIF 
dependent chemokines IP-10 and RANTES, however, show a clear trend towards 
decreased production in the synovium of arthritic joints of TLR4-/- mice.
Figure 3. Thelper subset analysis and cytokine release from synovium 4 hours after flare injection
Four hours after flare-up injection with 2 µg mBSA patella and surrounding synovial tissue was extracted 
and incubated in RPMI medium for 1 hour. (A) After incubation synovial tissue was minced and digested 
for 45 minutes with Liberase enzyme cocktail. Inflammatory cells were subsequently isolated with 
Lympholyte-M and stimulated with PMA and ionomycin for 4 hours. Cells were stained for extracellular 
CD4 and intracellular IFNγ and IL-17A. (B) IFNγ and IL-17A were measured with a bead-based multiplex 
immunoassay. Data represented as mean ± SEM, statistics: one-way ANOVA, with Bonferonni post test 
(TRIF-/- and TLR4-/-compared to WT), n=6, * p<0.05. 
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TLR4, but not TRIF, deficiency decreases Th17 cell numbers in synovium 
immediately after flare-up
RANTES is a chemokine for Th17 cells (14), whereas IP-10 is capable of attracting 
Th1 cells (15). Therefore we determined Th1 and Th17 cells in the inflamed joints. 
Additionally, we determined IL-17 and IFNγ production in synovium of arthritic 
knee joints. Figure 3 shows that TRIF deficiency did not affect the Th1 and Th17 
cell numbers nor the production of IFNγ. A minor increase of IL-17 production 
was observed, possibly due to increased in IL-6 and IL-1β production. Taken 
together, it appears that TRIF does not play a role in T-cell accumulation at the 
site of inflammation immediately after flare-up. In contrast, TLR4 does control 
the number of Th17 cells in the inflamed joint, since TLR4 knockouts showed 
reduced Th17 cells and reduced IL-17 production. Therefore, it appears that 
TLR4 mediated of IP-10 and RANTES expression could be important factors in 
controlling the accumulation of T-cells, and more specifically Th17 cells, at the 
site of inflammation.
TRIF and TLR4 maintain Th17 levels in later phase of arthritis 
To study the role of TRIF and TLR4 in controlling Th1 and Th17 levels during the 
resolution of arthritis, DLN and synovium of affected joints were isolated for 
Th1 and Th17 analysis. TLR4 knockouts show a slight decrease in Th1 levels in 
synovium and DLN, but again significant diminished levels of Th17 cells in DLN 
(Figure 4A and B). These results confirm the role of TLR4 in controlling the 
adaptive immunity and in particular Th17. In contrast to the earlier time point, 
we do find a decrease in Th17 cells in DLN of TRIF knockouts during the resolution 
phase. This might indicate that TRIF signaling plays a role in prolonging arthritis. 
To study whether IP-10 and RANTES are also involved in determining the T-cell 
levels during the resolution phase, we determined their production in synovium. 
Figure 4C shows marginal effects on IP-10 production, possibly linked to the slight 
changed in Th1 levels observed. RANTES expression is non-significantly decreased 
in TRIF and TLR4 knockouts and this could explain the marginal effects on Th17 
in synovium (Figure 4B). Since IP-10 production has considerably dropped and 
also RANTES levels are diminished, it is conceivable that both chemokines play a 
minor role in subsiding inflammation.
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TRIF regulates swelling and inflammatory cell influx
Swelling of knee joints was measured to study the effects of TRIF and TLR4 on 
inflammation. Both TRIF and TLR4 decreased joint swelling (Figure 5A), albeit 
TLR4 not significantly. The inflammatory cell influx into inflamed knee joints was 
examined on histology (Figure 5B), in which both TRIF and TLR4 appear to play a 
role, although TLR4 failed to reach statistical significance. Both the decreased joint 
swelling and cell influx could be caused by the decreased chemokine production 
in TRIF and TLR4 knockouts, due to diminished recruitment of inflammatory 
cells. Despite decreased number of Th17 cells and slightly reduced swelling 
and inflammatory influx in TLR4 knockouts, no improvements was observed on 
cartilage and bone degradation. TRIF signaling, however, appears to play a minor 
role in cartilage and bone destruction, since a trend is observed in decreased 
cartilage and bone erosion.
Figure 4. T helper subsets in  inguinal lymph nodes, and synovium 4 days after flare-up
Cells from inguinal lymph nodes (A) and synovium (B) were isolated and stimulated with PMA, 
ionomycin, and golgi-plug for 4 hours. Cells were stained for extracellular CD4 and intracellular IFNγ 
and IL-17A. (C) Synovial production of IP-10 and RANTES was measured with a bead-based multiplex 
immunoassay. Data represented as mean ± SEM, statistics: one-way ANOVA, with Bonferonni post test 
(TRIF-/- and TLR4-/-compared to WT), n=6 for spleen and inguinal lymph nodes, n=3 for synovium, * 
p<0.05.
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Discussion
In the present study the role of TRIF and TLR4 in T-cell dependent flare-up of 
arthritis was investigated. We show that TLR4 is important in accumulation of IL-17 
producing CD4+ T-cells directly after injection of antigen initiating inflammation. 
The chemokines IP-10 and RANTES potentially play a crucial role in the attraction 
of T cells. TRIF signaling, however, is involved in prolonging arthritis, since TRIF 
knockouts show reduced levels of Th17 during the resolution phase of arthritis. 
In accordance, joint swelling and inflammation in TRIF knockout animals was 
decreased compared with wild type animals.
TLRs bridge the innate and adaptive immunity by instructing T-cell development 
(1). The role of TLR4 has been extensively studied in Th17 differentiation and 
development and in this study we confirm a role of TLR4 in controlling Th17 cell 
numbers at the site of inflammation. Additionally, TLR4 plays an aggravating role 
in experimental arthritis (2). However, in this model we observe only a minor role 
Figure 5. Swelling and histopathological analysis 4 days after flare injection
(A) Swelling measured by Tc99 uptake. Ratio of left (non-inflamed joint) and right 
(inflamed joint). (1 = no swelling). (B) Arbitrary core (scale 0-3) of inflammation, (C) 
cartilage erosion and (D) bone erosion. Data represented as mean ± SEM, statistics: 
one-way ANOVA, with Bonferonni post test (TRIF-/- and TLR4-/-compared to WT), 
n=6, ** p<0.01. 
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of TLR4 in joint swelling. The effects of TLR4 on joint destruction was negligible 
however, which is likely due to very limited joint destruction generating little TLR4 
stimulating DAMPs and causing an inferior role of TLR4. This is in contrast with 
previous findings (16) where TLR4 knockouts were completely protected against 
joint destruction during primary AIA. Their immunization protocol differs greatly 
from our experimental design. Midwood et al., initiated primary AIA 7 days after 
immunization, whereas we allowed an immunization period of 28 days before 
initiating primary arthritis. This difference has a significant impact on the process 
involved, the protocol used by Midwood et al will not involve a strong adaptive 
immunity response. Therefore, the role of TLR4 could be entirely different in both 
protocols.
The role of TRIF signaling in inflammation is less well studied and here we describe 
an unexpected result where TRIF signaling decreases Th17 cell numbers at the site 
of inflammation during the resolution phase of arthritis. This is in contrast with 
previous reports in other experimental models of arthritis and multiple sclerosis 
that show an increase of Th17 development in TRIF knockout animals (10;17). 
First, TRIF played a protective role an experimental arthritis model induced 
by repeated local injections with streptococcal cell wall fragments (SCW). This 
model, however, is based on strong TLR2/NOD2 stimulation that does not signal 
through TRIF. Addiitonally, it has been shown that this model is less dependent 
on FcγReceptor triggering (22) and this could imply a minor role of B-cells and 
antibody formation, which is crucial for the AIA. Second, Guo et al. showed an 
anti-inflammatory effect of TRIF signaling by induction of IL-27, which limits Th17 
development. In contrast to our study, Guo et al have studied the onset and 
pathology of experimental autoimmune encephalomyelitis, whereas we studied 
the role of TRIF during flare-up of a smoldering arthritis. This potentially could 
have consequences for the IL-27-Th17 axis, making it of less importance during 
disease rather than the onset of disease. This requires further study however. 
Additionally, TLR4 mediated TRIF signaling in dendritic cells (DCs) is important for 
production of IL-23 (18), an important survival factor for Th17 cells (19). Moreover, 
TRIF signaling in DCs is crucial for optimal DC maturation and subsequent T-cell 
activation (20). TRIF signaling appears to play a proinflammatory role in a T-cell 
mediated flare-up of arthritis due to a possible less important role of IL-27 and 
potentially reduced levels of IL-23 produced by DCs.
Accumulation and migration of leukocytes is directed by chemokines. In this 
study we have determined the of RANTES (CXCL5) in synovium samples of 
inflamed joints. It appears that TLR4 controls chemokine production immediately 
after flare-up and this could be linked to the changes in Th1 and Th17. RANTES 
is involved in recruitment of Th17 cells towards tumors (14). In TRIF knockouts 
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no change in Th17 cells was found immediately after flare-up, neither was 
there a decrease in RANTES production. During the resolution phase however, a 
decrease of Th17 cells in DLN coincidently a decrease in TRIF dependent RANTES 
production in synovium was observed. Therefore, TLR4 and TRIF mediated 
production of RANTES appears to dictate Th17 cell accumulation during T-cell 
dependent flare-up of experimental arthritis. Additionally, we have studied IP-10 
(CCL10) production in inflamed synovium. Production of IP-10 was less affected 
in knockout animals and indeed we found that Th1 cell accumulation was only 
slightly affected, since IP-10 chemokine attracts Th1 cells (15).
Both IP-10 and RANTES are IRF3 dependent genes, but TLR mediated TRIF 
activation does not exclusively regulate IRF3. RIG-I and MDA-5 receptors are also 
involved in controlling IRF3 activation in a TRIF independent manner (21). This 
redundancy in the IRF3 control probably causes only a minor decrease in IRF3 
responsive genes in TLR4 and TRIF knockouts. Therefore, the production of IRF3 
genes is only partially reduced and leads to partial reduction of T-cell attraction to 
the inflammatory site. Moreover, the difference between TLR4 and TRIF signaling 
caused a discrepancy in timing of chemokine production and T-cell accumulation. 
This complex system needs further study to elucidate this interesting difference 
in timing of TLR4 and TRIF mediated T-cell accumulation at the inflammatory site. 
In summary, we show that TRIF signaling is involved in swelling and cellular 
infiltrate of T-cell dependent flare-up of experimental arthritis, while playing 
a minor role in joint destruction. However, both TLR4 and TRIF signaling are 
important in controlling Th17 cell numbers, likely through induction of RANTES 
production.
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Abstract
Hyperactivation of innate immunity by Toll-Like Receptors (TLR) can contribute 
to the development of autoinflammatory or autoimmune diseases. This study 
evaluated TAM receptor activation, physiological negative regulators of TLRs, by 
their agonists Growth arrest specific 6 (Gas6) and Protein S (Pros1) to prevent 
collagen-induced arthritis. Adenoviruses overexpressing Gas6 and Pros1 were 
injected intravenously (i.v.) or intra-articularly (i.a.) into mice during collagen-
induced arthritis. Splenic T-helper subsets of intravenously injected mice were 
studied by flow cytometry and knee joints of mice injected i.v. and i.a. were 
assessed histologically. Synovium of i.a injected mice was evaluated for cytokine 
and suppressor of cytokine signaling (SOCS) expression. Pros1 significantly 
reduced ankle joint swelling when overexpressed systemically. Further analysis 
of knee joints revealed a moderate reduction of joint pathology and a significant 
reduction of splenic T-helper 1 cells when Pros1 was overexpressed systemically. 
Local Gas6 overexpression decreased joint inflammation and joint pathology. 
Pros1 treatment showed a similar trend of protection. Consistently, Gas6 and 
Pros1 reduced cytokine production in synovium. Moreover, IL-12 and IL-23 
mRNA levels were reduced by Gas6 and Pros1 with a corresponding decrease 
in IFNγ and IL-17 production. TAM ligand overexpression was associated with an 
increase in SOCS3, which likely contributed to the amelioration of  arthritis. We 
provide the first evidence that TAM receptor stimulation by Gas6 and Pros1 can 
be used to ameliorate arthritis when applied systemically or locally. TAM receptor 
stimulation limits proinflammatory signaling and the adaptive immunity. This 
pathway provides a novel strategy to combat rheumatoid arthritis.
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Introduction
Rheumatoid arthritis is an auto-immune disease manifesting in articulating 
joints causing destruction of cartilage and bone. The cause of this disease is 
still unknown and treatment has focused on down regulating inflammation by 
blocking downstream signaling or neutralizing harmful cytokines. Although 
successful in the clinic, these therapies have substantial side effects and a high 
rate of non-responders among patients. Natural negative feedback mechanisms 
can potentially be used therapeutically to halt progression of the inflammatory 
process and initiate recovery. This approach could possibly limit side effects as 
the body’s own self-regulating responses are enhanced rather than uncontrolled 
and systemic blocking of cytokines, important in host defense.
One such controlling system of inflammation is that of the TAM receptors. Tyro3, 
Axl, and MerTK comprise a family of tyrosine kinase receptors and have been 
implicated in the negative regulation of inflammation. The regulatory role of TAM 
receptors in inflammation was found in triple knockout mice for the TAM receptors 
as these animals showed excessive lymphocyte proliferation and autoimmunity 
(1). Moreover, proinflammatory cytokine expression by macrophages is inhibited 
upon Gas6 treatment (2). Two ligands are described for the TAM receptor 
family, Gas6 and Pros1 (3). Both these ligands bind to phosphatidylserine on cell 
membranes and subsequently stimulate TAM receptors (4).
Gas6 has been shown to regulate Toll-Like Receptor (TLR) signaling in dendritic 
cells via activation of the Axl receptor (5). Stimulation of cells via the Axl receptor 
in conjunction with IFNAR leads to upregulation of suppressor of cytokine 
signaling (SOCS) proteins 1 and 3 (6;7), inhibitors of inflammation. SOCS1 blocks 
intracellular signaling e.g. NF-κB activation since SOCS1 can directly inhibit Mal, 
an adapter molecule for TLR2 and TLR4 (8). TLRs have also been implicated in 
maintaining the chronic inflammatory loop in RA synovium (9;10). and TLR2 and 
TLR4 play an important role in arthritis (11;12). SOCS3 also prevents binding 
of TRAF6 to TAK1, a key signaling molecule in e.g. TLR, IL-1 receptor and TNF 
receptor signaling (13;14). The protective role of SOCS proteins in experimental 
inflammatory mouse models has been shown  by ectopic overexpression of 
SOCS3 in collagen-induced arthritis (15). This resulted in altered splenic T helper 
cell responses towards antigens and ameliorated arthritis.
Taking into account that inflammation can be resolved by SOCS3 in CIA, we set 
out to determine if overexpression of Gas6 or Pros1 can ameliorate experimental 
arthritis. Here, we report for the first time to our knowledge that TAM stimulation 
can ameliorate arthritis. Systemic overexpression of Pros1 decreases arthritis 
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severity and is capable of reducing splenic Th1 cell numbers. Gas6 and Pros1 are 
both also capable of decreasing arthritis when overexpressed intra-articularly 
as joint pathology and synovial proinflammatory cytokine production were 
significantly reduced in the inflamed joint. 
Material and Methods
Mice
Male DBA/1 mice aged 10-12 weeks (Janvier, Elavage, France) were housed in 
filter-top cages and fed a standard diet with freely available food and water. All 
in vivo studies complied with national legislation and were approved by local 
authorities for the care and use of animals with related codes of practice.
Cloning strategy
The constructs pCDNA6AmGas6 and pCDNA6AmProS were cloned with KpnI and 
XbaI in the pShuttle vector behind the cytomegalovirus promoter (CMV). The 
pShuttleCMVmGas6 and pShuttleCMVmProS were cloned into the E1 deleted 
region of the adeno-5 virus backbone pAdEasyI.
Construction of adenoviral vectors
Viral vectors were E1A,B and E3 deleted and were produced according to 
the method described by (16). The purified recombinant adenoviral vector 
DNA was transfected into N52E6 viral packaging cells using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA). Virus was purified using two CsCl gradient 
centrifugations and stored in small aliquots at -80°C. The viral titer of the purified 
viral vectors was determined in human embryonic retinoblastoma 911 indicator 
cells by immunohistochemical detection of viral capsid protein, 20 hours after 
transfection.
Induction of CIA
Induction of collagen-induced arthritis has been described before (17). Briefly, 
bovine type II collagen was dissolved in 0.05M acetic acid to a concentration of 2 
mg/ml and was emulsified in equal volumes of Freund’s complete adjuvant (2mg/
ml of Mycobacterium tuberculosis strain H37Ra) (Difco, Detroit, MI) Mice were 
immunized intradermally at the base of the tail with 100µl of emulsion (50µg 
of bovine type II collagen). Subsequently, mice were given an intra-peritoneal 
booster injection of 100µg of type II collagen dissolved in phosphate buffered 
saline (PBS) on day 21. One day after the booster injection, immunized mice 
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were injected intravenously with 3x10E8 focus-forming units (FFU); for intra-
articular injection into both knees with 1x10E7 FFU Ad5.Gas6 or Ad5.ProS or 
Ad5.Luciferase. Two independent observers monitored clinical signs of arthritis 
in paws and ankle joints, macroscopically. Cumulative scoring based on redness, 
swelling, and, in later stages, ankylosis was as follows: 0=no changes; 0.25=1-2 
toes red or swollen; 0.5=3-5 toes red or swollen; 0.5= swollen ankle; 0.5=swollen 
footpad; 0.5=severe swelling and ankylosis (redness, excessive edema and 
deformation), with a maximal score of 2 per paw.
Histological analysis
Whole knee joints were dissected and fixed in phosphate buffered 4% 
paraformaldehyde followed by decalcification with 5% formic acid, and 
embedded in paraffin wax. Serial tissue sections (7µm) were stained with 
safranin O (BDH chemicals, Poole, UK) and counterstained with fast green (BHD 
Chemicals) or with hematoxylin / eosin (Merck, Germany) and eosin (Merck, 
Germany) (H&E). Serial sections were scored for histopathologic changes on a 
0-3 scale, by 2 independent observers in a blinded manner. Joint inflammation 
was determined by the presence of synovial cell infiltrates and inflammatory 
cell exudates. Connective tissue destruction was determined by the depletion 
of cartilage proteoglycan (loss of safranin O staining of the non-calcified upper 
cartilage layer) and by cartilage and bone erosion.  
RNA isolation and quantitative PCR analysis
Synovium and liver samples were disrupted using the MagNaLyser (Roche). Total 
RNA was extracted from the tissue homogenates and from cells using TRI reagent 
(Sigma) according to manufacturer’s protocol. Isolated RNA was treated with 
DNAse followed by reverse transcription of 1ug RNA into cDNA using Moloney 
murine leukemia virus reverse transcriptase 0.5µg/µl oligo(dT) primers, and 
12.5mM dNTPSs (Invitrogen). Quantitative real-time PCR was performed using 
the StepOnePlus sequence detection system (Applied biosystems, Foster City, CA) 
PCR was performed in a total reaction volume of 12.5 µl consisting of appropriate 
cDNA. Five µM of forward and reverse primer and the sYBR green PCR master 
mix (Applied biosystems). PCR protocol consisted of 2 min at 50°C and 10 min of 
95°C, followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C. Quantification 
of PCR signals was achieved by calculating the difference between the cycle 
threshold value (Ct) of the gene of interest with the Ct value of their reference 
gene glycerldehyde-3-phophate dehydrogenase (GAPDH) for each sample 
(delta Ct).
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Immunohistochemistry
Local expression of SOCS3 was evaluated on paraffin sections of the knee 
joints. Sections were deparaffinized and rehydrated. Endogenous peroxidase 
was blocked by 1% hydrogen peroxide for 15 minutes. Tissue sections were 
overnight incubated with anti-SOCS3 (Abbiotec, Emelca), followed by incubation 
with biotinylated goat α-rabbit. Peroxidase labeled streptavidine (Vectastain, 
Brunschwig) and diaminobenzidine were used for staining. Haematoxylin was 
used as counterstaining. Sections were arbitrarily scored on a scale from 0 to 3 on 
at least 2 sections per joint.
Assessment of anti-collagen antibody titers
Concentrations of anti-bovine CII IgG1 and IgG2a antibodies were determined 
using ELISA. Briefly, 96-wells plates were coated with 0.1 µg of bovine type II 
collagen. Non-specific binding sites were blocked by a 5% solution of milk powder. 
Serial dilutions of mice sera were added followed by incubation with isotype-
specific goat anti-mouse antibodies (peroxidase labeled) and 5-aminosalicylic 
acid as substrate. Absorbance was measured at 450 nm.
Flow cytometric analysis of splenic T-cells
Spleens from mice were mashed, filtered and erythrocytes were removed by 
osmotic shock. After washing CD3+ cells were isolated using the Pan T cell Isolation 
Kit (Miltenyi Biotec, Germany) according to manufacturer’s instructions. Purified 
CD3+ cells were stimulated in RPMI 1640 (Invitrogen) supplemented with 10% 
FCS penicillin/streptomycin and pyruvate with 50ng/ml PMA, 1µl/ml/10^6 cells 
Brefeldin A (BD Pharmingen) and 1µg/ml Ionomycin. After 4 hours of stimulation 
cells were stained with anti-mouse CD4-APC (1:200) (BD Pharmingen) or IgG2a-
APC control (BD Pharmingen) for 30 minutes at 4°C. Subsequently, cells were 
stained intracellular with anti-IL17-FITC and anti-IFNγ-PE or with their controls 
respectively IgG1-PE and IgG1-FITC according to instructions by manufacturer (BD 
Pharmingen). Stained cells were analyzed using FACScalibur (Becton Dickinson) 
and analyzed with FlowJow software.
Fluorescent imaging
CIA mice received an i.v. injection with activatable ProSense 680 NIR-fluorescent 
probe (150 µl, 2nmol) (PerkinElmer, Bedford USA) at day 28 of CIA. Probe 
becomes activated upon enzymatic cleavage by cathepsins (B,K,L,S) present in 
arthritic joints. Cathepsin activity is a measure of inflammation and especially 
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macrophage infiltration. At the time of imaging (24 hours post i.v. injection), 
mice were anesthetized with 2.5% isoflurane/oxygen, knee joints were shaved 
and placed on their back inside the light-tight chamber and imaged with the In 
Vivo Imaging System (IVIS) Lumina (Caliper Life Sciences), using the Cy5.5 filter. 
The collected data were analyzed using Living Image 3.0 (Caliper Life Sciences). 
Two-dimensional regions of interest (ROI) were drawn around the knee and ankle 
joints and fluorescent signal intensity was measured corrected for background 
and auto fluorescence signal.
Measurement serum levels IL-6 and KC
IL-6 and KC levels in serum were measured on a Luminex-100 System (Luminex 
corp.) using a magnetic bead-based multiplex immunoassay (Milliplex, Merck 
Millipore). Data analysis was performed with Bio-Plex Manager software (Bio-
Rad Laboratories).
Statistics
All data is represented as mean ± SEM and analyzed with GraphPad 5.0 software. 
Statistical significance was determined by either 1-Way ANOVA or Two-Way 
ANOVA with Bonferroni post test, comparing Ad-Gas6 and Ad-Pros1 groups with 
Ad-Luciferase.
Results
Systemic overexpression of Gas6 and Pros1 moderately reduces arthritis
Adenoviruses expressing Luciferase, Gas6, or Pros1 were administered 
intravenously to mice immunized with bovine collagen type II. As shown in 
Figure 1 overexpression of either Gas6 or Pros1 did not affect arthritis incidence. 
However, arthritis severity was slightly reduced 36 days post immunization when 
Gas6 was overexpressed. Moreover, Pros1 treatment resulted in a significant 
decrease in arthritis severity. In addition to scoring the macroscopic swelling and 
redness of the joints, knee joints were isolated to enable detailed examination 
on the effects of TAM activation on cell influx, bone and cartilage. This revealed 
a trend in decreased inflammation, cartilage erosion, and bone erosion when 
Gas6 or Pros1 were overexpressed systemically (Figure 1B-C). These data point 
towards a protective role of TAM activation in experimental arthritis. 
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Figure 1. Effect of systemically overexpressed Gas6 or Pros1 on arthritis. 
Mice with CIA intravenously injected with adenovirus encoding for either luciferase, Gas6, or Pros1 
after immunization and arthritis development was monitored over time. (A) Arthritis incidence and 
severity of hind paws. Severity was determined macroscopically; mean of the cumulative score of ankle 
and wrist joints per animal. Statistics: two-way ANOVA with Bonferroni post test, compared to Ad-
Luciferase (* p<0.05). (B) Histological analysis of knee joints for inflammation (HE stained sections), 
bone and cartilage erosion (safranin O stained sections). Data represented as mean ± SEM, n=9 per 
group. (C) Representative safranin-O stained sections indicating cartilage erosion (closed arrows) and 
bone erosions (open arrows). Scale bar = 100 µm. P = patella, F = femur.
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Systemically overexpressed Gas6 and Pros1 suppress the proinflammatory 
immune response
To study the effects on macrophage activity, serum was taken and evaluated 
for circulating cytokine levels. The TLR-inducible IL-6 and KC were detected in 
serum and Gas6 and Pros1 overexpression reduced circulating IL-6 levels in 
serum significantly by 59% and 78%, respectively. In addition, Pros1 caused a 68% 
decline in circulating KC levels (Figures 2A), potentially explaining a decrease in 
inflammatory cell influx into the inflamed joints. Moreover, serum IL-6 and KC 
levels significantly correlated with macroscopic arthritis scores (IL-6 correlation: 
R2 = 0.41, p value 0.001. KC correlation: R2 = 0.33, p value 0.004). This indicates that 
Gas6 and Pros1 decreased systemically produced cytokines during inflammatory 
conditions and possibly control antigen presenting cell (APC) activation and 
function. To study the effect of TAM ligand overexpression systemically on B-cells 
the antibody titers against bovine collagen type II were determined (Figure 2B). 
Both Gas6 and Pros1 did not have an effect on collagen type II specific IgG1 or 
IgG2a antibody titers. This suggests that TAM ligands did not influence B-cell 
function. To further analyze the effects of Gas6 and Pros1 overexpression on the 
adaptive immunity, splenic CD3+ cells were isolated and T cell differentiation was 
determined. TAM receptor stimulation significantly reduced Th1 levels, whereas 
Th17 levels were unaffected by either treatment (Figure 2C). In accordance, mRNA 
expression level of T-bet was decreased significantly, whereas RORγT expression 
was  unchanged (Figure 2D). This indicates that TAM activation has a clear effect 
on T-cell immunity by diminishing the development of Th1 cells, resulting in a 
reduction of arthritis.
Local overexpression of TAM ligands decreases inflammation and joint pathology
Gas6 and Pros1 show clear effects on Th1 development, but failed to ameliorate 
inflammation and joint pathology significantly. To study the effect of Gas6 
and Pros1 directly at the inflammatory site, adenoviruses were injected intra-
articularly in both knee joints before onset of CIA. During arthritis development 
the inflammation was measured with the ProSense probe at day 29 (Figure 
3A), and TAM activation significantly reduced inflammation in the treated knee 
joints. Further analysis of inflammation, cartilage, and bone destruction revealed 
that TAM activation is beneficial for halting joint destruction (Figure 3B-C). 
Inflammation of the non-treated (ankle) joints was unaltered by either treatment 
(data not shown) indicating that TAM activation occurred only locally in the knee 
joint. This indicates that TAM activation directly at the site of inflammation can be 
applied to treat inflammatory diseases.
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Figure 2. Serum cytokines, antibody titers, and splenic Th1 and Th17 analysis. 
(A) Serum was harvested at time of sacrifice (day 36 of CIA) and serum levels of IL-6 and KC were 
measured by Luminex. (B) Anti-bovine collagen type II antibodies in serum measured by ELISA. O.D. = 
Optical density. (C)Spleens from CIA mice were isolated at time of sacrifice (day 36 of CIA) and CD3+ 
cells were isolated by negative MACS selection. T-cells were subsequently stimulated with PMA and 
ionomycin for 4 hours and stained for CD4, IFNγ, and IL-17 and percentage of positive cells were 
determined by flowcytometry. (C) Percentages of splenic Th1 (CD4+/IFNγ+) and Th17 (CD4+/IL-17+) 
cells, gated on CD4+ cells. (D) mRNA expression analysis of transcription factors Tbet (Th1) and RORγT 
(Th17). Relative expression=2-dCt. Statistics: one-way ANOVA with Bonferroni post test, compared to 
Ad-Luciferase (* p<0.05, ** p<0.01, *** p<0.001). Data represented as mean ± SEM, n=9 per group.
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Figure 3. Effects of local overexpressed Gas6 and Pros1 on joint inflammation and histology. 
CIA mice were injected intra-articularly into the left and right knee joint with adenovirus encoding 
for either Luciferase, Gas6, or Pros1 and arthritis development was monitored over time. (A) Knee 
inflammation on day 29 of CIA measured with a cathepsin inducible fluorescent probe (ProSense) and 
knee swelling at time of sacrifice (day 31 of CIA) determined macroscopically (scale 0-2).  (B) Histological 
analysis of knee joints for inflammation (HE stained sections), bone and cartilage erosion (safranin 
O stained sections). Statistics: one-way ANOVA with Bonferroni post test, compared to Ad-Luciferase 
(** p<0.01, *** p<0.001). Data represented as mean±SEM. ProSense measurement n=20 per group, 
knee swelling n=10 per group, histology n=14 per group. (C) Representative safranin-O stained sections 
indicating cartilage erosion (closed arrows) and bone erosions (open arrows). Scale bar = 100 µm. P = 
patella, F = femur.
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Messenger RNA expression analysis of synovium showed that both Gas6 and Pros1 
mRNA were upregulated two days after virus injection (data not shown). Further 
analysis revealed that both Gas6 and Pros1 reduced matrix metalloproteinase 
(MMP) expression in synovium (Figure 4A-C). Gas6 and Pros1 significantly 
reduced MMP13 mRNA expression, whereas MMP14 and MMP9 expression were 
diminished significantly by overexpressing Gas6 or Pros1 respectively. Altogether, 
these data show that local TAM activation directly in inflamed joints decreases 
joint destruction by reduced MMP expression.
Gas6 and Pros1 decrease cytokine production in synovium
To study the effects of TAM activation on local cytokine production before clinical 
manifestation was observed, synovium was isolated at day 24 of CIA. Interestingly, 
TNFα production was detected before clinical manifestation and was significantly 
inhibited 87% and 62% by Pros1 and Gas6, respectively. IL-1β and IL-6 were 
only marginally produced on day 24, but were markedly induced when synovitis 
occurred (Figures 5A). Gas6 and Pros1 decreased IL-1β production at day 31 of 
CIA by the inflamed synovium by 65% and 78% respectively. In addition, IL-6 
production returned to near basal expression levels by overexpression of Gas6 
and Pros1 as IL-6 mRNA expression was significantly reduced by 74% and 92% 
Figure 4. MMP expression analysis in 
synovium of locally treated CIA mice. 
Matrix metallo-proteinase expression in 
synovium harvested at day 24 and day 31 
of CIA. (A) MMP9, (B) MMP13, (C) MMP14. 
Statistics: two-way ANOVA with Bonferroni 
post test, compared to Ad-Luciferase (* 
p<0.05, ** p<0.01). Data represented as mean 
± SEM, n=4 on day 24 and n=6 on day 31.
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respectively. The anti-inflammatory effects of Gas6 and Pros1 were also observed 
in production of T-cell activating cytokines IL-12 and IL-23. Figure 5B shows that 
overexpression of Gas6 and Pros1 caused a decline in IL-12 and IL-23 production 
in synovium resulting in reduced IFNγ and IL-17 levels in the synovium (Figure 5C). 
In addition, Figure 5D shows that T-cell transcription factors mRNA expression 
of T-bet and RORγT, responsible for Th1 and Th17 development respectively, 
was significantly reduced by Gas6 and Pros1. These cytokine expression profiles 
support the findings of reduced joint pathology, since IL-1 and IL-17 are key 
factors in cartilage and bone destruction. These data show that local TAM 
activation by Gas6 and Pros1 reduce proinflammatory cytokine production in 
inflamed synovium. This probably led to subsequently hampered T-cell activation 
and proliferation at the site of inflammation.
SOCS1 mediated anti-inflammatory effects of Gas6 and Pros1
To unravel the inhibitory mechanism of TAM receptor stimulation, mRNA 
expression of SOCS1 and SOCS3 was evaluated (Figure 6A). SOCS1 mRNA 
expression was upregulated 2.3 fold in synovium of mice injected with Gas6 
or Pros1 virus, whereas control animals showed a slight down regulation. In 
contrast, SOCS3 mRNA regulation was marginally affected by Gas6 overexpression 
and even slightly downregulated by Pros1 overexpression. Since this is in 
contrast with previous results (18), we determined SOCS3 protein levels by 
immunohistochemistry. Figure 6B shows representative images of the SOCS3 
staining and a clear trend is observed in upregulation of SOCS3 protein by Gas6 
and Pros1 (Figure 6C). This suggests that SOCS1 and SOCS3 mediate the anti-
inflammatory effects of TAM activation by Gas6 and Pros1. 
Discussion
A novel inhibitory pathway on TLR and cytokine signaling by TAM receptor 
activation has been exploited in this study to inhibit experimental arthritis. Here, 
we show that enhancing the negative feedback on inflammation by TAM receptor 
activation can be used to treat arthritis in a prophylactic setting. Systemic 
overexpression of Pros1 affected the T-cell immune response by decreasing Th1 
and ameliorated experimental arthritis moderately. Intra-articular overexpression 
of Gas6 and Pros1 reduced proinflammatory cytokine production in synovium, 
which was likely to be mediated by SOCS1 and SOCS3. Gas6 also significantly 
decreased joint destruction when overexpressed in the inflamed joint. We 
show for the first time that TAM receptor activation by Gas6 and Pros1 in vivo 
ameliorates arthritis. This puts the TAM pathway forward as a new therapeutic 
pathway to be exploited to treat arthritis. 
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Figure 5. Cytokine expression in synovium of locally treated CIA mice. 
Synovium was isolated two days after virus injection (day 24 of CIA) and at time of sacrifice (day 31 
of CIA) and mRNA was isolated. (A) mRNA expression of TNFα, IL-1β, and IL-6 was determined by 
qPCR. Statistics: two-way ANOVA with Bonferroni post test, compared to Ad-Luciferase (** p<0.01, 
*** p<0.001). Data represented as mean±SEM, n=4 on day 24 and n=6 on day 31. mRNA expression of 
cytokines (B-C) and transcription factors (D) at day 31 of CIA. Statistics: one-way ANOVA with Bonferroni 
post test, compared to Ad-Luciferase (* p<0.05, ** p<0.01). Data represented as mean ± SEM, n=6 per 
group.
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In our study Pros1 decreased splenic Th1 cells by 40% while leaving Th17 levels 
unaffected. This is in accordance with previous studies in Axl and MerTK double 
knockout animals. Naïve splenic CD4+ T cells from double knockout mice show 
a remarkable increase in IFNγ production when stimulated with anti-CD3 and 
anti-CD28 and no change in IL-17 production. In addition,  immunized double 
knockout mice show increased Th1 development and normal Th17 levels in 
spleen and DLN (19). In animals that lack the MerTK receptor in the diabetes 
prone NOD background, a strong Th1 response was observed when β-cells 
underwent apoptosis (20). Combined with our data, it appears that TAM 
activation on APCs primarily affects Th1 response in vivo while not influencing 
Th17 response. Since circulating IL-6 levels were significantly decreased 
by Gas6 or Pros1 overexpression in our study an effect on Th17 could be 
expected. However, previous studies have shown that Gas6 can regulate 
TGF-β expression. Clauser et al. (21) showed that increased Gas6 secretion from 
carotid plaques correlates with increased TGF-β secretion. In addition, Gas6 
knockout animals produce less TGF-β upon induction of liver damage (22). If 
Gas6, and perhaps Pros1, increase TGF-β levels this could compensate for the 
reduced IL-6 levels and leaving Th17 levels unaffected.
Gas6 and Pros1 appear to have differential effects depending on local or systemic 
overexpression. When overexpressed systemically, Pros1 seems slightly more 
efficacious than Gas6 and locally the reverse effect has been observed. But in fact, 
no significant differences between Gas6 and Pros1 were found on arthritis. The 
trends observed between Gas6 and Pros1 could be attributable to different target 
cells. Systemic overexpressed TAM ligands will affect systemic adaptive immunity 
by APC activity modulation in the spleen, which was also observed in our study. 
At the site of inflammation on the other hand, TAM ligands are expressed and 
secreted into the joint cavity affecting all the cells present, such as infiltrated 
macrophages, T-cells, and the synovial lining. Fibroblasts in the synovial lining are 
active contributors to the inflammation (23) and the effects of TAM ligands and 
TAM receptor expression on synovial fibroblasts is unknown and warrants further 
investigation. 
The anti-inflammatory effects of TAM receptors has been reported to be 
mediated by SOCS1 and SOCS3 (24;25). Rothlin et al. found that stimulation 
of the Axl receptor in conjunction with the IFNARI lead to an upregulation of 
SOCS1 and SOCS3 in dendritic cells, which interfere with intracellular signaling 
and NF-κB activation. The effects of local Gas6 or Pros1 overexpression appear 
to be mediated via SOCS1 and SOCS3. Overexpression resulted in upregulation 
of SOCS1 expression during arthritis, whereas control animals showed a slight 
downregulation of SOCS1. The pivotal role of SOCS1 in controlling inflammation 
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has been shown in macrophages from SOCS1 conditional knockout animals, in 
which TNF-α and IL-6 expression was down regulated upon LPS challenge (26). In 
our study we also observed a decrease in proinflammatory cytokine production in 
synovium by overexpressing Gas6 or Pros1 in the joint cavity. In contrast to SOCS1 
up regulation, little regulation of SOCS3 mRNA by TAM receptor activation was 
found. However, immunohistological staining revealed a trend towards increased 
SOCS3 protein after Gas6 or Pros1 overexpression. SOCS3 mRNA levels are partly 
controlled by TNF-α (27) and Il-6 (28), of which we found significant differences 
at day 24 and day 31 of CIA respectively. Therefore, mRNA expression at time 
of sacrifice could deviate from protein levels. In addition, cytokine signaling has 
been suggested to prevent SOCS3 turnover (29). The increase in SOCS1 and SOCS3 
are also in line with previous studies (30), showing the involvement of SOCS1 
and SOCS3 in TAM mediated downregulation of inflammation. Taken together, 
a significant increase in SOCS1 mRNA in synovium and a clear trend in increased 
SOCS3 protein could partly account for the anti-inflammatory effects observed 
by Gas6 and Pros1.
Figure 6. SOCS proteins are up regulated by Gas6 and Pros1. 
mRNA was isolated from synovium isolated two days after virus injection (day 24 of CIA) and at time 
of sacrifice (day 31 of CIA). (A) Fold increase in mRNA expression of SOCS1 and SOCS3 on day 31 of 
CIA compared to day 24 of CIA. Statistics: one-way ANOVA with Bonferroni post test, compared to Ad-
Luciferase (* p<0.05, *** p<0.001). Data represented as mean±SEM, n=4 on day 24 and n=6 on day 31. 
(B) Representative images of immunohistochemistry staining of SOCS3 in intraarticular injected knee 
joints. (closed arrows). Scale bar = 100 µm. P = patella, F = femur. (C) Arbitrary score of SOCS3 staining 
(scale 0-3). Data represented as mean±SEM, n=14 per group. 
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Another possible mechanism by which Gas6 and Pros1 exert their anti-
inflammatory effects is by inducing phagocytosis. Gas6 and Pros1 can opsonize 
apoptotic cells by binding to phosphatidylserine displayed on apoptotic cells. It 
has been shown before that joint inflammation can be reduced by prophylactic 
injection of apoptotic cells directly into the joint (31). Clearance of apoptotic 
leukocytes by lining macrophages decreases their chemotactic activity and 
thereby limits inflammation. MerTK is predominantly involved in phagocytosis 
(32) and plays a role in inflammation as well. It has been shown that MerTK 
downregulates TNF-α production upon LPS stimulation (33) and MerTK is also 
involved in LPS induced lung injury (34). Both Gas6 and Pros1 are ligands for the 
MerTK receptor and could therefore increase TAM signaling, via apoptotic cells 
or direct stimulation of the MerTK receptor on macrophages. However, the exact 
role of exogenous Gas6 and Pros1 in mediating phagocytosis of apoptotic cells to 
facilitate resolution of joint inflammation needs further investigation.  
Axl and Gas6 have been implicated in maintaining the abnormal vasculature in RA 
(35) and thereby contributing to inflammation.  Here, we show that the net effect 
of increasing TAM signaling is beneficial for experimental arthritis. TAM ligands 
could potentially induce SOCS1 and SOCS3 expression in human RA synovium 
and thereby decreasing inflammation. With decreasing inflammation also the 
process of angiogenesis will halt and TAM stimulation by Gas6 or Pros1 could 
potentially treat RA by controlling inflammation irrespective of its putative effect 
on angiogenesis.
In summary, we provide the first evidence that enhancing natural negative 
feedback on inflammation by TAM stimulation is efficacious to treat inflammatory 
arthritis. TAM receptors and their ligands Gas6 and Pros1 offer many possibilities 
and options to fine tune the negative feedback on inflammation to resolve auto-
inflammatory and autoimmune diseases.
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Summary
Toll-Like receptors have emerged as the pivotal factors in controlling the immune 
system. They are involved in activating the innate immunity and control the 
adaptive immunity. Moreover, a role for TLRs has been described for several 
autoimmune diseases, such as rheumatoid arthritis. An important role for TLRs 
has also been established in experimental arthritis animal models. Especially TLR4 
has been extensively studied using TLR4 knockout animals and TLR4 antagonists. 
These studies revealed an aggravating role of TLR4 in the chronic phase of 
arthritis, while leaving incidence unaffected.
In this thesis, we set out to evaluate the role of TLR4 on different cell populations 
and to gain insight into the signaling pathways of TLR4. This enables us to pinpoint 
the role of TLR4 in arthritis and allows us to design more specific therapies. First, we 
investigated the contribution of TLR4 on resident cells and bone marrow derived 
cells. Therefore, bone marrow transplantation was performed in order to make 
bone marrow chimeras in which TLR4 was absent on either bone marrow derived 
cells or resident cells (chapter 2). Arthritis development was monitored over time 
and we observed that animals lacking TLR4 on either the bone marrow derived 
cells, resident cells, or both developed reduced swelling and diminished joint 
pathology. Further analysis showed that both the bone marrow cells and resident 
cells are involved in generating Th17 cells in spleen, whereas the bone marrow 
derived cells are responsible for CD4- IL-17 producing cells locally in the lymph 
node. This unexpectedly indicated that TLR4 is necessary on both bone marrow 
derived cells and local resident cells to continue the self stunained inflammatory 
loop and achieve full blown arthritis. Although both chimeras showed an equal 
clinical outcome, the underlying mechanisms might differ considerably. The 
resident cells, such as chondrocytes, tissue macrophages and fibroblasts also 
express TLR4 and can be activated during inflammatory processes. Upon TLR4 
activation fibroblasts produce cyto- and chemokines as well as matrix degrading 
enzymes, contributing to joint destruction. The breakdown of extracellular matrix 
from cartilage, release of alarmins and intracellular proteins during arthritis 
provide potential endogenous ligands stimulating TLR4. 
To evaluate the role of TLR4 stimulating endogenous ligands in the joint cavity 
a local arthritis was induced by IL-1β overexpression (chapter 3). IL-1β is known 
to induce joint destruction and this will generate DAMPs potentially capable of 
stimulating TLR4. TLR4 knockout animals developed reduced joint pathology, 
indicating a pivotal role of TLR4 activated by endogenous ligands during 
inflammation and thereby mediating joint destruction locally in the joint.
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Many studies have been performed identifying potential endogenous ligands, 
such as fibronectin, heat shock proteins and serum amyloid A proteins. This 
research has been hampered by LPS contamination and probably the use of 
incorrect proteins. We, and others, have shown that a slightly modified serum 
amyloid A (SAA) recombinant protein can have profound proinflammatory 
capacities. However, when the non-modified natural form of SAA1 was used in 
the same assays, we observed only marginal proinflammatory activity (chapter 4). 
This implies that the search for endogenous ligands of TLRs is not only hampered 
by contamination, but that we should be cautious in using recombinant modified 
proteins.
Being Pattern Recognition Receptors it is tempting to view TLRs as immune 
receptors involved on immune cells and more specifically the antigen presenting 
cells (APCs). These cells sense the environment and mount an immune response 
when encountering pathogens carrying the ligands for TLRs. In this classical view 
of TLRs, we delineated the role of TLR4 on bone marrow derived cells further 
by specifically knocking down TLR4 expression on APCs in spleen (chapter 5). 
By intravenous delivery of a lentivirus we were able to target splenic APCs. The 
lentivirus encoded a short hairpin against TLR4, knocking down TLR4 expression. 
Despite lack of direct evidence that TLR4 expression was decreased in this 
experiment, we did find functional effects, since the IFNγ production by CD4- 
cells was diminished in draining lymph nodes. Unexpectedly, a slight increase in 
inflammation and swelling was found in animals treated with the hairpin against 
TLR4. These results could possibly be explained by a lack of negative feedback on 
the APC induced by TLR4 activation and thereby enhancing the APC activity under 
this condition.
Targeting TLR4 signaling
Besides the location where TLR4 should be inhibited or which cell should be 
targeted several ways to inhibit TLR4 signaling have been studied. TLR4 signaling 
can be divided in MyD88-dependent and TRIF-dependent pathways, resulting 
in activation of NF-κB and IRF3 respectively. Therefore, both pathways have 
been studied to evaluate their role in experimental arthritis and their value as a 
therapeutic tool. 
MyD88 signaling after TLR4 activation induces many proinflammatory cytokines 
and also MMPs. This makes the MyD88 signaling an interesting target and MyD88 
knockouts show strongly reduced arthritis (1). To block MyD88 signaling a kinase 
negative mutant of TGF-beta activated kinase-1 (TAK1) was overexpressed. 
Overexpression of the mutant was achieved cell specifically by intravenous 
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delivery of lentivirus (chapter 6). Here, we showed that blocking TAK1 signaling 
results in ameliorated arthritis, reduced Th17 development, and diminished 
bone erosion. This reduction might be mediated by targeting the osteoclast 
precursors and a reduction in the osteoclast forming factors RANK and RANKL in 
synovium. This indicates that inhibiting MyD88 mediated signaling by blocking 
TAK1 in splenic APCs is a potential efficacious treatment of arthritis. This triple 
MAP kinase, however, is used by many proinflammatory signaling pathways and 
is therefore not TLR(4) specific, but the capability of inhibiting several pathways 
might explain its effectiveness in treating inflammatory conditions. To evaluate 
the efficacy of TAK1 inhibition locally, the role of TAK1 in rheumatoid arthritis 
synovial fibroblasts was studied (chapter 7). Surprisingly, TLR4 signaling was 
TAK1 independent in these cells. TAK1 signaling can be circumvented by TLR4 
by using MEKK3 resulting in NF-κB activation and subsequent production of 
proinflammatory mediators. Considering the role of endogenous TLR4 ligands 
in the inflamed joint, TAK1 inhibition in rheumatoid arthritis synovial fibroblasts 
might not be a suitable method to treat arthritis. Taken together, TAK1 signaling 
in APCs poses as an interesting target for treatment of arthritis.
The second signaling pathway used by TLR4 is the TRIF pathway, a putative anti-
inflammmatory pathway. This pathway induces type I IFNs that subsequently 
induce the suppressor of cytokine signaling (SOCS) proteins (2). Additionally, 
TRIF signaling induces IL-27, which limits Th17 development (3). Because of its 
putative anti-destructive properties, we investigated the role of TRIF signaling 
during T-cell dependent flare of arthritis (chapter 8). After a primary arthritis the 
smoldering arthritis is flared using a sub arthritic dose of antigen. This results in 
rapid accumulation of inflammatory cells into the inflamed joint. TLR4 plays a 
crucial role in this process by inducing IP-10 and RANTES that draw T-cells to the 
site of inflammation, whereas TRIF signaling did not play a role. TRIF signaling, 
however, does appear to play a role in the resolution of the inflammation. Th17 
levels subsided more rapidly in TRIF knockouts during later phase of arthritis. 
Again, decreased expression of TRIF/IRF3-induced chemokines appeared to 
mediate T-cell migration during the resolution phase of arthritis. These results 
are in contrast with previous reports indicating anti-inflammatory properties of 
the TRIF pathway on arthritic bone erosion during SCW-induced chronic arthritis 
and in an experimental model of multiple sclerosis (3;4). In our experiment we 
studied the recruitment of T-cells to the site of inflammation rather than onset 
of disease. Therefore, the role of TRIF in autoimmune processes is multifaceted 
and the chemokines might play a more important role than type I IFNs or IL-27 in 
certain conditions.
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Enhancing natural negative regulatory feedback
TLR4 signaling is physiologically down regulated by several intracellular inhibitors, 
such as SOCS1 and SOCS3 (5). These proteins interfere with assembly of 
signaling protein interaction, inhibit kinase activity, and can induce proteasomal 
degradation. These mechanisms prevent activation and subsequent downstream 
proinflammatory signaling (2). Overexpressing SOCS3 has been proven to 
ameliorate arthritis and modulate T-cells (6). We have found a novel tool to 
upregulate expression of SOCS1 and SOCS3 through activation of TAM receptors 
by their natural ligands Gas6 and Pros1 (chapter 9). Systemic overexpression of 
Pros1 reduced Th1 levels in spleen and this moderately ameliorated arthritis. Gas6 
Figure 1. TLR4 signaling, gene induction, and inhibition
Activation of TLR4 results in signaling through MyD88 and TAK1, inducing proinflammatory cytokine 
production. After uptake of the TLR4 receptor with its ligand initiates TRIF signaling resulting in late 
NF-κB activation and production of Type I IFNs. These Type I IFNs in conjunction with TAM receptors 
(Tyro3, Axl, and MerTK) induces negative feedback on TLR4 signaling through SOCS proteins. TLR4 
can be inhibited by targeting the receptor by TLR4 antagonists, TAK-242 or decreasing its expression 
with siRNA (1) (Chapter 5). Also TLR4 signaling can be inhibited by blocking the key player TAK1 in 
downstream signaling (2) (Chapter 6) or blocking TRIF activation (3) (Chapter 8). Lastly, negative 
feedback can be enhanced by stimulating TAM receptors by Gas6 or Pros1 (4) (Chapter 9).
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and Pros1 were more effective in decreasing inflammation when overexpressed 
locally. This decrease was accompanied by the upregulation of both SOCS1 and 
SOCS3, pointing to the effectiveness of TAM activation in inhibiting inflammation. 
This breaks the inflammatory loops and prevents progression of arthritis sustained 
by endogenous ligands stimulating TLRs. This strategy possibly limits side effects 
as we have seen a potential increase in inflammation after specific deletion of 
TLR4 on APCs. By temporarily increasing the natural feedback on inflammation 
we can possibly circumvent side effects such as a dysfunctional immune system 
against invading pathogens.
Future perspectives
Rheumatoid arthritis treatment is dominated by the use of biologicals, such as 
various anti-TNF therapeutics and rituximab. These treatments are efficacious in 
the majority of patients, but a third of the patients are non-responders to current 
treatment. Moreover, treatment with biologicals pose a major economic burden 
as these therapeutics are expensive to produce. Therefore, small molecule 
therapeutics could supplement the current treatment of rheumatoid arthritis 
cost-effectively and possibly treat current non-responders.
The small molecule TAK-242 has been tested as a specific TLR4 inhibitor in a 
clinical trial for sepsis and the researchers concluded that it was ineffective in 
sepsis treatment (7). However, numerous issues have been raised concerning 
the experimental set up, therefore the efficacy of TAK-242 has not been ruled 
out (8). Nonetheless, the clinical trial showed that TAK-242 was well tolerated by 
patients, which makes it a potential treatment for rheumatoid arthritis. Besides 
a potential new therapeutic agent, this also provides a valuable tool to assess if 
TLR4 plays a role in rheumatoid arthritis. Although evidence is mounting that TLR4 
is playing a role in rheumatoid arthritis, TLR4 inhibition in rheumatoid arthritis 
has been performed on small scale using recombinant proteins of chaperonin 
10 (9). Despite the fact that TAK-242 treatment will not be cell or site specific, it 
could be an easy and valuable tool to further study the effects of TLR4 blocking 
in rheumatoid arthritis on a larger scale. The issue of cell specificity could be 
overcome by sophisticated delivery and release methods, such as antibody 
directed lipoplexes (10). This could achieve better and specific targeting of TLR4 
and thereby limiting side-effects. In addition to TAK-242 several LPS variants have 
been described to inhibit TLR4 activation, such as ultra pure LPS extracted from 
Bartonella quintanta (11). However, extensive use of these inhibitors is hampered 
by complicated culture, production, and purification procedures. Taken together, 
TAK-242 appears to the most promising tool to assess the role of TLR4 in RA and 
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is possibly an interesting therapeutic for systemic inhibition of TLR4 in RA patients 
in the future. 
Since we observed an important role of TLR4 on resident cells locally in the 
joint, inhibiting TLR4 at the site of inflammation could also be beneficial. Local 
application of TAK-242 would be difficult as it diffuses rapidly, like most small 
molecules. Therefore protein based TLR4 inhibitors or antibodies against 
TLR4 would be preferred. Unfortunately, antibody production against TLR4 is 
complicated to achieve, resulting in poor titers. Only few have been succesfull 
and its inhibitory effect was partially based on FcγRIIA (17). Therefore, we have 
made several attempts to produce protein based TLR4 inhibitors based on TLR4 
itself. TLR4 makes use of MD-2 and a natural splice variant scavenges LPS and 
subsequently prevents TLR4 triggering (12). Additionally, a soluble form of TLR4 
can sequester TLR4 ligands and prevent signaling. This soluble TLR4 is naturally 
occurring as a small peptide (13;14), but in order to potentially broaden ligand 
binding we also attempted to produce the complete extra cellular domain of 
TLR4. Unfortunately, both proteins were difficult to overexpress as recombinant 
proteins. The complex protein structure of TLR4 makes it very difficult to obtain 
sufficient expression levels. In a last attempt a fusion construct was used (14), but 
expression proved to be difficult yet again. Since TLR4 is a problematic transgene, 
other natural inhibitors could overcome this issue. Membrane bound inhibitors, 
such as RP105 (15) and ST2 (16), could be used locally. When overexpressed, 
using an adenoviral vector, these molecules could provide a valuable tool to 
identify the role of TLR4 on synovial fibroblasts. Gene therapy for rheumatoid 
arthritis should be focused on a stable integrating vector with a disease inducible 
promoter. When the targeted cells are exposed to inflammatory stimuli transgene 
expression is induced and inhibition occurs when necessary. Additionally, the 
inhibition will remain mainly in the joint cavity limiting side effects in combating 
invading pathogens. 
Enhancing natural negative feedback on TLR signaling locally by TAM stimulation 
provides a new and promising mechanism to treat arthritis. To circumvent 
inhibition of only one receptor on the targeted cells the secreted Gas6 and Pros1 
proteins affect all the cells in the joint. The use of a disease inducible promoter 
regulating transgene expression will help to fine tune treatment. Gas6 and Pros1 
stimulate the TAM receptor system inducing negative feedback on inflammation 
by upregulation of SOCS proteins, which inhibit proinflammatory signaling (5). 
This could potentially break the inflammatory loop in the joint space and halt 
progression of the clinical symptoms and induce recovery. 
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Nederlandse samenvatting
Reumatoïde artritis is een chronische aandoening waarbij de gewrichten 
ontstoken zijn. Deze continue ontsteking leidt, na verloop van tijd, tot 
beschadiging van kraakbeen en bot. Dit brengt de kenmerkende vergroeiingen 
van gewrichten teweeg die met reumatoïde artritis gepaard gaan. De oorzaak van 
deze chronische ontstekingen is tot op heden onduidelijk en lijkt een combinatie 
te zijn van genetische aanleg en omgevingsfactoren. In de afgelopen jaren is er 
veel onderzoek gedaan naar de mechanismen die de gewrichtsontsteking in 
stand houdt. Het is gebleken dat de zogenaamde Toll-Like Receptoren (TLRs), 
belangrijk zijn bij de activatie van met name het aangeboren immuun systeem. 
Ook is gebleken dat deze receptoren een cruciale rol spelen bij de verbinding 
tussen het aangeboren en het verworven immuunsysteem. Toll-Like Receptor 4 
(TLR4) blijkt een uitermate belangrijke rol te spelen in het activeren van immuun 
cellen die behoren tot de aangeboren immuniteit, zoals de macrofaag.
De rol van TLR4 in experimentele artritis is bestudeerd aan de hand van genetische 
knock-out muizen, die het TLR4 gen missen, en het blokkeren van TLR4 activatie. 
Hieruit is gebleken dat TLR4 een versterkende rol speelt in experimentele artritis. 
Dieren waarin het gen ontbrak, lieten een duidelijke verlaging zien van de 
ontsteking en hadden minder schade in de gewrichten. Na deze sterke aanwijzing 
dat TLR4 een belangrijke rol speelt in artritis, rees de vraag op welke cellen TLR4 
een belangrijke rol speelt. Middels een beenmerg transplantatie (hoofdstuk 2) 
tussen genetische knock-outs en normale dieren werd het onderscheid gemaakt 
tussen de cellen afkomstig uit het beenmerg, voornamelijk de bloedcellen, en 
de lichaamscellen. Hieruit is gebleken dat TLR4 op zowel de beenmergcellen als 
de lichaamscellen een cruciale rol speelt, doordat in dieren waarin TLR4 ontbrak 
op de bloedcellen, lichaamscellen of beide celtypen een verlaagde ontsteking 
te zien was en er minder schade in het gewricht was. Verdere analyse van het 
verworven immuunsysteem liet zien dat TLR4 op de bloedcellen een belangrijke 
rol speelt bij het ontstaan van IL-17 producerende T-cellen. Deze soort T-cellen 
zijn erg destructief tijdens de ontsteking.
Om de rol van TLR4 op de lichaamscellen verder te bestuderen, is een belangrijk 
pro-inflammatoir cytokine, interleukine 1 (IL-1), tot overexpressie gebracht in 
de gewrichtsholte (hoofdstuk 3). Uit dit experiment bleek dat TLR4 betrokken is 
bij gewrichtsschade, want wanneer TLR4 ontbrak, ontstond er minder schade. 
Omdat IL-1 niet direct TLR4 kan activeren, moeten er tijdens de ontsteking TLR4 
activerende producten ontstaan. Dit zijn zogenaamde endogene liganden die 
ontstaan tijdens een actieve ontsteking en weefselschade. Deze producten, of 
endogene liganden, activeren TLR4 waardoor de ontsteking sterker wordt.
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De stimulerende endogene liganden is grondig onderzocht. Een veel gebruikt 
model eiwit hiervoor is het recombinant serum amyloïd A1. Dit eiwit blijkt een 
ontstekingsbevorderende werking te hebben. Echter, dit recombinante eiwit is 
iets gemodificeerd en gebruik van het correcte lichaamseigen eiwit blijkt niet pro-
inflammatoir te zijn (hoofdstuk 4). Daarmee staat de rol van het lichaamseigen 
serum amyloïd A1 als belangrijk endogeen ligand ter discussie
Doordat TLRs tot expressie komen op immuun cellen, en in het bijzonder antigeen 
presenterende cellen (APCs), is het voor de hand liggend om TLRs te zien als 
immuun receptoren. Deze APCs scannen het lichaam op infiltrerende pathogene 
microben en initiëren een immuunrespons wanneer nodig. De rol van TLR4 op 
APCs is nader bestudeerd door de expressie van TLR4 op APCs te verlagen in de 
milt (hoofdstuk 5). Door een lentivirus intraveneus toe te dienen, worden de APCs 
in de milt getransduceerd en middels RNA interference kon de TLR4 expressie 
worden verlaagd in de getransduceerde cellen. Ondanks gebrek aan direct bewijs 
in de behandelde dieren dat de TLR4 expressie daadwerkelijk was verlaagd, zijn 
er wel functionele effecten gevonden. In de drainerende lymfeknopen werd 
minder van het cytokine interferon γ geproduceerd door CD4 negatieve cellen 
en was er een trend in verlaagde Th17 aantallen. Desondanks leek de artritis 
macroscopisch te zijn toegenomen. Deze resultaten kunnen wijzen op een gebrek 
aan negatieve terugkoppeling welke geïnduceerd wordt na activatie van TLR4 en 
daardoor wordt de activiteit van de APCs juist versterkt en de artritis ernstiger.
TLR4 signalering als doelwit
Naast de locatie en cel waar TLR4 geremd zou moeten worden om artritis te 
behandelen, is ook bestudeerd hoe TLR4 optimaal geremd kan worden. Hiervoor 
is er gekeken naar de intracellulaire signalering. Deze kan voor TLR4 verdeeld 
worden in twee routes; de MyD88 afhankelijke route en de TRIF afhankelijke 
route, welke respectievelijk NF-κB en IRF3 activeren. Beide signaal routes zijn 
bestudeerd om te bepalen of het therapeutische doelwitten zouden kunnen zijn.
MyD88 signalering na TLR4 activatie induceert veel cytokine en MMP productie, 
welke betrokken zijn bij ontsteking en weefselafbraak. Dit maakt de MyD88 
route een interessant doelwit. Bovendien laten dieren waarbij MyD88 ontbreekt 
een sterk verlaagde artritis zien. Om MyD88 signalering te blokkeren, is er een 
kinase negatieve mutant van TAK1 gebruikt, een kinase dat actief is in de MyD88 
signaleringsroute. De kinase negatieve TAK1 mutant werd door middel van 
intraveneus toedienen van lentivirus tot overexpressie gebracht (hoofdstuk 6) en 
dit resulteerde in verlaagde artritis, verminderde Th-17 ontwikkeling en minder 
botschade. De verminderde botschade werd mogelijk bereikt door het direct 
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transduceren van de voorlopers van bot afbrekende cellen, de osteoclasten. Ook de 
groeifactor en receptor, RANKL en RANK, die cruciaal zijn voor osteoclastogenese 
kwamen minder tot expressie in het synovium van de behandelde dieren. 
Hieruit bleek dus dat het stoppen van de MyD88 route door het blokkeren 
van TAK1 een mogelijk effectieve behandelstrategie zou kunnen zijn. Echter, 
TAK1 wordt niet enkel door TLRs, of TLR4 in het bijzonder, gebruikt en is zelfs 
een van de belangrijkste kinase eiwitten in vele ontstekingssignaleringsroutes. 
Dit zou overigens wel de effectieve anti-inflammatoire eigenschappen van deze 
behandeling kunnen verklaren. Aanvullend werd in vitro bestudeerd of het 
selectief remmen van TAK1 in synoviale fibroblasten ook effectief was (hoofdstuk 
7). Het bleek dat TLR4 in staat was NFκB te activeren zonder TAK1 daarbij te 
betrekken. Hetgeen suggereert dat andere kinases een dominantere rol spelen. 
Wanneer de TLR4 stimulerende rol van endogene liganden in overweging wordt 
genomen, is TAK1 remming in de synoviale fibroblast geen geschikte strategie. 
In APCs, echter, is TAK1 wel een interessant doelwit voor de behandeling van 
artritis.
De tweede signaal route die door TLR4 wordt gebruikt is de TRIF route, een 
veronderstelde anti-inflammatoire route. Activatie van deze signaal route 
induceert type I interferonen dat vervolgens resulteert in ‘suppressor of cytokine 
signaling’ (SOCS) eiwit productie. Ook induceert de TRIF route de aanmaak 
van IL-27, dat de ontwikkeling van Th17 cellen remt. Deze signaal route is 
bestudeerd in een T-cel afhankelijke opvlamming van artritis (hoofdstuk 8). Na 
een primaire ontstekingsfase is de sluimerende artritis aangewakkerd door een 
lage dosis antigeen. Dit zorgt voor een snelle ophoping van ontstekingscellen 
in het ontstoken gewricht. TLR4 speelt een cruciale rol in dit proces door het 
induceren van IP-10 en RANTES chemokines die T-cellen aantrekken naar de plek 
van ontsteking. Echter, TRIF signalering bleek geen rol te spelen in dit proces. 
TRIF lijkt wel een rol te spelen tijdens het verdwijnen van de ontsteking, omdat 
de Th17 cel populatie verlaagd was in de latere fase van artritis in dieren waarin 
geen TRIF aanwezig was. De oorzaak hiervan kan een verlaagde expressie zijn 
van chemokines. Deze resultaten zijn in contrast met andere studies die een 
duidelijk anti-inflammatoir effect hebben laten zien van de TRIF signaal route 
op bot erosie in bacteriële cel wand artritis en in een experimenteel model van 
multiple sclerose. In dit experiment hebben we echter de rekrutering van T-cellen 
bestudeerd en niet het begin van ontsteking. Daarom zou het zo kunnen zijn dat 
TRIF signalering een andere rol speelt bij de begin van de ontsteking dan bij het 
aantrekken van T-cellen.
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Versterken van natuurlijke negatieve terugkoppeling
De TLR4 signaleringsroutes worden in fysiologische condities geremd door 
verschillende intracellulaire remmers, zoals SOCS1 en SOCS3. Deze eiwitten 
interfereren met de samenstelling van signaleringseiwit complexen, remmen de 
kinase activiteit van de signaal eiwitten en induceren afbraak van deze eiwitten. 
Deze mechanismen voorkomen de activatie van pro-inflammatoire signalering. 
Het is reeds aangetoond dat overexpressie van SOCS3 artritis kan verlagen en 
T-cel response kan moduleren. Hier beschrijven we een nieuwe strategie om 
Figuur 1. TLR4 signalering, gen inductie en remming
Activatie van TLR4 resulteert in signalering via MyD88 and TAK1 en inductie van pro-inflammatoire 
cytokines. Na opname van de TLR4 receptor met het ligand wordt de TRIF signalering geactiveert, 
welke resulteert in late NF-κB activatie en productie van type I interferonen. Deze interferonen 
induceren negatieve terugkoppeling op TLR4 signalering in samenwerking met TAM receptoren (Tyro3, 
Axl en MerTK) door de expressie van SOCS eiwitten te induceren. TLR4 expressie kan verlaagd worden 
met RNA interferencen (1) (hoofdstuk 5). TLR4 kan ook geremd worden met het blokkeren van TAK1 
(2) (hoofdstuk 6) dat een sleutel rol speelt in de signaal route van TLR4, of het blokkeren van TRIF 
activatie (3( (hoofdstuk 8). Ten slotte kan de negatieve terugkoppeling op TLR4 worden versterkt door 
het stimuleren van TAM receptoren met Gas6 of Pros1 (4) (hoofdstuk 9).
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SOCS1 en SOCS3 expressie te induceren door activatie van TAM receptoren door 
de natuurlijke liganden Gas6 en Pros1 (hoofdstuk 9). Systemische overexpressie 
van Pros1 reduceerde Th1 cel aantallen in de milt en dit verlaagde de artritis in 
lichte mate. Gas6 en Pros1 waren effectiever in het verlagen van de ontsteking 
wanneer deze lokaal tot overexpressie werden gebracht. Deze overexpressie 
ging gepaard met een verhoogde expressie van zowel SOCS1 als SOCS3, wat 
wijst op de effectiviteit van TAM receptor activatie om de ontsteking te remmen. 
Dit breekt de ontstekingscascade en voorkomt progressie van artritis die door 
endogene liganden wordt onderhouden. Deze strategie limiteert mogelijk ook 
neveneffecten, zoals de gevonden verhoging van ontsteking die geobserveerd 
werd na specifieke verlaging van de TLR4 expressie op APCs. Door tijdelijk de 
natuurlijke negatieve terugkoppeling op de ontsteking te verhogen is het wellicht 
mogelijk om neveneffecten te voorkomen, zoals een dysfunctioneel immuun 
systeem tegen pathogenen.
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stage of opdracht. Ik wens jullie veel succes als analist, promovendus of elke 
andere carrière.
Ook mijn maatjes bij Obelix wil ik bedanken. De trainingen waren een goede manier 
om even de gedachten te resetten. En teamgenoten af en toe als stootkussen 
gebruiken is zeker een goede manier om de frustraties even te verwerken. De 
twee jaar als secretaris, in het bestuur Demmer en bestuur Vermue, gaf mij een 
welkome afwisseling tijdens het labwerk. In het bijzonder wil ik de Obelix Dames 
nog bedanken dat ik mijn coachingskills heb kunnen ontplooien. Af en toe een 
ongelooflijk kippenhok en slap geouwehoer, maar dat hield het wel lekker luchtig. 
Eric, Monique, Stan, Luc, Jorike en Saskia de gezellige weekendjes brachten ook 
een leuke afwisseling. Een dagje pretpark, parachute springen of trial rijden, 
hopelijk kunnen we deze weekendjes nog lang voortzetten.
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Chapter 11
Peter en Ana Karla, Els en Sebastiaan, als broer en zus met partners altijd 
beschikbaar voor een andere kijk op de wereld. Met de motor over het circuit 
scheuren of een paar neefjes erbij geeft toch wat relativering.
Ad en Phily, pa en ma, spa en smoeder, bedankt voor het mogelijk maken van 
alles. Ik heb altijd kunnen doen wat ik zelf koos en kunnen studeren wat ik wilde. 
Jullie zijn ook altijd beschikbaar voor advies of een klus.
Dionne, m’n mini, de laatste woorden zijn voor jou. De laatste anderhalf jaar heb 
je me enorm geholpen te relativeren en door te blijven gaan. Bedankt dat je mijn 
leven verrijkt hebt en helaas moet je weer een tijdje terug naar Nijmegen. Het zal 
even wennen zijn voor ons allebei, maar dat komen we wel te boven. Ik kijk uit 
naar de toekomst samen met jou.


